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Summary
1. The aim of this study was to examine the possibility that S-nitrosocysteine or S- 
nitrosoglutathione rather than nitric oxide functions as the inhibitory non- 
adrenergic, non-cholinergic (NANC) neurotransmitter in the bovine retractor penis 
(BRP) muscle. This was investigated firstly, by examining whether free sulfhydryl 
groups are required for NANC relaxation to take place upon nerve stimulation in 
the BRP muscle and secondly, by examining the properties of the new relaxant 
produced when nitric oxide is reacted with a range of sulfhydryl compounds.
2. Treatment of BRP muscle with the sulfhydryl oxidising agent, diamide (1 mM), 
inhibited NANC relaxation induced by nerve stimulation. This effect was 
completely prevented and almost completely reversed by treating the tissue with the 
sulfhydryl compounds, L-cysteine (3 mM), L-glutathione (3 mM) or dithiothreitol 
(3 mM). The inhibition was not specific, however, since the oxidising agent also 
inhibited the relaxant actions of glyceryl trinitrate (0.01-0.1 pM) and isoprenaline 
(0.01-1 pM).
3. Treatment of BRP muscle with the sulfhydryl alkylating agent, N- 
ethylmaleimide (0.3 mM), inhibited NANC relaxation induced by nerve 
stimulation. This effect was completely prevented but not reversed by treating the 
tissue with the sulfhydryl compounds, L-cysteine (3 mM), L-glutathione (3 mM) or 
dithiothreitol (3 mM). As with diamide, inhibition was not specific, however, since 
the alkylating agent also inhibited the relaxant actions of glyceryl trinitrate (0.01- 
0.1 pM) and isoprenaline (0.01-1 pM).
4. The weak vasodilator activity of sodium nitrite (10 pM) was greatly enhanced by 
acidification. The optimal pH for enhancement of vasodilator activity was pH 1-2. 
Deoxygenation before acidification further enhanced and bubbling to saturation with
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oxygen for 10 minutes before acidification inhibited relaxant activity. Increases in 
relaxant activity upon acidification were associated with decreases in nitrite content. 
Neutralisation of acidified samples led to a rapid loss of relaxant activity. These 
results are consistent with formation of nitric oxide upon acidification of nitrite and 
this is destroyed by oxygen and protected in an oxygen-free environment.
5. The first means adopted to form an S-nitrosothiol was to acidify nitrite (10 mM) 
in the presence of L-cysteine (1.5 M). The relaxant activity, assessed both in 
magnitude and duration, greatly exceeded that of equivalent solutions of acidified 
nitrite. Again maximum generation of relaxant activity occurred at pH 2, but unlike 
solutions of acidified nitrite, these solutions retained their relaxant activity upon 
neutralisation. These solutions were pink in colour and their relaxant activity was 
destroyed by the nitric oxide-binding substance, haemoglobin, but was unaffected 
by the inhibitor of nitric oxide synthase, N^-nitro-L-arginine.
6. In the spectrophotometer at 190-900 nm, nitric oxide in the gas phase produced 
several narrow absorption bands at wavelengths less than 230 nm, whereas in 
aqueous solution it produced only a single peak at 190 nm. Upon admission of 
oxygen, nitrogen dioxide was rapidly formed in both the gas and liquid phases 
assessed by formation of its characteristic absorption peaks at 300-400 nm.
7. A second means adopted for the formation of S-nitrosothiols was by reacting 
nitric oxide gas with L-cysteine. In phenylephrine (0.3 pM)-contracted rabbit aortic 
rings denuded of endothelium and in BRP strips, nitric oxide (1-1,000 nM) alone 
induced transient relaxation in a concentration-dependent manner, whereas L- 
cysteine (0.15-4.5 mM) was without effect. When aqueous solutions of L-cysteine 
(15 mM) were reacted with nitric oxide (5 mM) in nominally oxygen-free 
conditions at pH 3 for 10 minutes followed by purging with oxygen-free nitrogen to 
remove free nitric oxide and neutralisation and added to achieve bath
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concentrations equal to 10 nM nitric oxide and 30 fiM L-cysteine, however, more 
powerful and prolonged relaxation was produced than could be attributed to nitric 
oxide alone.
8 . In the HPLC, aqueous solutions of L-cysteine (10 mM) at pH 3.0 produced two 
peaks corresponding to L-cystine (~ 0.85 %, peak 1) and L-cysteine (~ 99.15 %, 
peak 2), respectively. After saturating this solution with nitric oxide gas for 10 
minutes under nominal oxygen-free conditions, the solution produced three peaks 
in the HPLC corresponding to L-cystine (“ 0.85 %), L-cysteine (“ 98 %) and a new 
substance (“ 1.15%, peak 3) which was entirely responsible for relaxant activity. 
Re-run of the peaks in the HPLC revealed that L-cystine was stable, whereas L- 
cysteine and the new relaxant decayed slowly to form L-cystine.
9. Using a series of structural analogues of L-cysteine (all at 15 mM) it was found 
that removal of the carboxyl group (L-cysteamine), replacement of the carboxyl 
with an ester function (L-cysteine methyl ester) or substitution at the amino group 
(N-acetyl-L-cysteine) had no effect on the ability to generate new relaxant activity 
upon reaction with nitric oxide (0.1 mM). In contrast, substitution at the sulfhydryl 
group (S-methyl-L-cysteine, L-cysteinesulfinic acid and L-cysteic acid), or 
formation of disulphides (L-cystine and L-cystamine) led to a complete loss of 
ability to generate relaxant activity. L-glutathione (reduced) was also able to react 
with nitric oxide to produce new relaxant activity, and this too was blocked upon 
substitution of the free sulfhydryl group (S-methyl-L-glutathione) or formation of 
disulphides (oxidised L-glutathione). Furthermore, methionine which contains a 
substituted sulfhydryl group and the non-sulfhydryl-containing amino acids, L- 
arginine, L-glycine and L-glutamic acid, were all unable to react with nitric oxide 
to generate new relaxant activity. A free sulfhydryl group was therefore required to 
generate relaxant activity following reaction with nitric oxide.
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10. UV-visible spectrophotometric analysis of this new compound revealed that it 
had three absorption bands with maxima at 218, 335 and 543 nm. The magnitude of 
absorption was: 218 > 335 > 543 nm.
11. Freeze drying of the relaxant under high vacuum overnight resulted in a 
complete loss of relaxant activity and the associated peak 3 in the HPLC, whereas 
storage at -20°C had little effect. Saturating the solution with pure oxygen for 10 
minutes did not result in any change in its relaxant activity and height of peak 3. 
Treatment in a boiling bath for 10 minutes substantially reduced the relaxant activity 
and associated peak 3 in the HPLC, whereas treatment for 10 minutes at 70°C was 
without effect. After mixing with methanol (1:1, vol./vol.) for 10 minutes at 0°C, 
the relaxant activity and height of peak 3 were reduced by 50 % and three new 
peaks were generated. Thus, the new relaxant formed was relatively stable to heat 
and the presence of oxygen, but was destroyed by methanol.
12. Despite attempting to standardise reaction conditions, the amounts of relaxant 
activity generated differed enormously from experiment to experiment. Clearly, 
some variable factor was having an important effect upon the outcome of the 
reaction between nitric oxide and L-cysteine. We considered the possibility that our 
reaction conditions were not completely oxygen-free and that oxygen might play a 
part in the reaction. We therefore devised more rigorous procedures in which we 
first purified nitric oxide and oxygen-free nitrogen gases by purging through 
Fieser's solution and sodium hydroxide to remove traces of oxygen and nitrogen 
dioxide, respectively.
13. Under such rigorous oxygen-free conditions, bubbling nitric oxide gas to 
saturation for 10 minutes in solutions of L-cysteine (10 mM) at pH 3 followed by 
purging to remove free nitric oxide generated novel relaxant activity together with 
its associated peak 3 in the HPLC and absorption peaks at 218 and 335 nm but the
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amounts formed were much smaller than when less rigorous oxygen-free conditions 
were employed. These solutions were colourless and no absorption peak at 543 nm 
was seen. Furthermore, these properties of the solution did not change upon 
exposure of the solution to the air.
14. In contrast, if under the same rigorous oxygen-free conditions, L-cysteine was 
reacted with nitric oxide and free nitric oxide was not removed from the solution 
before exposure to the air, the relaxant activity, magnitude of peak 3 in the HPLC 
and the absorption peaks at 218 and 335 nm were all some 40 times greater. 
Furthermore, upon exposure to the air, the solution instantly became pink in colour 
owing to the development of a new peak at 543 nm. Thus oxygen was critical for 
formation of the new relaxant activity and its associated peak 3 in the HPLC and its 
absorption peaks at 218, 335 and 543 nm.
15. In other experiments under rigorous oxygen-free conditions in a sealed cuvette 
when L-cysteine was reacted with nitric oxide and free nitric oxide was not 
removed by purging, absorbance peaks at 218 and 335 nm were small initially but 
grew with time. Furthermore, although no peak was visible initially at 543 nm, one 
began to appear by about 40 minutes and this too began to grow with time. These 
rises were likely to be due to entry of oxygen into the reaction chamber despite our 
rigorous efforts.
16. The new relaxant activity generated by reacting nitric oxide with L-cysteine or 
L-glutathione was abolished following treatment with the nitric oxide-binding agent, 
haemoglobin (3 mM), and the guanylate cyclase inhibitors, methylene blue (10 
mM) and N-methylhydroxylamine (100 mM), but was unaffected by the nitric oxide 
synthase inhibitor, N^-nitro-L-arginine (30 pM). Thus, the new relaxant owed its 
activity to the release of nitric oxide which subsequently activated soluble guanylate
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cyclase. It did not activate nitric oxide synthase in the NANC nerves and did not!act as 
a substrate for the enzyme.
17. Two agents that generate superoxide anion, pyrogallol (0.1 mM) and 
hydroquinone (0.1 mM), also inhibited this new relaxant activity as well as that of 
authentic nitric oxide (0.3 mM), but as previously reported had no effect on 
relaxation induced by NANC nerve stimulation. Furthermore, superoxide dismutase 
(100 u ml"*) potentiated the relaxation induced by the S-nitrosothiols, reversed the 
blockade induced by pyrogallol and hydroquinone but had no effect on NANC 
relaxation. Superoxide anion can therefore destroy the relaxant activity of nitric 
oxide and the S-nitrosothiols but has no effect on the NANC transmitter.
18. In conclusion, the reaction of nitric oxide with L-cysteine or L-glutathione 
generates relaxant activity which exceeds that of nitric oxide alone and probably 
results from formation of S-nitrosocysteine and S-nitrosoglutathione, respectively. 
The effects of pyrogallol and hydroquinone indicate that neither S-nitrosocysteine 
nor S-nitrosoglutathione are suitable candidates for the NANC inhibitory 
neurotransmitter in the BRP muscle and suggest that it is more likely to be a 
superoxide anion-resistant, nitric oxide-releasing molecule.
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Chapter 1. INTRODUCTION
Body function is controlled and integrated mainly by the nervous system and the 
endocrine system. Control by the nervous system depends primarily on the rapid 
electrical conduction of information in nerve fibres, then between the nerve cells, 
and finally between the axone terminal of the last neurone in the chain and the 
effector cells it innervates. The signals crossing junctions between cells are usually 
carried by chemical substances rather than electrical impulses. This chemical 
transmission takes place through the release of small amounts of neurotransmitter 
from the nerve fibre terminals into the region of the synapse or junction. The 
chemical neurotransmitter diffuses to the postsynaptic cell and binds to a specialised 
receptor.
The peripheral nervous system can be divided into two major functional 
subdivisions, the autonomic division and the somatic division. The autonomic 
nervous system in turn consists of two major portions, the sympathetic division and 
the parasympathetic division, and was originally based on anatomical differences. 
On the other hand, a different classification of the autonomic nervous system can be 
made, based on the neurotransmitter released from the nerve fibre terminals. 
Classically the autonomic nervous system consisted of a cholinergic nerve division 
and an adrenergic division, based on the release of either acetylcholine or 
noradrenaline. When dealing with the post-ganglionic fibres, the cholinergic system 
corresponds, with few exceptions, to the parasympathetic division and likewise the 
adrenergic to the sympathetic division (Langley, 1921; Dale & Gaddum, 1930; 
Dale, 1935; Dale, et al., 1936). The classical concept that the autonomic nervous 
system consisted of only cholinergic nerve and adrenergic nerve has, however, been 
challenged. Modem scientific developments in biochemistry, physiology and 
pharmacology have provided evidence for the existence or coexistence of many 
other neurotransmitters. For example, a variety of peptides such as substance P,
l
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purines such as ATP and other amines such as dopamine are now established as 
neurotransmitters (Bell, 1991). Furthermore, the process of cotransmission whereby 
a single nerve releases two substances both of which affect post-synaptic tissues is 
now generally accepted (Cuello, 1982; Bumstock, 1985; 1986a; 1986b; Campbell, 
1987; Furness, et al., 1989). For example, neuropeptide Y is co-released with 
norepinephrine from sympathetic nerves in many arteries and potentiates the 
contractile effects of norepinephrine (Ekblad, et al., 1984; Neild, 1987).
Part of the evidence for the existence of neurotransmitters other than noradrenaline 
and acetylcholine is a nerve response which is characteristically unaffected by either 
adrenergic or cholinergic blocking agents. The neurogenic origin of the response is 
proved by its abolition by tetrodotoxin. Such responses and the nerves producing 
them are referred to as non-adrenergic non-cholinergic (NANC) responses and 
nerves, respectively. A non-adrenergic non-cholinergic nerve innervation exists 
broadly in most peripheral smooth muscles including gastrointestinal tract, 
cardiovascular system, and the urinary and reproductive system and glands 
(Bumstock, 1969; 1972; 1975; 1978; Gillespie, 1972; 1987; Klinge & Sjostrand, 
1974).
1.1. Historical Development of NANC Innervation
The phenomenon of atropine-resistant responses to nerve stimulation was reported 
as early as the late 19th century and implied a non-cholinergic innervation. Langley 
and Anderson (1895) reported that in the rabbit atropine could not inhibit penile 
erection produced by electrical stimulation of the sacral parasympathetic outflow via 
the pelvic nerves. Bayliss and Starling (1899) reported that vagal stimulation in the 
dog small intestine causes first relaxation and subsequently a powerful contraction. 
Both the relaxation and the contraction were unaffected by atropine. Henderson and 
Roepke (1933), using penile perfusion in dog, found that physostigmine potentiates
2
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the effects of pelvic nerve stimulation on venous flow, while atropine has almost no 
effect. In 1934 they also reported that in the guinea pig the motor response of the 
urinary bladder to parasympathetic nerve stimulation is slightly reduced by low 
doses of atropine but the large residual motor effect is insensitive to even high 
doses. Henderson and Roepke (1934) suggested that atropine resistance in the 
bladder could be best explained by the release of a neurotransmitter other than 
acetylcholine or noradrenaline. Oppenheimer (1938) studied the cat retractor penis 
in vivo. He found that acetylcholine mimics the effect of this parasympathetic 
stimulation, however, atropine abolishes the effect of acetylcholine but not of 
parasympathetic nerve stimulation. He believed the relaxation of the retractor penis 
was caused by the release of the neurotransmitter acetylcholine. The resistance to 
atropine of the parasympathetic response was due to the proximity theory, the 
theory of Dale and Gaddum (1930) and reinvoked by Ambache (1955). The 
proximity theory was that the muscle cell membrane is in such close proximity to 
the nerve terminals as to deny access to exogenous blocking agents. However, 
electron-microscopical studies have disproved this theory because large gaps are 
found between the nerve terminal and the muscle cell membrane where the 
neurotransmitter is released and acts on the target membrane. Goldenberg (1965) 
found that in cat retractor penis injected nicotine produces relaxation which is 
blocked by hexamethonium but not by atropine. He believed the relaxation was not 
due to acetylcholine but to an unknown neurotransmitter released from the 
parasympathetic nerves stimulated by nicotine.
However, experimental proof of the existence of NANC nerves was delayed 
because no selective powerful adrenergic blocking drugs were available until the 
1960s. When adrenergic neurone blocking drugs were introduced and applied to 
analyse the response of the stomach to nerve stimulation, it was found that they 
have no effect on the inhibitory response to vagal stimulation in the guinea pig 
(Martinson, et al. , 1963) and to transmural stimulation in the guinea pig and mouse
3
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(Paton & Vane, 1963). The first definite proposal of the existence of non-adrenergic 
inhibitory nerves was based on the observation that nerve stimulation of the guinea 
pig taenia coli elicits a potent inhibitory response which is not blocked by bretylium 
(Bumstock, et al., 1963; 1964). The response is blocked by low concentration of 
tetrodotoxin and therefore considered neurogenic in origin (Bulbring & Tomita, 
1967).
Electropharmacological studies have also supported the existence of NANC 
inhibitory neurones. Following intramural nerve stimulation, large transient 
hyperpolarisations i.e. inhibitory junction potentials (UPs) of up to 30 mV have 
been recorded in several isolated smooth muscle preparations including taenia coli 
(Bumstock, et al., 1964; Bennett, et al. , 1966), jejumum (Kuriyama, et al., 1967), 
caecum (Small, 1972) and colon (Furness, 1969). Summation of UPs could be 
obtained by repetitive stimulation to produce maximum hyperpolarisations of up to 
35 mV at an optimum frequency of 10 Hz. In contrast, no change in the membrane 
potential of smooth muscle cells or in mechanical activity is observed by single 
pulse stimulation of either extrinsic or perivascular sympathetic nerves. While the 
hyperpolarisations in gastrointestinal muscle induced by both sympathetic nerve 
stimulation and exogenously applied noradrenaline are due to an increase in both 
potassium and chloride conductance, the hyperpolarisations associated with 
stimulation of the non-adrenergic inhibitory nerves in the guinea-pig taenia coli are 
due to a specific increase in potassium conductance (Bennett, et al., 1963; Tomita 
and Watanabe, 1973).
In the taenia coli of guinea pig the inhibitory relaxation is poorly sustained if 
continuous stimulation is applied (Bumstock, et al., 1966). In contrast, in the 
sphincteric muscle of the gut, particularly the internal anal sphincter the response to 
continued stimulation is well maintained (Rayner, 1979). Furthermore, in the cat 
stomach relaxation mediated by non-adrenergic inhibitory nerves is not readily
4
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fatigued (Abrahamson, 1973). Stimulation of the pelvic nerve brings about neither 
mechanical inhibition (Garry & Gillespie, 1955) nor inhibitory junction potentials in 
the smooth muscle cells of the large intestine (Furness, 1969), although transmural 
stimulation causes inhibitory junction potentials in both circular and longitudinal 
layers (Furness, 1969). These inhibitory junction potentials were reduced by 
hexamethonium suggesting an intrinsic cholinergic drive (Furness, 1970). Electrical 
and mechanical responses in the guinea pig taenia coli and urinary bladder are 
reduced by lowering the external calcium concentration (Bumstock, et al., 1978) 
implying that transmitter release is calcium dependent and that the transmitter itself 
is probably held in membrane-bound storage vesicles, whose contents are released 
by exocytosis. In the anococcygeus muscle, responses to field stimulation of motor 
adrenergic nerves and NANC inhibitory nerves are potentiated by tetraethyl 
ammonium which is known to prolong the nerve action potentials so allowing more 
time for calcium entry (Gillespie & Tilmisany, 1976).
There have been many reports providing evidence for the existence of an NANC 
innervation in a wide variety of tissues. They include the lower oesophageal 
sphincter muscle (Rattan, et al., 1977), oesophagus (Lund & Christensen, 1969), 
stomach (Martinson, 1965; Campbell, 1966), small intestine (Holman & Hughes, 
1965; Day & Warren, 1967; 1968; Weston, 1971; Hirst & McKirdy, 1974), large 
intestine (Bianchi, et al., 1968; Small 1972), taenia coli (Bennet, et al., 1966), gall 
bladder (Davison, eta l., 1978), trachea (Coleman, 1973; Cobum & Tomita, 1973), 
BRP (Klinge, 1970a; Klinge & Sjostrand, 1974; Ambache & Killick, 1978), 
anococcygeus (Gillespie, 1972; 1987; Gillespie & McGrath, 1973; 1974; Gibson & 
Gillespie, 1973; Creed, et al., 1977; Gibson & Mirzazadeh, 1989; Gibson, et al., 
1989; 1990; 1992; Gillespie, et al., 1989; 1990; Li & Rand, 1989; Liu, et al., 
1991; Martin & Gillespie, 1991; Martin, et al., 1993), rectococcygeus (King, et 
al., 1977; King & Muir, 1977; 1981), and certain blood vessels including portal 
vein (Hughes & Vane, 1967; Hughes & Vane, 1969; 1970), penile artery (Dorr &
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Brody, 1967; Klinge & Sjostrand, 1974; Liu, et al., 1991) and cerebral artery 
(Toda & Okamura, 1990a; 1990b) of various species.
The NANC nerves can be divided into an excitatory division and an inhibitory 
division. The existence of NANC excitatory nerves has been found in several 
smooth muscles. For example, the motor responses induced by stimulation of the 
sacral parasympathetic outflow via pelvic nerves to the mammalian urinary bladder 
are only partially blocked by atropine (Langley & Anderson, 1895; Henderson & 
Roepke, 1934; 1935; Ambache, 1955). This atropine-resistance is generally 
accepted to be due to the release of an excitatory transmitter rather than acetylcholine 
from the excitatory nerves (Henderson & Roepke, 1934; Ambache & Zar, 1970; 
Bumstock, et al., 1972) despite other explanations such as the proximity theory 
(Bale & Gaddum, 1930; Hukovic, et al., 1965; Carpenter, 1977). One proposal 
was that the nerve was purinergic (Bumstock, et al., 1978), but the response to 
nerve stimulation remains unchanged after the tissue is desensitised to ATP 
(Ambache, et al., 1977). Atropine-resistant contractions have also been recorded in 
the oesophagus (Lund & Christensen, 1969), the stomach (Semba & Mizonishi, 
1978) and the small intestine (Ambache & Freeman, 1968; Day & Warren, 1968).
Purinergic nerves constitute one group of NANC inhibitory nerve system. 
Bumstock (1972) proposed the existence of purinergic nerves which release 
adenosine triphosphate (ATP) or a related nucleotide as a transmitter. He found that 
ATP and the necessary enzymes for its synthesis are present in certain nerves. ATP 
is detected upon stimulation of these nerves and this is blocked by tetrodotoxin, 
implying a neurogenic origin. The enzymatic break down of ATP to ADP to AMP 
to adenosine which is subsequently taken up by tissues may represent its inactivation 
mechanism. In many tissues drugs have the same effects on responses to ATP and to 
nerve stimulation. Also, binding of ATP by quinacrine shows its existence in 
varicose nerve fibres in histochemical studies. The inhibitory purinergic nerves have
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been shown to innervate many tissues including the gastrointestinal tract, trachea, 
and portal vein (Bumstock, 1972; 1975; 1978).
1.2. Anococcygeus and Retractor Penis Muscles
The BRP and rat and mouse anococcygeus muscles are typical examples of smooth 
muscles receiving an NANC inhibitory innervation (Gillespie, 1972; Gibson & 
Gillespie, 1973; Gibson & Yu; 1983; Klinge & Sjostrand, 1974). Sertoli (1883) 
first studied the retractor penis muscle of several species both in vitro and in vivo. 
He found the muscle exhibits spontaneous activity. In a warm environment it 
relaxes and in the cold contracts. These findings were confirmed by De Zilwa 
(1901) in the dog retractor penis in vitro. However, except for local anaesthetics 
and tetrodotoxin, none of the drugs blocking known neurotransmitters had any 
effect on the inhibitory response to the NANC nerve stimulation and no known 
neurotransmitter could mimic the relaxant response to NANC nerve stimulation in 
the retractor penis and anococcygeus muscles (Luduena & Grigas, 1966; 1972; 
Gillespie, 1972; 1980; 1987; Gibson & Gillespie, 1973; Klinge & Sjostrand, 1974; 
Creed, et al., 1977; Gibson & Wedmore, 1981). One aim of this project was to 
identify the NANC inhibitory neurotransmitter in the bovine retractor penis muscle.
1.2.1. Innervation
The retractor penis muscle receives a double innervation. The motor sympathetic 
nerves originate from the spinal cord in the lumbar region. Most fibres emanate 
from the sacral ganglia of the sympathetic chain and reach the muscle via the pubic 
nerve. Some fibres seem to run in the hypogastric nerve and a few fibres may 
follow the pelvic parasympathetic nerves. The inhibitory nerves leave the sacral 
cord with their fibres in the pelvic parasympathetic nerves (Langley & Anderson, 
1895). Studies in the pig, cat, dog, elk, hedgehog, ox and rat have all revealed a
7
Introduction
common innervation of motor and inhibitory nerves (Langley & Anderson, 1895; 
Fletcher, 1898; Gruber, 1933). The motor response is blocked by a-adrenoceptor 
blocking agents and adrenergic neurone blocking agents and is therefore clearly 
adrenergic (Luduena & Grigas, 1966; Klinge & Sjostrand, 1974; Byrne & Muir, 
1984), although in pig and sheep it might not entirely be adrenergic due to 
incomplete blockade by these drugs (Ambache & Killick, 1978).
The anococcygeus muscle, which extends to form the retractor penis (Gillespie, 
1972), was initially described by Langley & Anderson (1895). However, it was 
Gillespie (1972) who reported that the rat anococcygeus muscle appears to possess 
many of the desirable features of an ideal innervated smooth muscle preparation for 
the study of adrenergic and NANC inhibitory neurotransmission. Like the retractor 
penis muscle, the anococcygeus muscle of the cat, mouse, rabbit and rat receives a 
dense adrenergic motor innervation via the lumbar sympathetic nerves and a NANC 
inhibitory innervation via the sacral parasympathetic nerves whose transmitter is 
unknown (Gillespie, 1972; Gillespie & McGrath, 1973; 1974; Creed, et al. , 1977; 
Gibson & Wedmore, 1981). Unlike the retractor penis muscle, the anococcygeus 
muscle of the rat lacks spontaneous tone (Gillespie, 1972). It was worth considering 
the possibility that NANC relaxation in the retractor penis and anococcygeus 
involved electrical rather than chemical neurotransmission. Electrical transmission 
of activity from one cell to another does occur in the giant motor synapse of the 
crayfish (Furshpan & Potter, 1959), and combined chemical and electrical 
transmission has been reported in the chick ciliary ganglion (Martin & Pilar, 1963a; 
1963b). Such electrical transmission can only take place, however, where a well- 
defined ultrastructural organisation between pre- and post-synaptic elements with low 
resistance connections is present (Bennett, 1966). The lack of such a well defined 
ultrastructure in the anococcygeus and retractor penis muscles does not support the 
involvement of electrical transmission in these tissues (Gillespie & Lullman-Rauch, 
1974; Eranko, et al., 1976; Gibbins & Haller, 1979).
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Histochemically, adrenergic, cholinergic and peptidergic nerves can all be identified 
in the retractor penis and anococcygeus muscles. A dense fluorescent adrenergic 
nerve net is observed in the both tissues in all species studied (Bell & McLean, 
1970; Gillespie, 1972; Gillespie & McGrath, 1974; Creed, et al. , 1977; Gibson & 
Wedmore, 1981). There is also evidence from acetylcholinesterase staining for a 
terminal cholinergic network in the retractor penis of the bull (Klinge, et al., 1970), 
dog (Bell & McLean, 1970), and in the anococcygeus of the cat (Garrett, et al., 
1972). However, no specific cholinesterase activity is observed in the rat 
anococcygeus (Gillespie, 1972). Vasoactive intestinal polypeptide (VlP)-containing 
terminal autonomic fibres representing peptidergic nerves are found in the human 
penis (Polak, et al., 1981) and in the anococcygeus muscle of the cat, rabbit and rat 
where they are resistant to 6-hydroxydopamine (Hunter, et al., 1984). Purinergic 
nerve terminals can also be traced by quinacrine which binds to ATP in rat 
anococcygeus (Bumstock, et al., 1978a). Fine beaded fluorescent, presumably 
purinergic, nerve fibres are found sparsely in the rat anococcygeus (Iijima, 1983).
Ultrastructural studies have been made with the expectation of providing convincing 
evidence for the existence and nature of the NANC nerves in the anococcygeus and 
retractor penis muscles. In an early electron microscopic study of the rat 
anococcygeus muscle Gillespie and Lullman-Rauch (1974) described two types of 
varicosities, one with agranular vesicles and another with granular vesicles, 
corresponding to cholinergic and adrenergic nerves respectively. After exposure to 
5-hydroxydopamine the number of the granular vesicles was greatly increased. 
There was no evidence of the nerve profiles containing predominantly large opaque 
vesicles (LOV) or p-type vesicles previously described as characteristic of 
purinergic nerves (Bumstock & Iwayama, 1971). In a subsequent study by applying 
a fixation technique not using permanganate, which was reported to destroy the 
axon profiles of the NANC nerves in the ureter (Hoyes & Barber, 1976), Gibbins
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and Haller (1979) were able to observe three types of nerve profile in this tissue. 
They found that of the varicose fibres seen, about 60% contain mainly small dense 
cored vesicles which disappear after 6-hydroxydopamine treatment and correspond 
to adrenergic nerves, 5% contain mainly small clear vesicles resistant to 6- 
hydroxydopamine and correspond to cholinergic nerves, and the remaining 40% 
contain large uniformly stained dense cored electron-opaque, chromaffin-negative 
vesicles of 85-110 nm in diameter and are smaller than the LOV of the gut 
(Bumstock & Iwayama, 1971). The third nerve profile was not destroyed by 
pretreatment with 6-hydroxydopamine and was therefore taken to be the NANC 
nerves in the tissue. These three types of nerve profile are also found in the bovine 
retractor penis muscle (Eranko, et al., 1976). Unfortunately, in a later report 
Gibbins (1982) revised his findings in the rat anococcygeus and described a range of 
varicosities with different proportions of small clear vesicles and small p-type 
vesicles which could not be divided clearly into two classes corresponding to 
adrenergic and NANC nerves. The small clear vesicles were at that time taken to be 
the likely source of the NANC transmitter.
1.2.2. Response to NANC inhibitory Nerve Stimulation
Electrical stimulation of the retractor penis muscle of several species in vivo and in 
vitro produces contraction and also sometimes relaxation (Sertoli, 1883). De Zilwa 
(1901) reported that in vitro the dog retractor penis muscle stimulated electrically 
produces contraction when it is in low tone but relaxation in high tone. When the 
tone is raised in the retractor penis and anococcygeus muscles, electrical field 
stimulation induces a biphasic response in which the initial motor component 
declines at higher levels of tone, leaving a powerful relaxation (Gillespie, 1972; 
Klinge & Sjostrand, 1974). If the adrenergic nerves are blocked with guanethidine, 
only a pure inhibitory response is observed. This relaxation is rapid and powerful. It 
is sometimes followed by a rebound contraction on stopping stimulation. In both
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tissues of all species studied, maximum NANC relaxation is induced at low 
frequencies of 4-8 Hz, whereas the motor response is maximal at frequencies of 30 
Hz or more (Gillespie, 1972; Klinge & Sjostrand, 1974; Gillespie & McGrath, 
1974; Creed , et al., 1977; Gibson & Wedmore, 1981).
The NANC inhibitory response in the retractor penis and anococcygeus muscles is 
neurogenically mediated since it is blocked by low concentrations of tetrodotoxin. 
Further, this relaxation is also produced by extrinsic nerve stimulation (Langley & 
Anderson, 1895; Gillespie & McGrath, 1973). It is not an example of co­
transmission by the motor adrenergic nerves because the inhibitory response is 
unchanged after the adrenergic nerves are partially destroyed by 
immunosympathectomy or completely destroyed by 6-hydroxydopamine (Gibson & 
Gillespie, 1973). This is further supported by the separate spinal origin of the motor 
and inhibitory fibres (Langley & Anderson, 1895; Gillespie, 1972; Gillespie & 
McGrath, 1973).
The effects of inhibitory nerve stimulation on membrane potential, membrane 
conductance and accompanying mechanical relaxation have been studied in the 
anococcygeus of the rabbit and rat, and in the retractor penis of the bull (Creed, 
1975; Creed, et al., 1975; Creed & Gillespie, 1977; Byrne & Muir, 1984). In the 
rat anococcygeus there is little change in membrane potential upon NANC nerve 
stimulation, at most a few millivolts of hyperpolarisation are seen associated with a 
small rise in membranejconductance(Creed, et al., 1975). Single pulse stimulation 
does not induce relaxation or change the membrane potential. There is no clear 
correlation between membrane hyperpolarisation and mechanical relaxation. In the 
rabbit anococcygeus muscle single pulse stimulation induces large hyperpolarisations 
of up to 30 mV and rises in membrane conductance, although they are not always 
associated with mechanical relaxation (Creed & Gillespie, 1977). The BRP 
resembles the rat anococcygeus in that field stimulation induces only small
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hyperpolarisations in association with relaxation (Byrne & Muir, 1984). It appears 
that only in certain tissues does NANC nerve stimulation increase membrane 
permeability to ions, possibly potassium. Such finding suggest that 
hyperpolarisation is the main mechanism responsible for the mechanical relaxation 
(Creed & Gillespie, 1977; Byrne & Muir, 1984; Bolton & Large, 1986). In the rat 
anococcygeus muscle the absence of hyperpolarisation suggests that NANC 
relaxation must be the consequence of biochemical rather than electrical coupling.
1.2.3. Early Search for the NANC inhibitory Neurotransmitter
Generally the criteria for a substance to be established as a neurotransmitter are 
(Eccles, 1964): 1). It is synthesised and present in the nerve fibres; 2). It is released 
by nerve stimulation; 3). It should mimic the nerve response to electrical 
stimulation; 4). It combines with its receptor specifically; 5). Its mode of action and 
that of neurotransmitter of nerve should be the same; 6). Drugs which potentiate or 
block the nerve response should have the same effect on the putative 
neurotransmitter; 7). An inactivation mechanism should be present consisting either 
of enzymatic breakdown and / or uptake.
Drugs which selectively block a nerve response can often reveal information 
concerning the nature of the neurotransmitter involved. After tone of the BRP and 
the rat anococcygeus muscles is raised by guanethidine, 5-HT or furmethide, field 
stimulation of the muscles uncovers the inhibitory response. This response is not 
inhibited by any drugs which block known transmitters such as hexamethonium, 
guanethidine, phentolamine, phenoxybenzamine, propranolol, atropine, d- 
tubocurarine, diethylamide, mepyramine, and burimamide (Luduena & Grigas, 
1966; 1972; Gillespie, 1972; Klinge & Sjostrand, 1974). Ethanol is one of the few 
chemicals found to inhibit selectively the relaxant response to NANC nerve 
stimulation in the rat and rabbit anococcygeus and BRP (Gillespie, et al. , 1982).
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The NANC response is also not mimicked by acetylcholine, isoprenaline, GABA, 
glycine, glutamine, glutamate, glutamic acid, aspartic acid, asparagine, alanine, 
valine, tyrosine, N-acetyltyrosine, tryptophan, cysteine, methionine, histidine, 
proline, hydroxyproline, lysine, histamine, 5-HT , dopamine, prostaglandins and a 
variety of peptides including VIP, leucine- and methionine-enkephalin, neurotensin, 
and isomatostatin (Gillespie, 1972; Gillespie & McGrath 1974; Klinge & Sjostrand, 
1974; Creed, et al., 1977; Sjostrand, et al., 1981; Bowman & Gillespie, 1983). 
Although bradykinin causes relaxation at low concentrations in the anococcygeus of 
the cat, rabbit and rat (Gillespie & McKnight, 1978), it is also excluded since it 
induces contraction in the bovine retractor penis at low tone (Klinge & Sjostrand,
1974). Drugs such as haemoglobin and ethanol which are known to block the 
response to NANC inhibitory nerve stimulation in the anococcygeus and retractor 
penis do not block the response to bradykinin (Gillespie, et al., 1981a; Bowman, et 
a l ,  1982a). The rat anococcygeus is a particularly valuable tissue in evaluating any 
possible candidates as the NANC neurotransmitter since few substances can cause 
relaxation in this tissue.
Despite the finding that ATP causes contraction in the anococcygeus of the rat, and 
the retractor penis of the bull and dog (Luduena & Grigas, 1966; Klinge & 
Sjostrand, 1974), it was suggested to be the NANC inhibitory transmitter in the 
anococcygeus and BRP (Bumstock, et al., 1978a). Bumstock et al. (1978) argued 
that the relaxant action of ATP is masked by its ability to produce contractile 
prostaglandins. However, indomethacin, a cyclo-oxygenase inhibitor, does not block 
the contractile response to ATP in the rat anococcygeus (Carpenter & Joshi, 1979) 
and contraction is only seen at high concentrations with no relaxation at low 
concentrations (Gillespie, 1972). Moreover, the relaxant response to NANC 
inhibitory nerve stimulation in the retractor penis of the bull and dog is unaltered 
after the tissue has developed tachyphylaxis to ATP following repeated exposure 
(Klinge & Sjostrand, 1974; Bowman & Gillespie, 1983). Furthermore, apamin, a
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polypeptide from bee venom, blocks the relaxant responses to exogenous ATP and 
inhibitory purinergic nerve stimulation in gastrointestinal smooth muscle (Banks, et 
al., 1979; Sjoqvist, et al., 1980), but is without effect on NANC inhibitory 
relaxation in the rat anococcygeus and BRP (Bowman & Gillespie, 1982). In 
contrast, ethanol, at concentrations inhibiting the relaxant response to NANC 
inhibitory nerve stimulation in the rabbit anococcygeus, actually potentiates ATP- 
induced relaxation (Gillespie, et al., 1982). Haemoglobin uniformly blocks the 
NANC inhibitory nerve response in the anococcygeus of the mouse, rat and rabbit 
and the retractor penis muscles of the bull, but is completely ineffective in blocking 
the responses induced by ATP in the anococcygeus (Bowman & Gillespie, 1981; 
1982; 1983; Bowman, et al., 1982b; Gibson & Tucker, 1982; Gibson & Yu, 1983). 
Also, it doesn't block the relaxation to inhibitory purinergic nerve stimulation in the 
taenia coli of the guinea-pig (Bowman & Gillespie, 1983). In addition, an 
ultrastructural study has shown that purinergic fibres are sparse in the rat 
anococcygeus and thus such an innervation is unlikely to account for the powerful 
and complete relaxation induced by the NANC nerves (Iijima, 1983). Clearly, these 
results convincingly reject ATP as the inhibitory neurotransmitter in the 
anococcygeus and retractor penis muscles.
Over the years, three potential candidates emerged for the NANC transmitter in the 
anococcygeus and the retractor penis muscles; the inhibitory factor (IF) extracted 
from the BRP, endothelium-derived relaxing factor (EDRF), and nitric oxide (NO) 
or NO-releasing compounds such as S-nitrosothiols, since they all cause relaxation 
of the muscles, act through stimulation of soluble guanylate cyclase, increase cGMP 
levels, and are blocked by haemoglobin.
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1.3. Inhibitory Factor
One of the fundamental criteria to establish a substance as a neurotransmitter is to 
demonstrate its release upon nerve stimulation (Eccles, 1964). In this laboratory 
several attempts were made to try to detect the release of the NANC inhibitory 
transmitter in the rat anococcygeus and the BRP by bioassay. Although there was no 
difficulty in detecting EDRF released from the rabbit aorta using the same 
biodetection system (Gillespie & Sheng, 1988), all attempts to detect the NANC 
transmitter were without success. Therefore, efforts were made to try to extract the 
transmitter for subsequent identification. An early attempt failed to extract the 
transmitter from the rat anococcygeus with water or phosphate buffer (Gillespie, 
unpublished results). Later, Ambache and his colleagues (1975) were able to extract 
a substance from the BRP with dilute hydrochloric acid. This extract mimicked the 
relaxant response to NANC inhibitory nerve stimulation and its action was 
unaffected by drugs which block the effects of established transmitters. The 
physical, chemical and pharmacological properties of this activity termed inhibitory 
factor (IF) were further studied in an attempt to identify its chemical nature and to 
establish if it was indeed the transmitter (Gillespie & Martin, 1978; 1980; Bowman 
& Gillespie, 1981; 1982; Bowman, et al., 1981; Gillespie, et al., 1981; Crossley & 
Gillespie, 1983; Bowman, etal., 1986; Martin, etal., 1988).
1.3.1. Acid Activation
IF extracted with neutral buffer or methanol is biologically inactive (Gillespie & 
Martin, 1980), but its relaxant activity is generated by exposure to an acid pH. 
Some activity was generated at pH 4.0 and maximum activity was generated at pH 
2.0. This occurred rapidly and within a few minutes but a standard time of 10 
minutes was adopted before neutralisation and assay. Neutralisation of the acid-
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activated IF does not lead to loss of its activity. This acid-activation explains 
Ambache's success in the original extraction of IF.
1.3.2. Solubility
IF does not partition into ether implying it is not a prostaglandin (Ambache, et al.,
1975). It is hydrophilic, soluble in water, methanol, less soluble in ethanol and 
insoluble in acetone, ether, chloroform (Gillespie, et al.t 1981b). Pure methanol 
can destroy the activity of IF but it is stable in solutions of 70% methanol or less.
1.3.3. Thermolability
The unactivated form of IF is stable but the acid-activated form loses its activity at 
room temperature in 24 hours (Gillespie & Martin, 1980; Gillespie, et al., 1981b). 
This loss can be fully reversed by acidification for a second time, although only 
partial reversal is obtained if activity is lost by placing in a boiling water bath for 2  
minutes. The acid-activated form of IF is stable on ice for several hours and this is 
the preferred means of storing the material during experiments. The thermolability 
of the acid-activated form of IF is observed in solution and is a result of a 
temperature-sensitive interaction with water. While lyophilised and sealed in 
ampoules, IF remains active at least for periods of up to three years.
1.3.4. Molecular Weight
The molecular weight of the unactivated and acid-activated forms of IF was assessed 
by their ability to pass through a series of ultrafiltration membranes (Gillespie, et 
al. , 1981b). Both forms of IF were found in the filtrate passing through membranes 
retaining molecules of 500 Daltons and no concentration was observed in the 
retentate. These findings were interpreted as suggesting the molecular weight of
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both forms of IF was below this value. There was no evidence that the process of 
acid activation occurred with a change in molecular weight.
1.3.5. Electrical Charge
As IF was soluble in polar but not in non-polar solvents, it was likely to possess an 
electrical charge. This was examined by its retention and elution profile on ion- 
exchange resins (Gillespie, et al. , 1981b). IF, both in the inactive and acid-activated 
forms, was completely retained on an anion exchange column (Bio Rad AG1-X8, 
formate form) and was fully recovered upon elution with sodium chloride (500 
mM). However, a cation exchange column (Bio Rad AG50-W, sodium form) was 
unable to retain IF in both the inactive and acid-activated forms. Therefore, IF in 
both the inactive and acid-activated forms is negatively charged and no evidence 
was obtained to suggest that the process of acid-activation occurred with a change in 
electrical charge.
1.3.6. Distribution
One of the conventional criteria necessary to establish a substance to be a 
neurotransmitter is to obtain evidence of its storage in nerve terminals. The 
possibility that IF, like established neurotransmitters, was held in storage vesicles 
was examined (Gillespie & Hunter 1982). If IF is the NANC transmitter, it should 
be present in storage vesicles and selectively concentrated in the high speed P3  
pellet after ultracentrifugation. BRP muscle was homogenised and separated into the 
conventional P i, P2 , P3  and S3  fractions. The results showed activity in all 
fractions but with a seven-fold higher concentration in IF in P3 , suggesting storage 
in association with some form of sub-cellular particle.
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If IF was the transmitter, it would be expected to be extracted only from tissues 
receiving NANC inhibitory innervation. IF has been extracted from the NANC 
innervated smooth muscles such as the BRP muscle and the rat anococcygeus 
muscle. It was also, however, extracted from the poorly innervated rat uterus and 
the uninnervated human umbilical artery. It was also extracted from the cat 
ventricle, skeletal muscle and liver, the tendon of the bovine hoof and the vitreous 
humour of the bovine eye (Gillespie & Martin, 1980; Gillespie, 1987). This 
widespread distribution of IF argues against it being the NANC inhibitory 
neurotransmitter. However, other established transmitters are present in non-neural 
tissue. For example, acetylcholine is present in the uninnervated placenta (Chang & 
Gaddum, 1933) and 5-hydroxytryptamine is found in blood platelets (Garattini & 
Valzelli, 1965).
1.3,7. Chemical Composition
An attempt was made to classify IF into one of the general classes of biological 
materials, i.e. protein, lipid or carbohydrate (Gillespie, et al., 1981b). It was 
considered unlikely that IF was a protein or peptide since incubation with a range of 
proteases and peptidases such as the endopeptidases, pepsin, trypsin, and subtilisin 
and the exopeptidases, aminopeptidase or pyroglutamate aminopeptidase, did not 
lead to any loss of its inhibitory activity. IF was inactivated by carboxypeptidase but 
this was not an enzymatic action since it was time-independent and persisted after 
boiling the enzyme. Further evidence against it being a protein or peptide was 
obtained upon finding that the relaxant responses to IF and inhibitory nerve 
stimulation were not potentiated by the broad-spectrum protease inhibitor, 
Aprotinin, or the specific bradykinin/angiotensin converting enzyme inhibitor, 
SQ20881. The possibility that IF contained a carbohydrate group was suggested by 
the indirect evidence that the oxidant, periodic acid, and the reductant, sodium 
borohydride, destroyed IF (Gillespie, et al., 1981b). The possibility existed,
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however, that inactivation by these agents was simply due to more generalised 
reduction or oxidation reactions. The insolubility of IF in acetone or ether suggested 
that it was unlikely to be a lipid such as a prostaglandin.
Furchgott (1988) proposed that both EDRF and IF are nitric oxide and that the 
inactive form of IF is inorganic nitrite. He showed that the weak vasodilator activity 
of sodium nitrite is greatly enhanced by acidification, which is due to generation of 
nitric oxide from acidified nitrite according to the following chemical reactions 
(Sisler, 1956):
NO2 '  +  H + -» HNO2 (1)
2 HNO2  -> NO + NO2  +  H2 O (2 )
2NO + O2  -* 2NC>2 (3)
2NC>2 <-> N2 O4 (4)
2 NC>2 +  H2 O 0  HNO2  +  HNO3 (5)
This proposal was further supported by the evidence that the rank order of 
effectiveness of IF, EDRF and nitric oxide in relaxing the rabbit trachea and aorta, 
and the rat anococcygeus and BRP is similar (Gillespie & Sheng, 1988). Moreover, 
Martin and his colleagues (1988) reported that solutions of unactivated IF contain 4 
(iM nitrite. The activation of IF by exposure to acid at pH 2 for 10 minutes and 
subsequent neutralisation is in association with a 75% loss of nitrite, according to 
the above equation (2). Furthermore, the inactivation of the acid-activated IF by 
boiling was accompanied by an increase of nitrite content and the reactivation of 
this IF is linked with a further loss of nitrite content. However, an explanation by 
the above reactions is not completely consistent with certain properties of IF. For 
example, the relaxant activity of solutions of acid-activated and neutralised IF in 
open containers is stable for hours if kept on ice (Gillespie & Martin, 1980; 
Gillespie, et al., 1981b), whereas that of acidified nitrite in open containers is
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immediately lost upon neutralisation (Furchgott, 1988). Further differences are that 
nitric oxide is neutral but IF is negatively charged, and IF can be freeze dried and 
stored in the solid state (Gillespie & Martin, 1980; Gillespie, et al., 1981b), 
whereas nitric oxide gas clearly can not. Martin and his colleagues (1988) believed 
that these apparent differences between IF and nitric oxide can be explained if IF 
extracted from the BRP contains an additional anionic substance which reversibly 
binds and stabilises nitric oxide. They suggested that unactivated IF extracted from 
the BRP is nitrite, whose acid-activated derivative is stabilised nitric oxide.
The proposed nitric oxide-stabilising substance in IF has been suggested to be a 
thiol such as L-cysteine and L-glutathione (Yui, et al., 1989; Kerr, et al., 1992). 
This was based on the finding that IF contains 8  pM nitrite and the loss of nitrite 
following acidification of IF is closely related to the content of sulfhydryl groups in 
the extract. Yui et al. (1989) proposed that the relaxant activity generated from IF 
by acidification was due to formation of S-nitrosothiols, although they neither 
monitored the formation of S-nitrosothiols nor measured relaxant activity. Kerr et 
al. (1992) confirmed that IF contains 1-10 pM nitrite and 40-200 pM total thiol. 
They found that S-nitrosothiols, but not nitric oxide from acidified nitrite, could 
reproduce the properties of IF including its smooth muscle relaxant activity, 
stability to argon purging and ability to stimulate cGMP formation by platelet- 
soluble guanylate cyclase. Other substances such as proteins, thiols and sugars have 
also been shown to reversibly bind and stabilise nitric oxide (Braughler, et al.,
1979).
1.3.8 Pharmacology
IF mimics the effects of NANC nerve stimulation in the BRP, the rat anococcygeus 
and the penile artery, not only in the degree of relaxation but also in the time course 
of the response (Bowman & Gillespie, 1983; Crossley & Gillespie, 1983). The
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mode of action of IF and nerve stimulation is identical in these tissues. For 
example, both IF and nerve stimulation produce membrane hyperpolarisation in the 
BRP (Byrne & Muir, 1985). They cause relaxation, however, by raising cyclic 
GMP levels (Bowman & Drummond, 1984) and both effects are blocked by 
haemoglobin (Bowman & Gillespie, 1981; 1982; Bowman, et al., 1982b), N- 
methylhydroxylamine (Bowman & Drummond, 1984) and methylene blue 
(Bowman, et al., 1986) and potentiated by a selective inhibitor of cyclic GMP 
phosphodiesterase, M & B 22948 (Bowman & Drummond, 1984). Ethanol also 
selectively inhibits the relaxation of the rat anococcygeus and BRP to both NANC 
nerve stimulation and to IF without effect affecting the relaxant response to 
isoprenaline, sodium nitroprusside or the phosphodiesterase inhibitor, 
isobutylxanthine. The mechanism of action of ethanol might be to reduce calcium 
binding to cell membranes or to reduce the efficiency of receptor coupling 
(Gillespie, etal., 1982).
Thus IF fulfils many of the requirements of the NANC inhibitory neurotransmitter 
in the BRP and rat anococcygeus, but the need for acid activation and its widespread 
presence in tissues lacking the appropriate NANC innervation are inconsistent with 
such a role (Gillespie & Martin, 1980).
1.4. Endothelium-Derived Relaxing Factor
1.4.1. Discovery
Endothelium-derived relaxing factor (EDRF) was first discovered by Furchgott and 
Zawadzki (1980) in experiments with isolated preparations of arteries. In such 
preparations the relaxant effect of acetylcholine was found to be strictly dependent 
on the presence of endothelial cells on the intimal surface of the arteries. This 
discovery resolved the paradox that acetylcholine though a powerful vasodilator in
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vivo often produces no relaxation or even contraction on isolated preparations of 
arteries in vitro. The explanation was that established procedures for preparing 
arteries for tension recording usually led to the endothelium being rubbed off.
1.4.2. Detection of EDRF Release
EDRF released from donor tissues e.g. a rabbit aortic strip or ring with intact 
endothelium (Furchgott, 1984) or bovine cultured aortic endothelial cells (Cocks, et 
al., 1985) has been detected by an assay tissue e.g. a rabbit endothelium-denuded 
aortic strip in a "sandwich” bioassay (Furchgott, 1984), and a rabbit endothelium- 
denuded coronary artery perfusion cascade (Griffith, et al., 1984). These 
experiments demonstrated the humoral nature of EDRF.
1.4.3. Stability
It was only possible to analyse the stability of EDRF following its successful 
detection using a cascade bioassay system. By the use of this technique, it was 
established that EDRF is a very short-lived substance with a half-life of only about 
3 to 50 seconds in oxygenated physiological salt solutions (Griffith, et al., 1984; 
Forstermann, etal., 1984; Cocks, etal., 1985).
1.4.4. Endothelium-Dependent Relaxation
EDRF is a powerful vascular smooth muscle relaxant. It can be released from 
vascular endothelial cells of arteries, veins and microvessels following stimulation 
with acetylcholine, bradykinin, substance P and some related peptides, ATP and 
ADP, histamine, serotonin, thrombin, arachidonic acid and the calcium ionophore 
A23187 (Furchgott & Zawadzki, 1980; Furchgott, 1981; 1984; Altura & Chand, 
1981; Chand & Altura, 1981), although differences exist in the responsiveness of
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different species and blood vessels. Some other stimuli such as hypoxia, increased 
flow and electrical stimulation also cause EDRF-induced relaxation in vitro 
(Moncada, et al., 1991). These initial observations led to the recognition that 
vasodilators could be classified into two groups, those that act via the endothelium 
and those such as nitrovasodilators and calcium channel blockers that do not require 
endothelial cells to produce their effect (Furchgott, 1984). Cross-tolerance occurs 
among endothelium-dependent relaxants but this tolerance does not affect 
endothelium-independent relaxants (Gold, et al., 1989). After removal of the 
endothelial cells, the vasoconstrictive actions of noradrenaline and serotonin are 
significantly more powerful (Cocks & Angus, 1983), indicating that under normal 
circumstances contraction is depressed due to release of EDRF by these agonists. In 
addition to relaxing smooth muscle, EDRF also inhibits platelet aggregation and 
adhesion to vascular endothelium (Azuma, et al., 1986; Radomski, et al., 1987a; 
1987b; 1987c).
The action of EDRF, like that of the NANC transmitter, is mediated through 
stimulation of soluble guanylate cyclase and consequent elevation of cyclic GMP 
levels within smooth muscle (Diamond & Chu 1983; Furchgott & Jothianandon 
1983; Rapoport & Murad 1983a; 1983b).
The selective inhibitor of cyclic GMP phosphodiesterase M & B 22948 potentiates 
effects of EDRF (Martin, et al., 1986), and superoxide dismutase can prolong 
relaxation of a bioassay tissue induced by EDRF released from a donor tissue 
(Gryglewski, et al., 1986; Rubanyi & Vanhoutte, 1986). Cytochrome C and 
superoxide dismutase potentiate the activity of EDRF by scavenging superoxide 
anions (Moncada, etal., 1986).
Drugs and experimental conditions which inhibit endothelium-dependent relaxation 
include anoxia (De Mey & Vanhoutte, 1983), methylene blue which inhibits soluble
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guanylate cyclase, haemoglobin which efficiently binds EDRF (Martin, et al., 
1985), quinacrine which inhibits phospholipase A2  (Furchgott, et al., 1982; 1983; 
Singer & Peach, 1983), ETYA (5,8,11,14-eicosatetraynoic acid) which inhibits 
lipoxygenase and cyclooxygenase (Furchgott & Zawadzki, 1980), BPB (p- 
bromophenacylbromide) and NDGA (nordihydroguiaretic acid) which inhibit 
lipoxygenase and act as antioxidants (Furchgott, et al., 1982; 1983), Fe^+ 
(Gryglewski, et al., 1986), hyperoxia (Rubanyi & Vanhoutte, 1986), and a number 
of antioxidants including borohydride, hydroquinone and dithiothreitol (Griffiths, et 
a l , 1984;).
1.4.5. Identification as Nitric Oxide
Chemical identification of EDRF was difficult and some early research suggested 
that EDRF might be a product of arachidonic acid metabolism via lipoxygenase ( 
Singer & Peach, 1983a; Forstermann & Neufang, 1984) or the cytochrome P-450 
enzyme system (Pinto, et al., 1985; MacDonald, et al., 1986), or alternatively, a 
compound with a carbonyl group near its active centre (Griffith, et al. , 1984). 
Based on the similar pharmacological properties of EDRF and nitric oxide, 
Furchgott in 1986 suggested that EDRF might be nitric oxide (Furchgott, 1988). At 
the same meeting, Ignarro et al. (1988) also speculated that EDRF might be nitric 
oxide or a related substance.
Nitric oxide can be directly measured as a chemiluminescent product of its reaction 
with ozone (Downes, et al., 1976). Using this technique, nitric oxide was detected 
in the fluid perfusing cultured porcine aortic endothelial cells following stimulation 
by bradykinin at concentrations that induce EDRF release (Palmer, et al., 1987). 
Furthermore, the amounts of nitric oxide released by the cells were sufficient to 
account for relaxation of vascular strips.
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The identification of EDRF as nitric oxide was further supported by their 
indistinguishable biological actions on vascular (Palmer, et al., 1987; Gillespie & 
Sheng, 1988) and non-vascular smooth muscles (Gillespie & Sheng, 1988), and on 
platelets (Radomski, et al., 1987b). They decay at the same rate during passage 
down a bioassay cascade (Palmer, et al., 1987), their actions on vascular strips and 
on platelets are similarly potentiated by superoxide dismutase (SOD) and 
cytochrome C and inhibited by Fe^+ and some redox compounds including 
pyrogallol and hydroquinone which generate superoxide anion (Palmer, et al., 
1987; Hutchinson, et al., 1987; Radomski, et al., 1987b). The actions of these 
redox compounds as inhibitors of EDRF-induced and nitric oxide-induced vascular 
relaxation are attenuated by SOD to a similar extent.
1.4.6. Controversy of Nitric Oxide as EDRF
Although very strong evidence supports nitric oxide as EDRF, other studies have 
shown differences between nitric oxide and EDRF. The half-life of EDRF is 
variable from 3 to 50 seconds (Griffith, et al., 1984; Forstermann, et al., 1984; 
Rubanyi, et al., 1985; Cocks, et al., 1985; Gryglewski, et al., 1986). However, 
this variation might be explained, as in the case of nitric oxide, in terms of 
differences in oxygen tension and superoxide anion concentrations in the 
experimental conditions in different laboratories. Early reports that EDRF generated 
from endothelium only relaxed vascular smooth muscle whereas exogenous nitric 
oxide relaxed vascular, tracheal and taenia coli smooth muscles might be due to the 
low concentrations of EDRF generated (Shikano & Berkowitz, 1987; Dusting, et 
al., 1988a), since tracheal and taenia coli smooth muscle is less sensitive to nitric 
oxide and EDRF than vascular smooth muscle (Dusting, et al., 1988b; Gillespie & 
Sheng, 1988). Moreover, EDRF and nitric oxide have been clearly shown to 
produce relaxation in vascular and non-vascular smooth muscle preparations in a 
bioassay system (Gillespie & Sheng, 1988; Angus & Cocks, 1989; Buga, et al.,
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1989; Furchgott, et al., 1990). Activity of EDRF was lost following application to 
an anion exchange column (Cocks, et al., 1985; Long, et al., 1987), whereas that 
of nitric oxide was not (Long, et al., 1987) or was lost to a less extent (Khan & 
Furchgott, 1987). In these experiments the loss could have been non-specific since 
no group was ever able to subsequently elute EDRF from a column. The 
stabilisation of EDRF but not nitric oxide by acidification (Murray, et al., 1986) 
might be explained by EDRF being a nitric oxide-releasing molecule rather than 
nitric oxide itself. Recently, Myers et al. (1990) suggested that EDRF is much more 
likely to be a nitrosylated compound, such as a nitrosothiol i.e. S-nitrosocysteine, 
than authentic nitric oxide. Indeed, a comparison of properties of nitric oxide, S- 
nitrosothiols and the NANC transmitter was a major objective of my studies.
1.5. Nitric Oxide
1.5.1. Physical and Chemical Properties and Metabolism
Nitric oxide is a colourless neutral and lipophilic gas and thus readily permeates 
through biological membrane. Its taste and odour are not known. Its melting and 
boiling points are -163.6°C and -151.8°C, respectively (Hammond, 1966), so that 
it is difficult to liquefy. It is only very slightly soluble in water, 7.3 ml at 0°C and 
2.4 ml at 60°C in 100 ml of water. It contains an odd number of electrons and is 
therefore paramagnetic and a free radical, but behaves very different from other 
molecules having an odd number of electrons. In particular it has a slight tendency 
to dimerize in the gaseous state or in solution and has relatively low chemical 
reactivity when compared to other free radicals (Cotton & Wilkinson, 1972). Its 
reactivity with other substances is very high since it is a free radical. It is 
thermodynamically unstable at 25°C and 1 atm. At high pressures it readily 
decomposes:
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3N0 -> N2 O + NO2
Because nitric oxide is both a Lewis acid and Lewis base, it can undergo numerous 
reactions even under biological conditions. Since nitric oxide, in an intermediate 
oxidation state, can donate and receive electrons, it behaves both as an oxidant and 
a reductant. Some of the important chemical reactions involving nitric oxide are 
discussed below (Committee on Medical and Biological Effects of Environmental 
Pollutants, 1977; Moody, 1991):
1.5.1.1. Reactivity with oxygen
The overall reaction of nitric oxide and oxygen is (Committee on Medical and 
Biological Effects of Environmental Pollutants, 1977; Olbergts, 1985):
2NO + O2  —> 2NC>2
with the intermediate steps:
NO + O2  O-O-N-O 
O-O-N-O + NO -> 2N02
although no direct evidence supports the existence of the hypothetical transient 
species, O-O-N-O. The rate of nitrogen dioxide formation in the above reaction is 
given by the following third-order rate equation:
4NC>2]= 2£[NO]2[C>2]<*
i.e. the reaction is second order with respect to nitric oxide and first order with 
respect to oxygen. The reaction can take place in the gas phase or the liquid phase,
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but the rate is much higher by a factor of about 4,000 in aqueous solution 
(Pogrebnaya, et al. , 1975). The dependence on the square of the nitric oxide 
concentration results in a marked change in the rate of the reaction with changes in 
the nitric oxide concentration. Thus, at low concentrations of nitric oxide the 
reaction is slow, but at higher concentrations it is much more rapid.
Nitrogen dioxide, which exists in equilibration with its dimeric form, dinitrogen 
tetroxide (N2 O4 ), dissolves in water to form a mixture of nitric acid and nitrous 
acid, of which the latter undergoes further decomposition, eventually forming nitric 
acid (Cotton & Wilkinson, 1972; Moody, 1991):
2 NC>2 + H2 O -> HNO3  + HNO2  
3HN02 -> HNO3  +  2NO + H2 O
However, nitrogen dioxide dissolves in alkaline solutions to yield a mixture of 
nitrite and nitrate (Keilin & Hartree, 1937; Kelm, et al., 1988):
2N02 +  20H- -> NC>2 “ + NO3 - +  H2 O
The inactivation of nitric oxide in oxygenated physiological salt solutions can be 
accounted for by spontaneous oxidation of nitric oxide to nitrite. In these salt 
solutions at least 90% of nitric oxide is converted to nitrite with little or no 
formation of nitrate (Feelisch, et al., 1987; Kelm, et al., 1988).
I.5.I.2. Reactivity with superoxide anion (02")
Nitric oxide reacts with superoxide anion to form the unstable intermediate 
peroxonitrite anion ("OONO), which rearranges to yield nitrate (NO3 ", Blough & 
Zafiriou, 1985):
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NO + O2 " -> "OONO -> NO3 -
This reaction represents one of only a few known examples of a radical-radical 
coupling of superoxide anion with another odd-electron species to generate a 
diamagnetic product.
Superoxide anion can rapidly and nearly completely destroy nitric oxide 
(Gryglewski, et al. , 1986; Moncada, et al., 1986; Rubanyi & Vanhoutte, 1986; 
Ignarro, et al. , 1988) and superoxide dismutase protects nitric oxide by destroying 
superoxide anion (Gryglewski, et al., 1986; Rubanyi & Vanhoutte, 1986; Ignarro, 
etal., 1988).
1.5.1.3 . Reactivity with ozone (O3)
Nitric oxide reacts rapidly with ozone to yield an activated or high-energy state 
nitrogen dioxide. The excited nitrogen dioxide is of sufficient energy to dissociate to 
ground state nitrogen dioxide in association with the generation of light which can 
be detected by chemiluminescence (Fontijn, et al., 1970; Zafiriou & McFarland,
1980):
NO + O3  -» NO2  (excited) + O2  
NO2  (excited) —» NO2  +  hv
These principles have been applied to the measurement of nitric oxide in biological 
systems (Palmer, etal., 1987)
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1.5.1.4. Reactivity with oxyhaemoglobin
Nitric oxide reacts with oxyhaemoglobin to yield methaemoglobin and inorganic 
nitrate in association with the characteristic spectral changes from oxyhaemoglobin 
to methaemoglobin. This is the principle supporting a spectrophotometric 
measurement of nitric oxide using oxyhaemoglobin (Kelm, et al., 1988). The 
overall reaction is:
HbC>2 +  NO -» metHb +  NO3 "
The intermediate reactions are:
Hb3 + 0 2 '  +  NO -> metHb +  ‘OONO
and
"OONO -> NO3 -
Oxygen binds as superoxide anion to the haeme iron atom of haemoglobin (Wallace, 
et al., 1974), and this species reacts rapidly with nitric oxide to yield the 
peroxonitrite anion, which rapidly isomerizes to nitrate (Blough & Zafiriou, 1985).
1.5.1.5. Reactivity with haeme iron
Nitric oxide reacts with haeme iron (Fe^+) to yield nitrosyl-haeme adducts (Keilin 
& Hartree, 1937; Kon, 1968; Gibson & Roughton, 1957). Reduced iron (Fe2+), 
complexed with protoporphyrin IX to form haeme, has a high binding affinity for 
and reactivity with nitric oxide and this is also true for haemoproteins. The biding 
affinity of haemoproteins is about 1,500 times higher for nitric oxide than for
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carbon monoxide (Gibson & Roughton, 1957) and about 200 times higher for 
carbon monoxide than for oxygen (Giardina & Amiconi, 1981). Therefore, 
haemoproteins such as haemoglobin, myoglobin, and soluble guanylate cyclase react 
readily with nitric oxide to form the corresponding paramagnetic nitrosyl-haeme 
(NO-haeme) adduct. This explains why haemoglobin and myoglobin can block 
actions of nitric oxide. This reaction can take place in vivo and leads to the 
formation of relatively large amounts of nitrosyl haemoproteins in animals treated 
with nitric oxide or carcinogen (Woolin & Commoner, 1970; Oda, et al., 1975; 
Case, et al., 1979). Solutions of reduced haemoproteins, oxidised haemoproteins, 
and nitrosyl-haemoproteins are dark red, brown, and bright pink-red, respectively. 
The spectral characteristic changes from reduced or oxidised haemoproteins to 
nitrosyl haemoproteins have been applied in the spectrophotometric measurement of 
nitric oxide (Ignarro, et al., 1987b). The pink-red colour of nitrosyl haemoproteins 
has been applied in the meat industry where the colour of freshly cut meat has been 
preserved by adding sodium nitrite and ascorbic acid to react with myoglobin to 
yield pink-red nitrosyl myoglobin. In addition, nitric oxide, like carbon monoxide, 
can form complexes with transition metals unassociated with haeme, such as in 
femcyanide, and with non-haeme-iron-containing proteins such as lipoxygenase 
(Galpin, etal., 1978).
1.5.1.6. Reactivity with thiols
Nitric oxide reacts with thiols (R-SH) to form S-nitrosothiols (R-SNO). Details of 
these reactions will be discussed in a separate section.
1.5.1.7. Some other reactions
Nitric oxide is also involved in numerous N-nitrosating reactions even in 
mammalian cells (Marietta, 1988). One of the well-known examples is the
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formation of AT-nitrosomorpholine from morpholine by cytotoxic murine 
macrophages activated by lipopolysaccharide and interferon y, in which nitric oxide, 
nitrite and nitrate are the reaction products. Since some iV-nitrosamines are well- 
known carcinogenic agents, N-nitrosating reactions have been extensively studied 
(for reviews, Ridd, 1961; Mirvish, 1975; Challis, 1981). Moreover, nitric oxide 
reacts with sulfanilic acid at acid pH to yield a diazo product which can be further 
coupled with N-( 1 -naphthyl)ethylenediamide to form an intense chromophore. This 
is the well-known diazo or Griess reaction for the measurement of nitric oxide and 
inorganic nitrite spectrometrically (Ignarro, et al., 1987).
I.5 .I.8 . Half-life
The fate of nitric oxide depends mainly on its diffusion and reactions with other 
substances. The half-life of nitric oxide was reported to be 3 to 5 seconds at 
concentrations of 10-50 nM, but about 30 seconds or more at concentrations in 
excess of 300 nM (Ignarro, 1990). Under experimental conditions, the biological 
half-life of endothelium-derived nitric oxide is roughly about 3 to 5 seconds, which 
is identical to that of authentic nitric oxide at concentrations of 10 to 50 nM 
(Palmer, et al., 1987; Ignarro, et al., 1987). However, it has been observed that 
cultured endothelial cells, bovine pulmonary artery and human umbilical vein can 
produce large amounts of nitric oxide with a half-life in excess of 30 seconds 
(Ignarro, 1990).
Other factors could affect the biological half-life of nitric oxide. The haemoproteins 
could act as a sink for nitric oxide and rapidly bind it because of their extremely 
highly binding potency (Gibson & Roughton, 1957). Cellular oxidative systems 
could also facilitate the inactivation of nitric oxide. On the other hand, nitric oxide 
could be protected by nitric oxide-stabilising substances such as L-cysteine. It is
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difficult to determine the biological half-life in vivo since it is very difficult to 
measure nitric oxide due to its labile nature and low concentrations.
1.5.2. Synthesis
1.5.2.1. Chemical synthesis
Nitric oxide can be synthesised in numerous chemical reactions which are most 
unlikely to take place in biological systems. Two of the most common reactions are 
(Cotton & Wilkinson, 1972):
Fe2+ +  NC>2 " +  2H+ -» Fe3+ +  NO +  H2 O
and
2N02' +  21- +  4H+ -> 2NO + I2 + 2 H2 O
1.5.2.2. Biosynthesis
Enzymatic formation of nitric oxide could occur in biological systems. Some 
enzymatic reactions known to generate nitric oxide involve azide anion (N3 “), 
hydroxylamine (NH2 OH), hydrazine (NH2 NH2 ), and L-arginine as substrates. 
Azide anion and hydroxylamine undergo nitrogen oxidation to nitric oxide in a 
complex enzymatic reaction catalysed by catalase (Keilin & Harttee, 1954; Nicholls, 
1964). A similar reaction with hydrazine requires addition of a peroxide.
The enzymatic formation of nitric oxide plus L-citrulline from L-arginine in a 
reaction catalysed by nitric oxide synthase has been discovered in the last several 
years (Hibbs, et al., 1988; Palmer, et al., 1988a; Moncada & Palmer, 1990). Prior
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to-the discovery that vascular endothelial cells can synthesise nitric oxide (Palmer, 
et al., 1988a), Stuehr and Marietta (1985) reported that murine macrophages 
synthesise nitrite and nitrate in response to Escherichia coli lipopolysaccharide. 
They further extended these observations to the activation of macrophages by 
Mycobacterium bovis BCG infection, lymphokines, or gamma interferon (Stuehr & 
Marietta, 1987). Although in these studies nitric oxide was not implicated even as a 
possible labile intermediate precursor of nitrite and nitrate, the same group did 
report an unrecognised clue that activated murine macrophages catalyse the 
nitrosation of amines (Miwa, et al., 1987). At that time it was known that at neutral 
pH nitric oxide was a more powerful nitrosating species than nitrite and nitrate.
Soon afterwards, an L-arginine-dependent biochemical pathway was identified as 
the source of nitrite and L-citrulline in cultured macrophages (Hibbs, et al., 1987a). 
This pathway was inhibited by A^-monomethyl-L-arginine, a close structural 
analogue of L-arginine. The structural analogues of L-arginine, N^N^-dimethyl-L- 
arginine (asymmetrical) and N^N^-dimethyl-L-arginine (symmetrical), were also 
found to block the formation of nitrite and L-citrulline, an effect competitively 
reversed by L-arginine (Hibbs, et al., 1987b). Furthermore, another report showed 
that L-arginine was necessary for the formation of nitrite, nitrate and nitrosamines 
by cytotoxic activated murine macrophages (Iyengar, et al., 1987). Employing gas 
chromatography-mass spectrometry and L-^waraV/o-l^N] arginine-loaded
macrophages, it was established that the nitrogen of nitrite, nitrate and the nitroso 
moiety of N-nitrosamines was derived exclusively from one of the terminal 
guanidino nitrogens of L-arginine.
Nitric oxide was subsequently established to be the L-arginine-derived intermediate 
of nitrite and nitrate production by macrophages using a similar mass spectrometric 
technique (Iyengar, et a l , 1987). A study using ^ 0 2  and mass spectrometry 
showed that molecular oxygen is incorporated into both nitric oxide and L-citrulline
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(Leone, et a l ,  1991). By applying a radiochemical technique involving 
[^H]arginine coupled with mass spectrometry, L-citrulline was confirmed to be a 
product derived from L-arginine in endothelial cells (Moncada & Palmer, 1990). 
This formation was specific since the metabolism of L-arginine was competitively 
blocked by A^-monomethyl-L-arginine but not its D-isomer (Palmer, et al., 1988). 
Further, endothelium-dependent relaxation is also inhibited by other L- but not D- 
analogues of L-arginine, an effect competitively reversed by L- but not D-arginine 
(Sakuma, et a l ,  1988; Schmidt, et a l ,  1988a; 1988b; Gold, et a l  1989). These 
inhibitors include A/^-nitro-L-arginine (L-NOARG), its methyl ester L-NAME, and 
A^Mminoethyl-L-arginine, and their actions resemble those of L-NMMA in 
vascular tissue in vitro and in vivo (Moore, et a l ,  1989; Ishii, et a l ,  1990; Mulsch 
& Busse, 1990; Rees, et a l ,  1990). Interestingly, dimethylarginine
(asymmetrical dimethylarginine, ADMA) and L-NMMA are both found in human 
urine and plasma (Kakimoto & Akazawa, 1970; Park, et a l ,  1988), and both 
inhibit nitric oxide formation (Vallance, et a l ,  1992).
Further evidence showing the critical role for L-arginine is that cultured bovine 
endothelial cells grown in its absence fail to produce nitric oxide in response to 
bradykinin or A23187, an effect reversed by restoring L- but not D-arginine 
(Palmer, et a l ,  1988a). The associated L-arginine-dependent increase of cGMP was 
accompanied by the formation of L-citrulline from L-arginine in the vessel wall 
(Moncada & Palmer, 1990). This L-arginine-nitric oxide pathway is NADPH- and 
calcium/calmodulin-dependent (Mayer, et a l ,  1989; Busse & Mulsch, 1990; 
Moncada & Palmer, 1990; Mulsch, et a l , 1989).
Biochemical evidence supports the existence of an enzyme system responsible for 
the nitric oxide formation from L-arginine. The simultaneous formation of nitric 
oxide and L-citrulline is catalysed by the soluble fraction from cytotoxic activated 
macrophages (Marietta, et a l ,  1988). Subsequently, Palmer & Moncada (1989)
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reported that a novel L-citrulline-forming enzyme activity was found in the cytosolic 
fraction of vascular endothelial cells, although the concomitant formation of nitric 
oxide was not demonstrated in the same reaction mixture. This nitric oxide-forming 
enzyme was termed nitric oxide synthase (Moncada & Palmer, 1990).
Nitric oxide synthase has been purified from brain (Bredt & Snyder, 1990) and 
vascular endothelial cells (Pollock, et al., 1991). The purified enzyme is 
phosphorylated by cAMP-dependent protein kinase, protein kinase C (PKC) and 
calcium/calmodulin-dependent protein kinase II (Bredt, et al., 1992). The regulation 
by PKC phosphorylation provides a potential "cross-talk" mechanism with another 
messenger system. Molecular cloning has revealed its structural similarity with 
cytochrome P-450 reductase, particularly in its C-terminal portion, and with 
bacterial sulphite reductase (Bredt, et al., 1991b). The enzyme has an a  helical, 
calmodulin-binding consensus sequence, a cAMP-dependent protein kinase 
phosphorylation sequence, and well-defined sites for binding of nicotinamide 
adenine dinucleotide phosphate (NADPH), flavin mononucleotide (FMN) and flavin 
adenine dinucleotide (FAD). The purified enzyme from brain migrates as a single 
150 kDa band on electrophoresis and appears to be a monomer (Bredt, et al., 
1991b). The nitric oxide synthase in macrophage has substantial homology with the 
enzyme in brain (Bredt & Snyder, 1992). It has been suggested that the previously 
reported NADPH-dependent monoxygenase in brain is in fact identical to nitric 
oxide synthase (Hibbs, et al., 1988; Marietta, et al., 1988), since nitric oxide 
synthase containing neurones co-localise with the staining for NADPH diaphorase 
(NDP, Bredt, et al., 1991a; Dawson, et al., 1991). Furthermore, nitric oxide 
synthase activity fully accounts for all NDP catalytic staining in experiments using 
cloned and expressed nitric oxide synthase (Dawson, et al., 1991).
Generally there are two types of nitric oxide synthase, the constitutive nitric oxide 
synthase and the inducible nitric oxide synthase. Both are very similar. They use L-
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arginine as their substrate, form nitric oxide with L-citrulline stoichiometrically, 
require NADPH as an electron donor and contain one molecule each of FAD and 
FMN probably forming an electron transport chain in each enzyme (Bredt, et al., 
1991b; Stuehr, et al., 1991). However, i t  should be noted that L-citrulline 
formation should not be necessarily equated with nitric oxide synthase activity. For 
example, an enzymatic activity exists in the rat kidney 1 0 ,0 0 0  x g supernatant 
fraction which catalyses the direct conversion of A ^ A ^ -d im e th y l-L -a rg in in e  or 
A/G-monomethyl-L-arginine to L-citrulline plus dimethylamine and methylamine, 
respectively, without concomitant formation of nitric oxide (Ogawa, et al., 1987). 
This citrulline-forming enzyme is not nitric oxide synthase.
The constitutive enzyme in endothelium is mainly membrane-bound ( Boje & Fung, 
1990; Forstermann, et al., 1991; Mitchell, et al., 1991), although it was initially 
reported to be cytosolic ( Palmer & Moncada, 1989; Mulsch, et al., 1989). In the 
brain, however, this enzyme is cytosolic (Schmidt, et al., 1989). Formation of 
nitric oxide by the constitutive enzyme is found in the vascular endothelium (Mayer, 
et al., 1989; Mulsch, et al., 1989; Palmer & Moncada, 1989), the blood platelet 
(Radomski, et al., 1990), the CNS (Bredt & Snyder, 1990; Knowles, et al., 1990), 
the peripheral nervous system (Gillespie & Xiaorong, 1989; Gillespie, et al., 1989; 
Gibson, et al., 1989; 1990; Li & Rand, 1989), the adrenal gland (Palacios, et al.,
1989) , endocardial cells (Schulz, et al., 1991), megakaryoblastic cells (Lelchuk, et 
al., 1992), neuroblastoma cells (Ishii, et al., 1989), kidney epithelial cells 
(Schroder & Schror, 1989; Ishii, et al., 1989), mast cells (Salvemini, et al., 1990), 
mesangial cells (Schultz, et al., 1991) and the retina (Venturini, et al., 1991).
The inducible enzyme exists in the cytosolic fraction of macrophages (Marietta, et 
al., 1988). It is NADPH-dependent and was initially reported to be calcium- 
/calmodulin-independent. However, Nathan (1992) has shown that calmodulin is 
firmly bound to the inducible enzyme and is required for activity. L-Canavanine
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inhibits this enzymatic activity but not that of the constitutive enzyme (Iyengar, et 
al., 1987). Usually it is not detectable in cells (Stuehr & Marietta, 1985; 1987) but 
its expression is induced by lipopolysaccharide (LPS), y-interferon (IFN-y), tumour 
necrosis factor (TNF), granulocyte macrophage-colony stimulating factor (GNCSF) 
and interleukins (ILs)-l, 2 and 6 (Ding, et al., 1988; Drapier, et al., 1988; Wemer- 
Felmayer, et al., 1990; Beasley, et al., 1991; Denis, et al., 1991; Nussler, et al., 
1991; Schini, etal., 1991). Furthermore, its expression is inhibited by transforming 
growth factor P, platelet-derived growth factor and interleukins(ILs)-4, 8 and 10 
(Ding, et al., 1990; Liew, et al., 1991; Pfeilschifter & Vosbeck, 1991; McCall, et 
al., 1992; Schini, et al., 1992). Induction of this enzyme requires de novo protein 
synthesis (Marietta, et al., 1988), and is inhibited by glucocorticoids (Di Rosa, et 
al., 1990; Radomski, et al., 1990b; Rees, et al., 1990b). Induction of nitric oxide 
synthase has been found in macrophages (Hibbs, et al., 1988; Stuehr, et al., 1989), 
neutrophils (McCall, et al., 1991a; 1991b), vascular endothelial cells (Knowles, et 
al., 1990b; Radomski, et al., 1990b; Rees, et al., 1990b), vascular smooth muscle 
cells (Beasley, et al., 1991; Busse & Mulsch, 1990b; Knowles, et al., 1990; Rees, 
et al., 1990; Schini, et al., 1991), cardiac myocytes (Schulz, et al., 1992), Kupffer 
cells (Billiar, et al., 1989), hepatocytes (Curran, et al., 1989), tumour cells 
(Amber, et al., 1988; Radomski, et al., 1991; Wemer-Felmayer, et al., 1992), 
megakaryoblastic cells (Lelchuk, et al., 1992), fibroblasts (Wemer-Felmayer, et 
al., 1990), chondrocytes (Stadler, et al., 1992), mesangial cells (Marsden & 
Ballerman, 1990; Pfeischifter & Schwarzenbach, 1990; Shultz, et al., 1991), the 
liver (Knowles, et al., 1990c), and lung (Knowles, et al., 1990c).
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1.5.3. Nitric Oxide in the Nerve System
1.5.3.1. The Central Nervous System
Early evidence implying the involvement of nitric oxide in the CNS is that nitric 
oxide stimulates soluble guanylate cyclase in the homogenates of mouse cerebral 
cortex (Miki, et al., 1977). Moreover, the soluble fraction of rat forebrain contains 
a low molecular weight substance which activates soluble guanylate cyclase and 
whose action is blocked by haemoglobin (Deguchi, 1977). L-Arginine was 
subsequently identified as the endogenous activator of the soluble guanylate cyclase 
in brain (Deguchi & Yoshioka, 1982).
A-Methyl-D-aspartate (NMDA), a glutamate receptor agonist, stimulates rat 
cerebral cells and induces an increase in cGMP levels in association with the release 
of an EDRF-like substance (Garthwaite, et al., 1988). The cGMP elevation in 
response to NMDA stimulation is enhanced by L-arginine and inhibited by L- 
NMMA (Bredt & Snyder, 1989; Garthwaite, et al., 1989). Moreover, addition of 
L-arginine to rat synaptosomal cytosol in the presence of NADPH induces the 
formation of nitric oxide and L-citrulline by acting as a substrate for nitric oxide 
synthase (Knowles, et al, 1989).
Using antibodies raised against nitric oxide synthase purified from cerebellum, the 
enzyme was immunohistochemically localised exclusively in neurones (Bredt, et al., 
1990). Within the brain, no glia were stained. The highest densities of nitric oxide 
synthase were found in the cerebellum, olfactory bulb and the accessory olfactory 
bulb. This enzyme occurs mainly in processes of granule cells. It is also highly 
concentrated in basket cells but is absent from the Purkinje cells of the cerebellum.
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The demonstration of long-term depression by exogenous nitric oxide or cGMP in 
the rat cerebral slices suggests the involvement of L-arginine: nitric oxide system in 
motor learning (Shibuki & Okada, 1991). Moreover, the neurotoxicity mediated by 
NMD A in vitro (Dawson, et al., 1991) and in vivo (Mollace, et al., 1991) is 
diminished by nitric oxide synthase inhibitors and potentiated by L-arginine. Nitric 
oxide is therefore involved in a number of fundamental process within the CNS.
1.5.3.2 The Peripheral Autonomic Nervous System
Experimental evidence has been accumulating to suggest that nitric oxide is also 
involved in the peripheral autonomic nervous system. Following the discovery that 
nitric oxide could account for the activity of EDRF (Palmer, et al., 1987), we 
began to examine the possibility that it was also the NANC transmitter in the BRP. 
Initially we attempted to deplete BRP of L-arginine by applying continuous 
electrical field stimulation but no decline in relaxation was observed with time. We 
also stored BRP in the cold and although a decline in NANC relaxation was 
observed it was not reversed by addition of L-arginine and was probably due to 
denervation (Gillespie & Xiaorong, 1989). The involvement of nitric oxide in the 
NANC nerves was first revealed by ability of L-NMMA and N^-nitro-L-arginine to 
block NANC relaxation in the anococcygeus of the rat and mouse, and the retractor 
penis of the bull (Gillespie & Xiaorong, 1989; Gillespie, et al., 1989; 1990; 
Gibson, et al., 1989; 1990; Li & Rand, 1989;). Gradually, similar abilities to block 
NANC relaxation were reported in various tissues including [ guinea-pig trachea (Tucker, 
et al., 1990; Li & Rand, 1991), rat gastric fundus (Li & Rand , 1990), canine 
lower oesophageal sphincter (Man, et al., 1991; Tottrup, et al., 1991), canine 
ileocolonic junction (Bult, et al., 1990), guinea-pig taenia coli (Gustafsson, et al.,
1990), canine proximal colon (Dalziel, et al., 1991), dog (Toda & Okamura, 
1990a), monkey (Toda & Okamura, 1990b) and porcine (Chen & Lee, 1990) 
cerebral artery and human (Holmquist, et al., 1991; Goessel, et al., 1992) and
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rabbit corpus cavemosum (Ignarro, et al., 1990; Goessel, et al., 1992). The nitric 
oxide synthase inhibitors, L-NMMA and L-NOARG, act prejunctionally in blocking 
the NANC relaxation since they do not affect relaxation to exogenously applied 
nitric oxide or nitrovasodilators (Gillespie, et al., 1989; Liu, et al., 1991). Another 
effect of the inhibitors of nitric oxide synthase in the anococcygeus of the rat is a 
modest rise in tissue tone, suggesting that there is a basal release of nitric oxide 
from the nerves in the absence of stimulation.
Bult et al. (1990) have reported that electrical field stimulation of the NANC nerves 
in the canine ileocolonic junction induces the release of a factor whose biological 
actions, chemical instability, inactivation by superoxide anion and haemoglobin, 
inhibition by L-NOARG, and potentiation by L-arginine all suggest it to be nitric 
oxide. Moreover, an enzyme isolated from the soluble fraction of the homogenised 
BRP catalyses formation of nitric oxide and L-citrulline from L-arginine (Sheng, et 
al. , 1992) and is believed to be the nitric oxide synthase from the NANC inhibitory 
nerves.
The above evidence clearly demonstrated the involvement of nitric oxide in NANC 
neurotransmission. However, authentic nitric oxide is a highly lipophilic gas that 
could readily diffuse through lipid membranes. It could not fulfil one of the 
conventional requirements of any neurotransmitter i.e. that it is present in storage 
vesicles in nerve fibres. Furthermore, the superoxide anion generators, pyrogallol 
and hydroquinone, destroy the relaxant activity of nitric oxide in a superoxide 
dismutase-reversible manner, but have no effects on the NANC relaxation induced 
by nerve stimulation (Gillespie & Sheng, 1990). Nitric oxide, therefore, may be 
reversibly bound by a stabilising substance. The aim of this study was to identify 
the nature of this nitric oxide-containing transmitter.
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1.6. S-Nitrosothiols
Descriptions of the physical and chemical properties of S-nitrosothiols differ 
enormously, which might reflect a variety of different conditions employed in the 
preparation and handling of these compounds in different laboratories.
Most S-nitrosothiols (also termed thionitrites)are unstable in the solid form or in 
aqueous solution and spontaneously decompose to nitric oxide gas and 
corresponding disulphides, in a process reported to be enhanced by heat, light, 
oxygen, and alkaline pH (Ignarro, 1990; Feelisch, 1991):
2R-SNO -> R-SS-R +  2NO
S-Nitroso-iV-acetylpenicillamine (SNAP) is the only known exception, and is stable 
indefinitely as dry crystals at 0-5°C. The half-life of SNAP in aqueous solutions 
ranges from 4-5 hours in air at 37°C to 500 hours under nitrogen (Ignarro, et al. , 
1981; Bauer & Fung, 1991). One group has, however, reported that S- 
nitrosoglutathione is also unusually stable; after storage for 30 days in the solid state 
under air nearly no decomposition was seen at 4°C and 25% decay was seen at 
room temperature (Park & Means, 1989). In contrast, S-nitrosocysteine in the 
crystal state rapidly decomposes and cannot been stored (Ignarro, 1990; Myers, et 
al., 1990). When prepared in acidified methanol (1%[vol./vol.] 1N.HC1 in absolute 
methanol) at -20°C it is stable indefinitely (Ignarro, 1990). When present at high 
concentration in aqueous solution it has a half-life of 1.1 hours under air at 37°C 
and 15 minutes under oxygen at 37°C, whereas at concentrations less than 1 pM in 
dilute oxygenated aqueous solutions at 37°C it has a half-life of 30 seconds or less 
(Ignarro, 1990; Myers, et al., 1990). Others, however, have reported that the half- 
life of S-nitrosocysteine in aqueous solution to be between 60 minutes (Feelisch,
1991) and 7-10 days (Ignarro, et al., 1980). The chemical stability of S-nitroso
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derivatives of 2-mercaptoethylamine, 3-mercaptopropionic acid, penicillamine, 
dithiothreitol, glutathione, thioglucose, and A-acetylcysteine lies between that of 
SNAP and S-nitrosocysteine (Ignarro & Gruetter, 1980; Ignarro, et al. , 1980a; 
1980b; 1981). Ignarro (1990) explained that the relative chemical stability of SNAP 
is due to its A-acetyl group which structurally hinders its spontaneous decomposition 
to the corresponding disulphide. This explanation seems not to apply, however, in 
the case of S-nitroso-A-acetylcysteine since it is unstable in the crystalline state 
(Ignarro, et al., 1980b; Kowaluk & Fung, 1990).
S-Nitrosothiols have been reported to be readily formed by the reaction of thiols 
with nitric oxide (Ignarro, et al., 1981), nitrogen dioxide (Myers, et al., 1990), 
acidified nitrite (Saville, 1958), N-methyl-N'-nitro-N-nitrosoguanidine (Schultz, et 
al., 1977; Ignarro, et al., 1980a), nitroprusside (Ignarro, et al., 1981), and organic 
nitrate or nitrite esters (Ignarro, et al., 1981) under different reaction conditions. 
Two of the most commonly used reactions are:
1). R-SH + NO2 '  +  H + -> R-SNO +  H2 O
the intermediate reactions are:
NO2 " +  H + -> HNO2  
R-SH + HNO2  -> R-SNO + H2 O
and
2). R-SH + NO -» R-SNO + H +
However, the exact nature of the S-nitrosating species in these reactions remains a 
subject of much debate. For example, dinitrogen trioxide has been proposed in the
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case of acidified nitrite (Leaf, et al., 1990) and a higher oxide of nitrogen in the 
case of nitric oxide (Feelisch, 1991).
L-Cysteine has been proposed to directly react with nitric oxide under anaerobic 
conditions (Ignarro, et al., 1981) but this has been challenged by Feelisch (1991) 
who says that oxygen is mandatory. Also, L-cysteine has been reported to react with 
acidified nitrite indirectly, via generation of nitrous acid in aqueous solution 
(Saville, 1958). In each case the S-nitrosocysteine formed is a pink substance, 
which has been monitored by spectrophotometrically at 545 nm (Ignarro, et al., 
1981) and has two other absorption peaks at 335 nm and 210 nm (Feelisch, 1991; 
Myers, etal., 1990).
The pharmacology of S-nitrosothiols is indistinguishable from that of nitric oxide 
since they act by releasing nitric oxide. For example, they induce smooth muscle 
relaxation through activation of soluble guanylate cyclase and increases of cGMP 
levels (Ignarro & Gruetter, 1980; Ignarro, et al., 1980a; 1980b; 1981; Ignarro, 
1990; Myers, etal., 1990; Feelisch, 1991).
1.7. Common Properties of the NANC Transmitter, Inhibitory 
Factor, Endothelium-Derived Relaxing Factor, Nitric Oxide, and S- 
Nitrosothiols
The NANC inhibitory transmitter, IF, EDRF, nitric oxide and S-nitrosothiols share 
many properties (Gillespie, et a l ,  1990; Ignarro, 1990; Moncada, et al., 1991), 
typically acting through stimulation of soluble guanylate cyclase and increases of 
cGMP levels (Murad, et al., 1978; Rapoport & Murad, 1983b; Bowman & 
Drummond, 1984), in a manner potentiated by the phosphodiesterase inhibitor, 
M&B 22,948 (Bowman & Drummond, 1984), and superoxide dismutase, and 
inhibited by haemoglobin and methylene blue (Murad, et al., 1978; Bowman &
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Gillespie, 1982; 1983; Bowman, et al., 1982b; Bowman & Drummond, 1984; 
Bowman, etal., 1986; Martin, etal., 1985; Gibson & Mirazadeh, 1989).
1.8. Aim
The aim of this study was to identify the inhibitory non-adrenergic, non-cholinergic 
(NANC) neurotransmitter in the bovine retractor penis (BRP) muscle. The objective 
was to determine whether free nitric oxide, or S-nitrosothiol such as S- 
nitrosocysteine or S-nitrosoglutathione could be candidates.
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Chapter 2. MATERIALS AND METHODS
2.1. Preparation of Tissues and Tension Recording
2.1.1. Anatomy of BRP Muscle
The paired BRP muscles have their origin from the ventral surface of the first and 
second coccygeal vertebrae. From there the muscles run ventrally, one on either 
side of the colon, to pass the anal canal and proceed along the ventral surface of the 
bulbocavemosus muscle to the distal part of the penis where a broad insertion takes 
place. The paired muscles in the contracted state maintain the characteristic sigmoid 
flexure of the relaxed penis (Figure 1).
2.1.2. Preparation of BRP Strips
BRP muscles were obtained at Paisley Abattoir from bullocks of different breeds, 
weighing 200 to 1000 kg. The whole penis was removed at the level of the 
ischiocavemosus muscle and the bulbocavemosus muscle with the paired retractor 
penis muscles attached. The BRP muscles were dissected free from surrounding 
connective tissue and fat in the abattoir and only one of each pair was taken and 
transferred to the laboratory in a bottle containing freshly prepared Krebs' solution. 
The entire process from slaughter to preparation in the laboratory took place within 
1 hour. In the laboratory, the muscles were stored in Krebs' solution at 4 °C in a 
refrigerator until required. Muscles were used either immediately or after storage 
for periods up to 2 days. There was no indication that storage for up to 2 days 
adversely affected the responses of the tissue.
BRP muscles were pinned out on a glass Petri dish lined with Sylgard containing 
Krebs' solution. Any remaining connective sheath covering the muscles was
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ISCHIOCAVERN OSUS
MUSCLE PENIS
BULBOCAVERNOSUS RETRACTOR PENIS
MUSCLE MUSCLES
Figure 1. Schematic diagram of the contracted retractor penis muscles maintaining 
the relaxed penis of the bull with its characteristic sigmoid flexure.
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removed to expose the muscle fibre bundles. Parallel bundles of muscle fibres were 
selected and longitudinal strips, 15 mm in length and 1.5 mm in width, were cut. 
Both ends of each strip were tied with 5:0 braided silk. One end was kept short for 
tying the preparation to a hook in an organ bath, and the other was left long for 
connection to a Grass FT 03 C isometric tension transducer. Each preparation was 
suspended in a 20 ml organ bath containing Krebs' physiological saline at 37°C and 
gassed with 5 % CO2  and 95 % O2 . When responses to stimulation of intramural 
NANC nerve fibres were studied, one end of each strip was tied to a silver / silver 
chloride hook electrode and the muscle strip passed through a silver / silver chloride 
ring electrode embedded in Araldite (Bum & Rand, 1960) with the long thread tied 
to a Grass FT 03 C isometric tension transducer. Paired electrodes consisted of a 
ring electrode of a coil of 0.5 mm diameter silver wire, 4 mm in length and of 3 
mm inside diameter embedded in Araldite epoxy resin, and a hook electrode of 
silver wire was placed 4 mm directly below the coil. In experiments in which the 
responses to exogenous drugs were studied in the absence of nerve stimulation, the 
BRP strips were mounted on glass hooks.
In all experiments BRP muscle strips were set up initially with no applied tension 
and allowed to equilibrate for 30 minutes. They were then placed under 2 g resting 
tension by repeated stretching with the degree being controlled by the tension 
displayed on the recorder.
2.1.3. Preparation of Rabbit Aortic Rings
In many experiments, rabbit aortic rings were used as an alternative to BRP strips as 
they were roughly equal in sensitivity to nitric oxide and nitric oxide-releasing 
agents as BRP strips (Gillespie & Sheng, 1988), but their tone was more stable. 
New Zealand white rabbits, 2 to 3 kg of either sex, were killed by a lethal injection 
of pentobarbitone and exsanguination. The chest and abdomen was opened. The
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thoracic and abdominal aorta was carefully dissected and removed into Krebs' 
solution in a Petri dish. The aorta was cleared of adhering fat and connective tissue 
and cut into 2.5 mm wide transverse rings using a razor blade slicing device. 
Endothelial cells were removed from all rings by gently rubbing the luminal surface 
with moist filter paper. Rings were suspended under 2 g resting tension on stainless 
steel hooks in baths containing 20 ml of Krebs' solution at 37°C. Great care was 
taken during the whole procedure to avoid unnecessary stretch of the tissue. The 
rings were allowed to equilibrate for 60 to 90 minutes before experiments were 
begun. Removal of the endothelium was judged by the absence of relaxation to the 
endothelium-dependent relaxant, acetylcholine (0.1-lpM), against phenylephrine 
(0.3 pM)-induced tone.
2.1.4. Recording of Mechanical Responses
Mechanical responses of the BRP and rabbit aortic preparations were recorded 
isometrically by means of Grass isometric tension transducers (FT 03 C) and 
displayed on a six channel Grass Model 7D polygraph.
2.2. Experimental Conditions
2.2.1. Tone of the Preparations
When responses to stimulation of intramural NANC inhibitory nerve fibres in BRP 
muscle were to be studied, the adrenergic nerve blocking agent guanethidine (lOp 
M) was added to the preparations. Guanethidine is the most effective drug in 
uncovering the NANC inhibitory relaxation because it fulfils two major 
requirements: firstly, tone of the muscle must be raised and secondly the motor 
adrenergic responses must be blocked. In experiments in which responses to
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exogenous drugs were to be studied in the absence of nerve stimulation, tone of the 
BRP strips was raised by phenylephrine (0.3pM).
When rabbit aortic rings were used, phenylephrine (0.3pM) was used to raise tone 
of the preparations as it maintained a stable tone.
2.2.2. Field Stimulation
Field stimulation of intramural nerves in BRP strips was applied through the silver / 
silver chloride electrodes (Bum & Rand, 1960) with rectangular shocks of 0.5 
millisecond pulse width and supramaximal voltage. The pulses were simultaneously 
delivered from three Grass S8 8  stimulators with each channel controlling only one 
preparation. Where effects of drugs were examined on NANC responses to field 
stimulation, BRP muscle strips were stimulated with 20 pulses at 3 minute intervals. 
The frequency of the stimulation used was 2 Hz which is in the range of frequencies 
1-8 Hz to induce optimal NANC relaxation.
2.2.3. Krebs' Solution
The composition (mM) of the Krebs' solution used was based on that described by 
Krebs and Henseleit (1932):
NaCl 118.0 
MgS04  1.2 
Glucose 11.0
With the exception of glucose, each component was prepared as a concentrated 
stock solution with distilled water. When the stock solution of NaHCC>3 was made 
up, it was bubbled with CO2  gas (British Oxygen Company, UK) for 1 hour.
KC1 4.8 CaCl2  2.5
KH2 P 0 4  1.2 NaHC0 3  24.0
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Glucose in solid form was added once all other components had been added. The 
final Krebs' solution was bubbled with 5 % CO2  and 95 % O2  for 30 minutes 
before use.
2.2.4. Temperature
The Krebs' solution in organ baths and in the tubes delivering Krebs to the baths 
was maintained at 37°C by a water jacket heated by a thermostatically controlled 
pump (Techne Tempette Junior TE-8J).
2.3. Preparation of Nitric Oxide Solutions and Synthesis of S- 
Nitrosothiols
2.3.1. Purification of Nitric Oxide and Nitrogen
Before attempting to prepare aqueous solutions of nitric oxide, it was first necessary 
to deoxygenated distilled water. This was achieved by bubbling with commercially 
available "oxygen-free" nitrogen gas (British Oxygen Company). This was found, 
however, to contain trace amounts of oxygen which were sufficient to convert 
substantial amounts of nitric oxide to nitrogen dioxide. It was essential to remove 
this remaining oxygen from the "oxygen-free" nitrogen gas.
Commercially available nitric oxide gas in steel cylinders is at most 99.9% pure. 
The major impurities are higher oxides of nitrogen, particularly nitrogen dioxide 
(Committee on Medical and Biological Effects of Environmental Pollutants, 1977). 
Since these higher oxides of nitrogen are much more reactive and soluble than nitric 
oxide (Hammond, 1966; Cotton & Wilkinson, 1972), their presence in proposed 
experiments involving reactions of nitric oxide with amino acids such as L-cysteine
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and L-glutathione would greatly complicate matters (Hart, 1985; Hart, et al., 1985; 
Wink, etal., 1993).
Furthermore, in these early experiments variable smooth muscle relaxant activity 
was generated in different experiments despite controlling the reaction conditions 
such as concentrations of L-cysteine and nitric oxide, reaction pH, time and 
temperature. The magnitude of a peak in the HPLC associated with this relaxant 
activity was also variable. Clearly, some important variable was affecting the 
outcome of experiments despite our attempts to keep conditions identical. In these 
experiments commercially available oxygen-free nitrogen was used to deoxygenate 
L-cysteine solutions. Furthermore, nitric oxide from a cylinder was transferred by a 
sample-lock gas syringe into the L-cysteine solutions in a brown bottle sealed with a 
silicon stopper while surrounded by air. It was possible, therefore, that despite our 
best efforts, variable amounts of oxygen could gain entry to the reaction chamber 
and dramatically affect the outcome of the reaction.
In preliminary tests massive increases in the relaxant activity and in the height of the 
associated peak in the HPLC were observed if small amounts of oxygen (0.01 mM) 
were introduced into the mixture of L-cysteine (10 mM, pH 3) and nitric oxide (0.1 
mM). Therefore, it was essential in these experiments to purify nitric oxide gas in 
order to remove higher oxides of nitrogen and prevent contact with oxygen. More 
rigorous methods were developed to prevent introduction of oxygen and nitrogen 
dioxide during the reaction of L-cysteine with nitric oxide.
Removal of the remaining trace amounts of oxygen from commercial oxygen-free 
nitrogen (British Oxygen Company, UK) and nitrogen dioxide from nitric oxide 
(Air Products Ltd., UK) was performed by washing the gases with Fieser's solution 
and concentrated solutions (10%) of sodium hydroxide, respectively. Sodium 
hydroxide is an effective absorbent for nitrogen dioxide (Committee on Medical and
51
Materials and Methods
Biological Effects of Environmental Pollutants, 1977). Fieser's solution is an active 
absorbent to remove trace amounts of oxygen (Fieser & Fieser, 1967) and was 
prepared by dissolving 2 0  g of potassium hydroxide in 1 0 0  ml distilled water at 
35°C and adding 2 g of sodium anthraquinone-p-sulfonate and 15 g of sodium 
dithionite (Na2 S2 C>4 ). The mixture was stirred until a clear, blood-red solution was 
obtained and cooled to room temperature. The sulfonate anthrahydroquinone 
dianion absorbs oxygen with great speed and is continually regenerated by the 
dithionite. Since the reagent operates on a catalytic principle, the original efficiency 
is retained to the point of exhaustion of the dithionite. When the solution has lost its 
ability to absorb oxygen, this is indicated by a change in colour from bright blood- 
red to dull red or brown. This is also associated with the appearance of a 
precipitate. When prepared as above, the solution has the capacity to absorb 788 ml 
of oxygen.
Obviously, deoxygenation of L-cysteine solutions, introduction of nitric oxide gas 
and the removal of freely dissolved nitric oxide should be performed in a closed 
system. This system should also made with oxygen-impermeable materials. Keeping 
a positive pressure in this closed system was also considered essential during these 
procedures. Any remaining trace amounts of oxygen present in commercial 
"oxygen-free'1 nitrogen gas and trace of nitrogen dioxide in commercial nitric oxide 
gas should be removed prior to their introduction into the solutions. Such a system 
is illustrated in Figure 2. HPLC stainless steel capillary tubing was used to connect 
the gas cylinder to washing bottles by piercing them through silicon rubber 
stoppers. Polythene tubing was not used since it absorbs and reacts with nitrogen 
dioxide and is permeable to oxygen. The end of the fine stainless steel tubing was 
pierced through a silicon stopper in the Amicon chamber and then passed through a 
common dynamic needle (2 1  gauge) into the reaction chamber which was also 
sealed with a similar stopper. To minimise the introduction of air into the reaction 
chamber particularly when spectrophotometric studies were to be carried out, the
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1. Nitrogen cylinder 2. Nitric oxide cylinder 3. Fieser1 s solution
4. Lead acetate 5. Sodium hydroxide 6. Water
7. Reaction chamber 8. Amicon chamber 9. Water
Figure 2. Diagram of the closed system used to create rigorous oxygen- and 
nitrogen dioxide-free conditions in which aqueous solutions of L-cysteine or L- 
glutathione were gassed with purified nitrogen and nitric oxide. Arrows indicate the 
direction of gas flow.
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reaction of L-cysteine with nitric oxide was conducted in a quartz cuvette (UV- 
visible, 1.5 ml, Hellma, UK). This cuvette is sealed with a silicon stopper. A small 
needle was inserted through this stopper to vent the chamber contents and this too 
could be sealed when required. The nitric oxide and nitrogen gases entering the 
Amicon chamber could escape through a silicon rubber tube whose far end was 
submerged in water in a beaker. High vacuum silicon grease was used to seal all 
joints.
Nitric oxide gas in fine bubbles was washed in a sealed environment by slowly 
passing through a series of washing solutions ( all 1 0 0  ml); the first was a bottle of 
Fieser1 s solution to remove oxygen, the second was a bottle of sodium hydroxide 
(10%) to remove nitrogen dioxide and the last was a bottle of Milli-Q purified 
distilled deionised water to remove trace chemicals carried out from the other 
washing solutions. Oxygen-free nitrogen gas was purified in another sealed 
environment by passing through Fieser1 s solution to remove trace oxygen. Since a 
large amount of purified nitrogen gas was used to create an oxygen-free 
environment, it was passed through three consecutive bottles (all at 300 ml) of 
Fieser's solution to efficiently remove oxygen and finally a bottle (300 ml) of 
aqueous saturated lead acetate to remove trace amounts of H2 S generated from 
Fieser's solution. This purified nitrogen gas was used to create an external oxygen- 
free environment for a reaction chamber inside which nitric oxide would be reacted 
with L-cysteine. It was also introduced into the gas line supplying nitric oxide to 
prepare an oxygen-free pathway and into solutions of L-cysteine before the addition 
of nitric oxide. It was also, when stated, used to remove free nitric oxide from the 
reaction chamber after mixing L-cysteine with nitric oxide (see Results).
Usually the Amicon chamber, filled with distilled water, was deoxygenated by 
purified nitrogen gas for at least two hours. Solutions of L-cysteine in the sealed 
reaction chamber were submerged under water in the sealed Amicon chamber. The
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solution was then deoxygenated by purified nitrogen delivered via a needle in the 
silicon stopper for 30 minutes before addition of purified nitric oxide gas either in 
measured volumes by a gas syringe or bubbled to saturation for 10 minutes. Finally, 
free nitric oxide was removed by purging with purified nitrogen for 1 0  minutes, 
except when it was required to remain present.
2.3.2. Synthesis of Nitrogen Dioxide
Nitrogen dioxide was prepared by two different methods, however, the 
experimental results obtained were similar in each case.
The first method chosen to prepare nitrogen dioxide was to mix nitric oxide gas 
(99.9%, Air Products Ltd., UK) with oxygen (British Oxygen Company, UK) in a 
ratio of 2:1 (vol./vol.) in a sample-lock gas syringe for 5 minutes before use. Rapid 
formation of a brown gas inside the syringe indicated formation of nitrogen dioxide:
2NO +. O2  -> 2N02
The second, and apparently more reliable means of preparing nitrogen dioxide was 
based on the following principles:
1). The thermal decomposition of the nitrates of metals other than those of Group I 
in the Periodic Table of the elements yields nitrogen dioxide, oxygen and the oxide 
of the metals (Moody, 1991). Lead(II) nitrate was used in the preparation of 
nitrogen dioxide because it is anhydrous, so avoiding a reaction between nitrogen 
dioxide and water. The following reaction takes place upon heating:
2Pb(NC>3)2 - >  2PbO +  4NC>2 +  O2
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To remove any traces of water, lead(II) nitrate crystal should be ground to a fine 
powder and dried at 150-200°C before use. The reaction proceeds with 
decrepitation, fragments of crystal being ejected from the mass, and gas being 
evolved from the fused solid.
2). The freezing point and the boiling point of nitrogen dioxide are -11.2°C and 
21.2°C, respectively, whereas the freezing point and the boiling point of oxygen are 
-218.4°C and -183.0°C, respectively (Hammond, 1966). Thus, nitrogen dioxide 
can be easily separated from oxygen and collected by condensation at an appropriate 
temperature.
Specifically, nitrogen dioxide was generated by heating anhydrous fine powder of 
lead(II) nitrate (20 g) in a glass flask (200 ml) with a gas burner. The evolved gases 
passed through a glass cylinder (50 ml) cooled with crushed dry ice. Nitrogen 
dioxide condensed as a deep red-brown liquid first and was then frozen as a pale 
yellow solid, and oxygen remained in the gas phase and passed on. The solid 
nitrogen dioxide was stored under oxygen-free nitrogen in the sealed cylinder in a 
deep freeze at -20°C. When required, nitrogen dioxide gas was generated from the 
solid by gently heating the cylinder with warm water. After use, nitrogen dioxide 
was solidified again for future use.
2.3.3. Preparation of Solutions of Nitric Oxide
2.3.3.I. Preparation of solutions of nitric oxide under nominal oxygen-free 
conditions
At the beginning of this study, commercially available nitric oxide gas (99.9 %, Air 
Products Ltd., UK) and helium gas (British Oxygen Company) were used in 
preparation of nitric oxide solutions. Solutions of nitric oxide were prepared
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immediately before use. One end of a piece of soft rubber tubing (inside diameter 3 
mm) was connected to the cylinder containing nitric oxide gas and the other end 
submerged under water in a beaker. Enough gas was passed through the tube to 
clear the air from the tubing. A fine Hamilton air-tight syringe was then used to 
pierce the tubing wall near the cylinder and 4.5 pi of nitric oxide gas was drawn 
into the syringe and then immediately injected at atmospheric pressure into 2 0  ml of 
helium-deoxygenated distilled de-ionised water which filled completely a brown 
bottle sealed with a rubber seal. This produced a stock solution with a maximal 
nominal concentration of 10 pM. The solution of nitric oxide was protected from 
light.
2.3.3.2. Preparation of solutions of nitric oxide under rigorous oxygen-free 
conditions
Later in this study when it was realised that trace amounts of oxygen were still 
present in helium and commercially available "oxygen-free" nitrogen gases and 
nitrogen dioxide contaminated cylinders of nitric oxide gas, more rigorous 
procedures were used to prepare solutions of nitric oxide.
Solutions of nitric oxide gas (99.9%, Air Products Ltd., UK) were prepared 
immediately before use. They were prepared by submerging a brown bottle (20 ml) 
and a silicon rubber stopper in a beaker containing 300 ml of Milli-Q purified 
distilled deionised water and gassing with purified oxygen-free nitrogen (British 
Oxygen Company) for 1 hour. While still submerged, the rubber stopper was used 
to seal the bottle ensuring that no gas bubbles were left inside. One end of a long 
silicon rubber tube was connected using a "T" connector to the outputs of the gas 
washing bottles used to purify nitric oxide and nitrogen gases (see Figure 2), and 
the another end was submerged just under the water surface in another beaker. A 
sample-lock gas microsyringe (Dynatech series A, Precision Sampling Corporation,
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USA) was used to pierce the tubing wall at a point near its middle. This part of 
tubing and the attached needle were then submerged under water in the beaker 
containing the sealed brown bottle. Sufficient volume of purified gases, first 
oxygen-free nitrogen and then nitric oxide, were passed through to purge the tubing 
and the syringe. 4.5 pi of nitric oxide gas was then drawn into the syringe and 
injected into the sealed bottle under water. This produced a stock solution of nitric 
oxide with a nominal concentration of 10 pM. These solutions of nitric oxide were 
made up daily and protected from light. They retained their relaxant activity for 
several hours while remaining sealed.
2.3.4. Synthesis of S-Nitrosothiols
Two methods were used to synthesise S-nitrosothiols, i.e. by a acidification of 
nitrite in the presence of thiols and by reacting nitric oxide with thiols. These 
methods were based on those previously reported (Saville, 1958; Ignarro, et al., 
1981). Since the yields of S-nitrosothiols were not known, their concentrations 
stated in this study were expressed as a function of the concentrations of each of the 
reactants.
2.3.4.I. Synthesis of S-Nitrosocysteine by Reacting L-Cysteine with Acidified 
Nitrite and Measurement of Nitrite Content
One method used to synthesise S-nitrosocysteine was by reacting L-cysteine with 
acidified sodium nitrite (Saville, 1958). Aqueous solutions of L-cysteine (1 M) were 
mixed with sodium nitrite (10 mM) at various pH values ranging from 7.4 to 1.0 
for 10 minutes at 20°C followed by neutralisation and bioassay of relaxant activity. 
The effect of pH on generation of S-nitrosocysteine was assessed by bioassay of 
relaxant activity. The reaction pH was maintained by the strong buffering capacity 
of L-cysteine in aqueous solutions pre-adjusted with 1 M hydrochloric acid to the
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pH values required. The pH value was observed not to change following mixing 
with sodium nitrite in this study.
Also, this study investigated the relation between decreases in nitrite content and 
generation of relaxant activity in the acidified mixtures of L-cysteine and nitrite 
over a range of pH values. The nitrite content of the mixtures was measured by 
diazo formation according to the method previously reported (Martin, et al., 1988). 
At 20°C, a sample (0.3 ml) was mixed with 0.3 ml of 1 % (w. /vol.) sulfanilic acid 
in 2 M hydrochloric acid. After 5 minutes, 0.3 ml of 1 % (w./vol.) aqueous 
solution of N-(l-napthyl)-ethylenediamine dihydrochloride was added, and the 
absorbance of the pink complex was measured at 548 nm by a Shimadzu UV-240 
dual beam spectrophotometer connected to a Shimadzu Option Program / Interface 
OPI-2 which controlled the instrument. A standard concentration-absorbance curve 
was prepared with a series of standard solutions of sodium nitrite at concentrations 
of 0.00, 0.30, 1.00, 3.00, 10.00 and 30.00 pM. The content of nitrite in each 
sample was automatically determined by the spectrometer according to its 
absorbance against the standard curve.
2.3.4.2. Synthesis of S-nitrosothiols from reacting nitric oxide and nitrogen 
dioxide with L-cysteine and analogues
2.3.4.2.I. Synthesis of S-nitrosothiols under nominal oxygen-free conditions
The reactions between nitric oxide or nitrogen dioxide and L-cysteine or other 
compounds were studied. These other compounds included mainly analogues of L- 
cysteine and L-glutathione (reduced form), namely, N-acetyl-L-cysteine, L- 
cystamine, L-cysteamine, L-cysteic acid, L-cysteine methyl ester, L-cysteine ethyl 
ester, L-cysteinesulphinic acid, L-cystine, L-glutathione (oxidised form), L-
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methionine, S-methyl-L-cysteine, and S-methyl-L-glutathione, and three other non- 
sulfhydryl-containing amino acids, L-arginine, L-glutamic acid and L-glycine.
This method was based on that previously reported in synthesis of S-nitrosothiols by 
reacting thiols with nitric oxide (Ignarro, et al., 1981). In early experiments we did 
not know that commercially available cylinders of nitric oxide and oxygen-free 
nitrogen gases contain traces of nitrogen dioxide and oxygen, respectively. 
Consequently the procedures used initially were similar to those used in the 
preparation of nitric oxide solutions under nominal oxygen-free conditions described 
above. Aqueous solutions of these compounds (10-15 mM, pH 3) were purged with 
commercially available "oxygen-free” nitrogen, then reacted either with given 
volumes of nitric oxide or nitrogen dioxide (at concentrations of 0.1 or 1 mM as 
indicated in Results) or saturated with nitric oxide or nitrogen dioxide for 10 
minutes, and where necessary (as indicated in Results) purged with "oxygen-free" 
nitrogen again to remove free nitric oxide or nitrogen dioxide and neutralised.
In some experiments the effects of reactant concentrations, pH and oxygen tension 
were studied in more detail and these will be described in the Results .
2.3.4.2.2. Synthesis of S-nitrosothiols under rigorous oxygen-free conditions
In later experiments when it became clear that commercially available cylinders of 
nitric oxide and oxygen-free nitrogen contain traces of nitrogen dioxide and oxygen, 
respectively, far greater precautions were taken.
The reactions were carried out as far as possible under rigorous oxygen-free 
conditions in the closed system (see Figure 2) following the same procedures 
described above for purification of nitric oxide and nitrogen gases. Aqueous 
solutions of these compounds (10-15 mM, pH 3) were purged with oxygen-free
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nitrogen, then reacted either with given volumes of nitric oxide or nitrogen dioxide 
(at concentrations of 0.1 or 1 mM as indicated in Results) or saturated with nitric 
oxide for 10 minutes, and where necessary (as indicated in Results) purged with 
purified oxygen-free nitrogen again to remove free nitric oxide and neutralised.
2.3.5. High Performance Liquid Chromatography Analysis
The HPLC analysis was performed using a system consisting of the following 
components:
1). Pump: A constant flow pump, Waters Model 6000A Solvent Delivery System, 
was used. Constant flow of the solvent was achieved with a pair of specially-driven 
positive-displacement pumping chambers.
2). Injector: A Rheodyne manual injector model 7125 was used.
3). Column and Guard Column: The Waters analytical and preparative reverse 
phase chromatography systems were used. The analytical system consisted of a p 
Bondapac Guard-Pac C l8  reverse-phase insert (particle size 10pm, pore size 125A) 
in a Guard-Pak holder and a pBondapac Radial-Pac C l8  reverse-phase cartridge (8  
x 100 mm, particle size 10pm, pore size 125A) in a RCM 8  x 10 cartridge holder. 
The preparative system consisted of a pBondapac Guard-Pac C18 insert (particle 
size 10pm, pore size 125A) connected to a pBondapac Radial-Pac C l8  reverse- 
phase cartridge (25 x 100 mm, particle size 10pm, pore size 125A) in a RCM 25 x 
1 0  cartridge holder.
4). Detector: A Waters UV absorbance detector model 440 was used. It has two 
separated detection systems which operate in two consecutive cells in series. The
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wavelengths of the detector can be fixed at 254 or 280 nm, but in this study both 
were set at 254 nm.
5). Recorder: A Phillips Model PM8252 dual-pen standard compact recorder was 
used. It was connected to the output of the UV detector for recording of absorption.
6 ). Solvent: The solvent system used in experiments was varied during the course of 
this study. Methanol was used initially but as it destroyed the relaxant synthesised 
from the reaction of L-cysteine and nitric oxide (see Figure 27), it was abandoned. 
Phosphate buffer (pH 3.0, 1/15 M) failed to give adequate separation of peaks and 
was also abandoned. PIC A (tetrabutylammonium phosphate ion-pairing agent) was 
also rejected as a solvent since it reacted with samples generating numerous 
irregular peaks with high absorption, and the retention time of some of the peaks 
was often as long as an hour. Milli-Q purified water (pH 3.0), however, gave a 
good separation of peaks and produced low basal noise in the HPLC detection 
system. It was, therefore, used for most of the HPLC analyses.
Specifically, the purified HPLC grade water used in this study was prepared using 
glass-distilled water purified by passing through a Waters Milli-Q Reagent-Grade 
Water System which removed dissolved organic materials by absorption into 
activated charcoal, ionised compounds by mixed bed deionization and all micro­
organisms larger than 0.22 pM by Millipore membrane filtration. The purified 
water was then adjusted to pH 3.0 with hydrochloric acid (IN, analytical grade). 
Finally, it was filtered through a Waters filtration membrane disc (47 mm, type 
HA, pore size 0.45 pM) and degassed under high vacuum in a Millipore all-glass 
filter system connected to a high vacuum pump (single stage model 1SC50, 
Edwards High Vacuum Limited, UK). During analysis the solvent was continuously 
degassed by bubbling with helium (British Oxygen Company).
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HPLC detection was performed at 254 nm in both channels with a 10-fold 
difference in the two sensitivities. The absorption detected in each channel of the 
UV detector was continuously monitored on the dual pen recorder. When analysis 
was performed with the 8  x 100 mm analytical column, the flow rate was set at 1.5 
ml per minute. Chart speed was set at 1.0 cm per minute and the sample volume 
was usually 10 pi. When analysis was performed with the 25 x 100 mm preparative 
column, the flow rate was set at 9.0 ml per minute. The chart speed was set at 2.0 
cm per minute, and the sample volume was generally 1 .0  ml
On rare occasions, small particles formed in samples of L-cysteine after reaction 
with nitric oxide or nitrogen dioxide. In order to avoid blockage of the column by 
these particles, such solutions were filtered through a Sartorius filter (Minisart 
NML, pore size 0.45 pM) and the filtrate was then loaded into the injector.
In order to maintain good resolution and column life, the column was washed after 
each experiment first with the normal solvent (Milli-Q purified water pH 3.0) and 
then with 50 % (vol./vol.) methanol in Milli-Q purified water for at least at five 
column volumes. At the beginning of each analysis the entire HPLC system was 
flushed and equilibrated with Milli-Q purified water (pH 3.0) for 30 minutes.
2.3.6. Ultra-violet and Visible Spectrophotometric Analysis
The absorption spectra of L-cysteine, nitric oxide, nitrogen dioxide, and products 
from reacting L-cysteine with nitric oxide or nitrogen dioxide were analysed by 
continuous scans at wavelengths from 900 to 190 nm in a Shimadzu UV-240 dual 
beam spectrophotometer connected to a Shimadzu Option Program / Interface OPI-2 
which controlled the instrument. Two Hellma UV-visible quartz cuvettes (1.5 ml 
capacity) were used when making measurements. Where necessary to keep
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deoxygenated samples from contact with air, the cuvettes were completely filled 
with the samples and sealed with silicon stoppers in an oxygen-free environment.
2.4. Drugs and Compounds
Acetylcholine chloride, N-acetyl-L-cysteine, L-arginine, L-cystamine, L- 
cysteamine, L-cysteic acid, L-cysteine, L-cysteine methyl ester, L-cysteinesulphinic 
acid, L-cystine, L-glutamic acid, L-glutathione, guanethidine sulphate, haemoglobin 
(bovine), hydroquinone, isoprenaline hydrochloride, L-methionine, S-methyl-L- 
cysteine, methylene blue, S-methyl-L-glutathione, N-methylhydroxylamine 
hydrochloride, N^-nitro-L-arginine, phenylephrine hydrochloride and superoxide 
dismutase (bovine erythrocyte) were obtained from Sigma Chemical Company 
Limited (UK); diamide, dithiothreitol, N-ethylmaleimide, hydrochloric acid, 
methanol, potassium hydroxide, sodium anthraquinone-p-sulfonate, sodium 
dithionite, sodium hydroxide were obtained from Aldrich Chemical Company 
Limited (UK); pyrogallol was obtained from BDH (UK) and glyceryl trinitrate 
(10% w/w in lactose) was obtained from Napp Laboratories (UK).
Solutions of drugs and compounds were made up as concentrated stocks in deionised 
distilled water unless indicated otherwise. Serial dilutions to the required 
concentrations were made up from the stocks in distilled deionised water 
immediately before use. Usually they were all kept on ice during use. These drugs 
and compounds were added into 20 ml organ baths in volumes of 1 to 300 pi 
(usually 10pi) using micro syringes or Gilson automatic pipettes. The concentrations 
in the text and the Figures are the final concentrations in the baths, except where 
indicated.
Acetylcholine was made up as 10 mM stock solutions in phosphate buffer (10 mM, 
pH 4.0). The stock solution was divided into 1 ml aliquots put into small plastic
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containers and stored in a deep freeze at -20°C for future use. Dilutions were made 
in distilled deionised water from the stock immediately before use.
Solutions of oxyhaemoglobin were prepared according to the procedures previously 
described (Bowman, et a l ,  1982b). Human haemoglobin was obtained from the 
Sigma Chemical Company Ltd. (UK). It consists predominantly of 
methaemoglobin, as pure oxyhaemoglobin is unstable and readily oxidised when 
stored. Oxyhaemoglobin was prepared from the commercially available 
haemoglobin as follows: sodium dithionite 2  mg was added to 2  ml of an aqueous 
solution of "haemoglobin" (15 mg ml"l). This reduced the methaemoglobin to 
deoxyhaemoglobin and the colour changed from brown to purple. Excess dithionite 
was removed immediately by passing the solution through a gel filtration column 
(Columns PD-10, 12 x 50 mm, Sephadex G-25M, Pharmacia Fine Chemicals, 
Sweden). During passage through the column, the deoxyhaemoglobin became 
oxygenated and its colour changed from purple to red as it separated from 
dithionite. The oxyhaemoglobin was eluted from the column with distilled deionized 
water. Its concentration was spectrophotometrically monitored against standard 
haemoglobin solution (Sigma Chemical Company Limited, UK). The resulting 
solution was stored in aliquots at -20°C for up to 14 days.
2.5. Statistics
The number of observations in each experiments was no less than 8 . Sets of 
observations were expressed as the mean ± the standard error of the mean (s.e.m) in 
appropriate tables and charts. Differences between sets of means were analysed and 
estimated normally by using Student's t-test. A probability of 0.05 or less was 
considered significant.
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While non-adrenergic non-cholinergic (NANC) nerves are known to innervate the 
bovine retractor penis muscle (Klinge, et al., 1970; Klinge & Sjostrand, 1974; 
Ambache & Killick, 1978) and the rat and mouse anococcygeus muscle (Gillespie, 
1972; Gibson & Gillespie, 1973; Gillespie & McGrath, 1973; Gillespie & 
McGrath, 1974; Creed, et al., 1977; Gibson & Wedmore, 1981; Gibson & Tucker, 
1982; Gibson & Yu, 1983), the neurotransmitter was still unknown at the beginning 
of this study. Many substances especially some known neurotransmitters were 
rejected as the non-adrenergic non-cholinergic neurotransmitter (Klinge & 
Sjostrand, 1974; Gillespie, 1972; Gillespie, et al., 1990). Many attempts were 
made to analyse and classify the non-adrenergic non-cholinergic neurotransmitter 
based on the effects of drugs on the NANC response (Klinge & Sjostrand, 1974; 
Gillespie, 1972; Martin & Gillespie; 1991). Other attempts were made to purify and 
chemically identify IF extracted from the BRP but with only partial success 
(Gillespie & Martin, 1978; 1980; Gillespie, et al., 1981b; Martin, et al., 1988). 
Attempts were also made to detect the NANC neurotransmitter released from a 
donor tissue i.e. a BRP or rat anococcygeus strip by an assay tissue such as a rabbit 
aortic ring or a BRP or rat anococcygeus strip but these were also unsuccessful. 
Now the most likely candidates are IF, EDRF, nitric oxide and S-nitrosothiols 
because they share many properties in common (Gillespie, 1987; Gibson, et al., 
1989; 1990; Gillespie, et al., 1989; 1990; Li & Rand, 1989; Yui, et al., 1989; 
Myers, etal., 1990; Martin, etal., 1991; Liu, et al., 1991; Kerr, et al., 1992).
The involvement of the L-arginine: nitric oxide system in the inhibitory NANC 
neurotransmission in the BRP and the rat and mouse anococcygeus has been well 
established (Gibson, et al., 1989; 1990; Gillespie, et al., 1989; 1990; Li & Rand, 
1989; Liu, et al., 1991). However, nitric oxide might not be the exact form of the 
transmitter since superoxide anion generators such as pyrogallol blocked exogenous
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nitric oxide-induced relaxation but not the NANC inhibitory response to electrical 
field stimulation in the BRP and mouse anococcygeus (Gillespie & Sheng, 1990; 
Gibson, et al., 1992). Furthermore, it has been suggested that EDRF is much more 
likely to be a nitrosylated compound, such as a nitrosothiol e.g. S-nitrosocysteine, 
than authentic NO (Myers, et al., 1990). S-Nitrosothiols have also been proposed to 
act as active intermediates in vascular smooth muscle relaxation induced by organic 
nitrates, nitrites, nitroprusside and nitric oxide (Ignarro, et al., 1981). Furthermore, 
activation of guanylate cyclase by glyceryl trinitrate specifically requires L-cysteine 
(Ignarro & Gruetter, 1980). Therefore, the roles of intracellular free sulfhydryl 
groups and S-nitrosothiols in the inhibitory NANC neurotransmission in the BRP 
are worthy of investigation.
3.1. Role of Free Sulfhydryl Groups in NANC Neurotransmission
If free sulfhydryl groups are involved in the inhibitory NANC neurotransmission in 
the BRP, the relaxant response to intramural nerve stimulation should be inhibited 
by depleting the tissue of free sulfhydryl groups. This is investigated by using two 
chemicals, diamide and N-ethylmaleimide, which oxidise and alkylate sulfhydryl 
compounds, respectively.
3.1.1. Inhibition of NANC Relaxation by Diamide
Diamide is a thiol-oxidising agent (Kosower, et al., 1969) which converts free 
thiols to the corresponding disulphides:
2R-SH + (CH3)2NCON=NCON(CH3)2 -> R-S-S-R + (CH3)2NCONHNHCON(CH3)2
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It has a particularly high affinity for L-glutathione, being some 10 time higher than 
for L-cysteine. As can be seen from the above equation, it stoichiometrically 
oxidises L-glutathione to the corresponding disulphide.
Diamide (1 mM) had two effects on the BRP muscle precontracted with 
guanethidine (10 pM, Figure 3). First, it partially inhibited (30-50 %) the NANC 
inhibitory relaxation induced by electrical field stimulation (2 Hz, 20 pulses) within 
10-15 minutes. Secondly, it lowered guanethidine-induced tone in most preparations 
by around 20%, although no decrease or up to a 50% decrease of the tone was 
observed in a few preparations. The inhibition of both the NANC relaxation and 
guanethidine-induced tone was almost completely reversed by treatment with the 
sulfhydryl compounds, L-cysteine, L-glutathione or dithiothreitol all at 3 mM.
Pretreatment of the BRP preparations with L-cysteine, L-glutathione or 
dithiothreitol (all at 3 mM) prevented the diamide-induced inhibition both of the 
NANC response to intramural nerve stimulation and of guanethidine-induced tone 
(Figure 4).
Furthermore, these three sulfhydryl-containing compounds had a common additional 
effect (Figures 3 & 4): they all caused a transient decrease of guanethidine-induced 
tone of the BRP preparations lasting about 15 minutes prior to their reversal of the 
effects of diamide. When dithiothreitol (3 mM) was added to strips of BRP, it first 
caused a transient fall in tone, simultaneously reduced the NANC relaxant response 
by about 30 %, and then raised the tone to a level higher than before addition of 
dithiothreitol (Figure 4). The development of raised tone is consistent with 
inhibition of the NANC relaxation since both effects are also seen to occur 
following treatment with L-nitroarginine (Liu, et al. , 1991). Both of these effects of 
dithiothreitol were sustained, were not reversed by addition of diamide (1 mM, 
Figure 4) or superoxide dismutase (100-8,000 u ml"*, Figure 5), and were not
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Diamide 1 mM L-G luta th ione 3 mM
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Figure 3. Treatment of BRP muscle with diamide (1 mM) partially inhibited 
NANC relaxation induced by field stimulation (2 Hz, 20 pulses, pulse width 0.5 ms 
and supramaximal voltage). This inhibition was reversed by treating the tissues with 
L-cysteine (3 mM), L-glutathione (3 mM) or dithiothreitol (3 mM). Tone of the 
BRP muscle was raised by guanethidine 30 pM.
L-Cysteine 3 mM D iam ide 1 mM
r r m r r m r m r m
L-G luta th ione 3 mM Diamide 1 mM
D ith io th re ito l 3 mM Diamide 1 mM
3 m in
Figure 4. Pretreatment of BRP muscle with L-cysteine (3 mM), L-glutathione (3 
mM) or dithiothreitol (3 mM) completely prevented inhibition by diamide (1 mM) 
of the inhibitory response to NANC nerve stimulation (2 Hz, 20 pulses, pulse width 
0.5 ms and supramaximal voltage). Tone of the BRP muscle was raised by 
guanethidine 30 pM.
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Results
prevented by pretreatment with superoxide dismutase (1,000 u ml~l, Figure 5). 
Furthermore, superoxide dismutase (1,000 u ml"l) did not affect the NANC 
response to the nerve stimulation (Figure 5).
The selectivity of the ability of diamide to block NANC relaxation was examined by 
assessing its effects on relaxation induced by other stimuli. Pretreatment of BRP 
preparations with diamide at a concentration of 1 mM for 20 minutes completely 
blocked the relaxation induced by glyceryl trinitrate (10-100 nM) or isoprenaline 
(10-1000 nM) and this blockade was not reversed after addition of the free 
sulfhydryl-containing compounds L-cysteine, L-glutathione or dithiothreitol ( all at 
3 mM, Figure 6).
3.1.2. Inhibition of NANC Relaxation by N-Ethylmaleimide
N-Ethylmaleimide like diamide is a sulfhydryl-depleting agent but its mechanism of 
action is through alkylation of free sulfhydryl groups (Siegle, et al., 1993).
N-Ethylmaleimide (0.3 mM) caused 50-70% inhibition of the NANC relaxation 
induced by field stimulation (2 Hz, 20 pulses) and gradually reduced guanethidine 
(10 pM)-induced tone in the BRP strips (Figure 7). Neither of these effects of N- 
ethylmaleimide was reversed by addition of the sulfhydryl compounds L-cysteine, 
L-glutathione or dithiothreitol (all at 3 mM). However, pretreatment of the BRP 
preparations with these three sulfhydryl-containing compounds completely prevented 
the ability of N-ethylmaleimide to inhibit NANC relaxation and to lower tone 
(Figure 8). Furthermore, at a concentration of 1 mM dithiothreitol itself did not 
either inhibit NANC relaxation or raise guanethidine-induced tone (Figure 8).
As with diamide, the ability of N-ethylmaleimide (0.3 mM) to inhibit NANC 
relaxation to nerve stimulation in the BRP muscle was not selective since this agent
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Figure 6. Treatment of BRP muscle with diamide (1 mM) for 20 minutes 
completely blocked relaxation induced by glyceryl trinitrate (10-100 nM) or 
isoprenaline (10-1000 nM). This blockade was not reversed after addition of L- 
cysteine (3 mM) for 20 minutes. Tone of the BRP muscle was raised by 
phenylephrine 0.3 pM.
N -E thylm ale im ide 0 .3  mM L-Cysteine 3 mM
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Figure 7. Treatment of BRP muscle with N-ethylmaleimide (0.3 mM) partially 
inhibited NANC relaxation induced by field stimulation (2 Hz, 20 pulses, pulse 
width 0.5 ms and supramaximal voltage). This inhibition was not reversed by 
treating the tissues with L-cysteine (3 mM), L-glutathione (3 mM) or dithiothreitol 
(3 mM). Tone of the BRP muscle was raised by guanethidine 30 pM.
L-Cyste ine 1 mM N -E thylm ale im ide 0 .3  mM
L-G luta th ione 1 mM
N -E thylm a le im ide 0 .3  mM
]5g
5 m in
D ith io th re ito l 1 mM N-E thylm a le im ide 0 .3  mM
Figure 8 . Pretreatment of BRP muscle with L-cysteine (1 mM), L-glutathione (1 
mM) or dithiothreitol (1 mM) completely prevented inhibition of the inhibitory 
response to NANC nerve stimulation (2 Hz, 20 pulses, pulse width 0.5 ms and 
supramaximal voltage) by N-ethylmaleimide (0.3 mM). Tone of the BRP muscle 
was raised by guanethidine 30 pM.
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also completely blocked the relaxation induced by glyceryl trinitrate (10-100 nM) or 
isoprenaline (10-100 nM) and this blockade was not reversed after addition of the 
free sulfhydryl-containing compounds L-cysteine, L-glutathione or dithiothreitol ( 
all at 3 mM, Figure 9) .
3 .2 . Role o f S-N itrosothiols in NANC N euro transm ission
Nitric oxide is a highly lipophilic gas which readily diffuses across biological 
membranes. Owing to its odd electron, it is also chemically highly reactive with 
many intracellular and extracellular substances in the body such as oxygen. These 
properties make free nitric oxide an unlikely candidate for a neurotransmitter. 
However, these disadvantages of nitric oxide could be overcome if it binds to a 
carrier which protects it and delivers it to guanylate cyclase intact. Since S- 
nitrosothiols share many properties with the inhibitory NANC neurotransmitter an 
investigation was conducted to determine if such substances could act as an effective 
nitric oxide carrier.
3.2.1. Relaxation Induced by Solutions of Sodium Nitrite and M ixtures of 
Sodium Nitrite and L-Cysteine a t Different pH Values
We first examined the relaxant activity of sodium nitrite with and without the 
presence of L-cysteine at different acid pH values in aqueous solutions by bioassay.
Figure 10 shows that the relaxant activity of sodium nitrite (10 pM) assessed on a 
rabbit endothelium-denuded aortic rings precontracted by phenylephrine (0.3 pM) 
was increased by lower pH. Given the same bath concentrations of 10 pM, sodium 
nitrite at pH 7.4 produced a small and slowly developing relaxation in the 
contracted ring, whereas when acidified to pH 4 or below, it added into baths, 
produced an additional quickly developing relaxation prior to the slow relaxation.
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G TN  C o n tro l Iso p re n a lin e
10 100 nM 1 0  100 nM
0 .3  mM N -E thylm ale im ide 30  min
•  •
] 5g
J
3 mM L-Cyste ine 30  min 3 m in
Figure 9. Treatment of BRP muscle with N-ethylmaleimide (0.3 mM) for 30 
minutes completely blocked relaxation induced by glyceryl trinitrate (10-100 nM) or 
isoprenaline (10-100 nM). This blockade was not reversed after addition of L- 
cysteine (3 mM) for 30 minutes. Tone of the BRP muscle was raised by 
phenylephrine 0.3 pM.
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Results
The generation of this new relaxant activity was optimal at pH 2. The slowly 
developing relaxation was not affected by lowering the pH in the solutions of 
sodium nitrite. However, neutralisation of the acidified (pH 2) nitrite led to a rapid 
loss of the new relaxant activity. Simultaneous measurement of nitrite content in the 
stock solutions at various pH revealed that this new relaxant activity was associated 
with decreases in nitrite content (Figure 11). The powerful relaxant activity at pH 2 
in the stock solution (Figure 10) was associated with a 27 % decrease in nitrite 
content (Figure 11), whereas at pH values above 4 where no new relaxant activity 
was generated (Figure 10) decreases in nitrite content were less than 3 % (Figure 
11). Furthermore, the new relaxant activity was increased by purging the stock 
solution with oxygen-free nitrogen for 15 minutes before acidification in an open 
beaker, but was decreased by gassing the stock solution with oxygen for 15 minutes 
before acidification (Figure 12). Again, the slow relaxant activity was neither 
increased by purging the stock solution with oxygen-free nitrogen nor decreased by 
gassing the stock solution with oxygen.
When aqueous solutions of sodium nitrite (10 mM) were mixed with L-cysteine (1.5 
M) at pH 7.4 and added to achieve bath concentrations equal to sodium nitrite 10 p 
M and L-cysteine 1.5 mM, the relaxation produced was faster in onset and greater 
in magnitude (Figure 13) than that induced by sodium nitrite alone (Figure 10). 
Furthermore, when acidified to pH values of pH 6 to pH 2, more powerful and 
prolonged relaxant activities were produced in presence of L-cysteine (1.5 M, 
Figure 13) than in its absence (Figure 10). These greatly increased relaxant 
activities (Figure 13) were also associated with an acid pH-dependent decrease in 
nitrite content in the stock solutions of sodium nitrite (10 mM) and L-cysteine (1.5 
M, Figure 14): the loss of nitrite was 68 % at pH 4 and almost 100 % at pH 3 and 
below (Figure 14). Unlike solutions of acidified sodium nitrite (10 mM), mixtures 
of L-cysteine (1.5 M) and sodium nitrite (10 mM) did not lose their relaxant activity 
when neutralised (Figure 13).
70
N
itr
ite
 
C
on
te
nt
 
(/
^M
)
10
8
6
4
2
0
7.4 6 5 3 24
PH
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p H - d e p e n d e n t  d e c r e a s e  in n i t r i t e  c o n t e n t  in 
a q u e o u s  s o l u t i o n s  of s o d i u m  n i t r i t e  (10 f iM).
* P < 0 .0 5  i n d i c a t e s  a  s i g n i f i c a n t  r e d u c t i o n  of 
n i t r i t e  c o n t e n t .
O  p h e n y l e p h r i n e  0 . 3  p M ® Nal\l02 1 0  pM
O
b ) .
3  m i n
c).
o
Figure 12. This figure shows the new relaxant activity generated by acidification 
(pH 2) of aqueous stock solutions of sodium nitrite (10 mM) at a), ambient oxygen 
tension; b). after purging with oxygen-free nitrogen for 15 minutes; c). after 
gassing with oxygen for 15 minutes. This activity was enhanced by deoxygenation 
but reduced by oxygenation of the solutions. The concentrations in the figure are 
final bath concentrations. Bioassay was performed on a rabbit endothelium-denuded 
aortic ring submaximally contracted by phenylephrine (0.3 pM).
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Fi g u r e  14. Ac id i f i c a t i on  fo r  10 m i n u t e s  l ed  t o  
a  p H - d e p e n d e n t  d e c r e a s e  in n i t r i t e  c o n t e n t  in 
a q u e o u s  m i x t u r e s  of L—c y s t e i n e  (1.5 mM) a n d  
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Results
At bath concentrations equal to sodium nitrite 10 pM and L-cysteine 1.5 mM, this 
new powerful relaxant activity generated by mixing sodium nitrite (10 mM) with L- 
cysteine (1.5 M) at pH 2 was completely blocked by haemoglobin (3 pM) but not 
by pretreatment of the rabbit aortic ring with L-nitroarginine for 15 minutes (Figure 
15).
Thus, acidified nitrite in the presence of L-cysteine greatly enhanced relaxant 
activity. If S-nitrosothiols were produced in vivo, they would be formed from the 
reaction of nitric oxide and not nitrite with thiols. Consequently, a study was 
conducted to investigate the reactions of nitric oxide with thiols.
3.2.2. Relaxation Induced by Nitric Oxide and M ixtures of N itric Oxide 
and L-Cysteine or L-Glutathione
Based on the report that the properties of S-nitrosocysteine more closely resembled 
those of EDRF than authentic nitric oxide (Myers, et al., 1990) and that L-cysteine 
and L-glutathione are two of the most abundant free sulfhydryl-containing 
substances in the body, L-cysteine and L-glutathione were chosen to be studied.
When added into the bath, nitric oxide prepared in oxygen-free Milli-Q purified 
water induced a rapid concentration (1-1000 nM)-dependent transient relaxation of 
rabbit aortic rings denuded of endothelium and precontracted by phenylephrine (0.3 
pM, Figure 16). The tone of the tissues was not affected by L-cysteine at 
concentrations of 0.15 to 4.5 mM but was slowly reduced at a concentration of 15 
mM. L-Cysteine (1 mM) slightly reduced the magnitude but significantly prolonged 
the duration of subsequent exogenous nitric oxide (10 nM)-induced relaxation. It 
also changed the time course of the relaxation both in onset and offset from fast to 
slow. After washing L-cysteine out of the bath five times in 10 minutes, the
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p h e n y l e p h r i n e  0 .3  pM
N a N C > 2  10 pM + L-cysteine 1 .5  mM
Haemoglobin 3 pM
p h e n y l e p h r i n e  0 . 3  pM
N a N 0 2  10  pM + L-cysteine 1.5  mM
L - n i t r o a r g i n i n e  3 0  pM
p h e n y l e p h r i n e  0 .3  pM
Figure 15. The powerful relaxant activity generated by mixing sodium nitrite (10 
mM) with L-cysteine (1.5 M) in aqueous stock solutions at pH 2 for 10 minutes 
followed by neutralisation was completely blocked by haemoglobin (3 pM) when 
assayed on a rabbit endothelium-denuded aortic ring submaximally contracted by 
phenylephrine (0.3 pM). However, pretreating the tissue with L-nitroarginine (30 p 
M) for 15 minutes did not affect the relaxant activity. The concentrations in the 
figure are final bath concentrations.
NO
0 .1 5  0 .4 5
L-Cysteine 
1.5 4 .5 15 mM
5g
3 m in
NO 10 nM L-Cyste ine 1 mM NO 10 nM NO 10 nM NO 10 nM NO 10 nM
1 Omin 
Washing
1 Omin 1 Omin
Figure 16. Nitric oxide (1-1000 nM), but not L-cysteine (0.15-15 mM), induced in 
a concentration-dependent manner transient rapid relaxation in rabbit phenylephrine 
(0.3 pM)-contracted aortic rings denuded of endothelium. In the presence of 
exogenous L-cysteine (1 mM) relaxation induced by exogenous nitric oxide (10 nM) 
was slightly reduced in magnitude and the time course of both onset and offset was 
slowed. After L-cysteine was washed out by changing the Krebs' solution 5 times in 
10 minutes, the magnitude and duration of nitric oxide-induced relaxation were 
reduced. These effects of L-cysteine were slowly reversed within 30 minutes of 
washing.
Results
magnitude and the duration of nitric oxide-induced relaxation were greatly reduced. 
This reduction in magnitude and duration slowly recovered within 30 minutes of 
washing.
Mixing nitric oxide (5 pM) with L-cysteine (0.75 M) in nominally oxygen-free 
aqueous solution at pH 2 followed by removal of free nitric oxide by purging with 
oxygen-free nitrogen and neutralisation with sodium hydroxide ( I N )  and giving 
final bath concentrations equivalent to 10 nM nitric oxide and 1.5 mM L-cysteine 
produced more powerful and sustained relaxation than nitric oxide (10 nM) alone 
(Figure 17).
Since neither nitric oxide (10 nM) nor L-cysteine (1.5 mM) alone could account for 
such powerful and sustained relaxation, it was possible that a new substance had 
been generated from this mixture which was responsible for the relaxation. If this 
were true, then this new substance might be separable from the mixture by HPLC 
and only this new substance collected from HPLC should induce relaxation on a 
bioassay tissue. L-Cysteine (10 mM) produced two peaks in the HPLC (Figure 18), 
the first one (peak 1) corresponded to its oxidised form, L-cystine. L-Cysteine is 
slowly oxidised to L-cystine during storage and the retention time of peak 1 in L- 
cysteine solutions was identical with that of standard L-cystine solutions (Figure 
19). The second peak (peak 2) corresponded to authentic L-cysteine (Figure 18). 
Mixing L-cysteine (10 mM) with nitric oxide (50 pM) in nominally oxygen-free 
aqueous solution at pH 3 followed by removal of free nitric oxide with oxygen-free 
nitrogen produced three peaks; the first two peaks corresponded to oxidised and 
reduced forms of L-cysteine respectively, with the third peak (peak 3) being the 
new substance. This new substance collected from the HPLC exhibited powerful 
and sustained relaxant activity when assayed on phenylephrine (0.3 pM)- 
precontracted rabbit thoracic aortic rings, whereas the reduced or oxidised forms of 
L-cysteine had no relaxant activity. There was no difference in the height of peak 1
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Figure 17. Nitric oxide (10 nM) induced a transient relaxation on rabbit 
endothelium-denuded aortic rings precontracted by phenylephrine (0.3 pM), 
whereas L-cysteine (1.5 mM) had no effect. Given the same bath concentrations, L- 
cysteine (0.75 M) mixed with nitric oxide (5 pM) in aqueous deoxygenated solution 
at pH 2.0 for 10 minutes followed by purging with oxygen-free nitrogen and 
neutralisation produced complete and sustained relaxation of the tissue.
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Figure 18. In the HPLC L-cysteine (10 mM) in aqueous solution at pH 3.0 
produced two peaks, the first representing its oxidised form, L-cystine, and the 
second L-cysteine. After mixing this solution with nitric oxide (50 pM) under 
nominally oxygen-free conditions at pH 3.0 for 10 minutes followed by purging 
with oxygen-free nitrogen, this solution produced a new peak associated with 
powerful and sustained relaxant activity in the bioassay. HPLC analysis was 
performed with an analytical column using water at pH 3.0 as the solvent. Bioassay 
was conducted on a rabbit endothelium-denuded aortic ring precontracted by 
phenylephrine 0.3 pM.
L-Cystein 10 mM L-Cystine 
10 pM 30 pM 50 pM
<
CNI
o
o
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Figure 19. In the HPLC L-cysteine (10 mM) in aqueous solution at pH 3.0 
produced two peaks; peak 1 was identical in retention time to that of standard 
solutions of L-cystine (pH 3.0). The magnitude of peak 1 was equivalent to L- 
cystine at around 40 pM. HPLC analysis was performed with an analytical column 
using water at pH 3.0 as the solvent.
Results
before and after mixing with nitric oxide, whereas the height of peak 2 was reduced 
by 2% after mixing with nitric oxide.
L-Glutathione (10 mM) in aqueous solution (pH 3.0) produced one peak in HPLC 
(Figure 20). Mixing L-glutathione (10 mM) with nitric oxide (50 pM) in nominally 
oxygen-free aqueous solution at pH 3 followed by removal of free nitric oxide by 
purging with oxygen-free nitrogen produced two peaks; the first peak corresponded 
to L-glutathione in retention time and the second peak corresponded to a new 
substance. When bioassayed on rabbit aortic rings precontracted by phenylephrine 
(0.3 pM), this new substance collected from the HPLC exhibited powerful and 
sustained relaxant activity, whereas L-glutathione produced no relaxation. The peak 
height of L-glutathione after mixing with nitric oxide was reduced by an amount 
equivalent to the height of the new peak. Thus, the new relaxant appeared to have a 
similar extinction coefficient to L-glutathione.
3.2.3. Characteristics of the Relaxant Generated in M ixtures of Nitric 
Oxide and L-Cysteine
L-Cysteine (10 mM) was made up with Milli-Q purified water and adjusted to pH 3 
with hydrochloric acid (1 N). An aliquot of this solution was gassed to saturation 
with nitric oxide under nominally oxygen-free conditions at pH 3 for 10 minutes 
followed by removal of free nitric oxide by purging with oxygen-free nitrogen. 
Separation of the two peaks in the original solution of L-cysteine and the three 
peaks following mixing nitric oxide with L-cysteine was performed in the HPLC. 
The five separated samples were collected from only the top 5% of each peak to 
ensure a high degree of purity.
3.2.3.1. Peak Maxima in UY-visible Spectrophotometry
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Figure 20. L-Glutathione (10 mM) in aqueous solution at pH 3.0 produced one 
peak in the HPLC. After mixing with nitric oxide (50 pM) under nominally 
oxygen-free conditions at pH 3.0 for 10 minutes followed by purging with oxygen- 
free nitrogen, this solution produced a new peak associated with powerful and 
sustained relaxant activity in the bioassay. HPLC analysis was performed with an 
analytical column using water at pH 3.0 as the solvent. Bioassay was conducted on 
a rabbit endothelium-denuded aortic ring which was precontracted by phenylephrine 
0.3 pM.
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Results
The UV-visible spectrophotometric characteristics of each of the five peaks were 
investigated by differential absorbance against the solvent Milli-Q water (pH 3) in a 
continuous scan at wavelengths from 900 nm down to 190 nm. HPLC peak 1 and 
peak 2 each contained only one absorption peak with maxima at 193 nm and 195 
nm, respectively. The results were the same whether they were obtained from 
solutions of L-cysteine or from nitric oxide-bubbled solutions of L-cysteine (Figure 
21). HPLC peak 3 produced three absorption peaks with maxima at 193, 218 and 
335 nm; the highest was at 218 nm and the lowest was at 335 nm.
3.2.3.2. Stability
When each of the three separated peaks from nitric oxide-bubbled L-cysteine 
solutions was collected and immediately re-run in the HPLC, it was revealed that 
peak 1 was very stable but peaks 2 and 3 were not (Figure 22); when re-run, peak 
1, previously identified as L-cystine, gave only one peak at the same retention time. 
Peak 2, previously identified as L-cysteine, was split into two peaks whose retention 
times were equal to those of peak 1 and peak 2, respectively. Peak 3, previously 
identified as the novel relaxant, also generated another peak whose retention time 
was equal to that of peak 1. Thus, both peak 2 (L-cysteine) and peak 3 (novel 
relaxant) decayed to give peak 1 (L-cystine).
Peaks 1, 2 and 3 were collected and stored in glass test tubes at -20°C in the deep 
freeze for 12 hours and then retested in the HPLC and bioassay. Peak 1 still ran as a 
single peak, peak 2 partially decayed to peak 1, and peak 3 also partially decayed to 
peak 1 but retained much of its relaxant activity when assayed on phenylephrine 
(0.3 pM)-contracted BRP strips (Figure 23). Following freeze drying for 12 hours 
and reconstitution in an identical volume, peak 1 still ran as a single peak in the 
HPLC, peak 2 partially decayed to peak 1, but peak 3 completely decayed to peak 1 
and this was associated with loss of all of its relaxant activity. Thus the novel
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Figure 21. Differential spectrophotometry of the peaks collected following HPLC 
separation of L-cysteine (10 mM) before (Cysteine) and after (NO-Cysteine) gassing 
with nitric oxide in aqueous deoxygenated solutions at pH 3.0 for 10 minutes and 
followed by purging with oxygen-free nitrogen. HPLC peaks 1 (PI) and 2 (P2) each 
had one absorption peak with a maximum at 193 nm and 195 nm, respectively. 
HPLC peak 3 (P3) had three absorption peaks with maxima at 193, 218 and 335 
nm.
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Figure 22. In the HPLC the three peaks (P I, P2 and P3) were separated from a 
solution in which L-cysteine (10 mM) at pH 3.0 was bubbled to saturation with 
nitric oxide for 10 minutes under nominal oxygen-free conditions followed by 
purging with oxygen-free nitrogen. Re-run of P I, P2 and P3 collected from the top 
5% of each peak showed that PI was stable, and that P2 and P3 partially decayed 
to PI. HPLC analysis was performed with an analytical column using water at pH
3.0 as the solvent.
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Figure 23. Following separation by HPLC, peaks 1 (PI), 2 (P2) and 3 (P3) were 
collected and stored in the deep freeze (-20°C) or freeze dried overnight. Peak 1 
was stable after freezing or freeze drying. Peak 2 partially decayed to peak 1 after 
freezing or freeze drying. Peak 3 gradually decayed to peak 1 after freezing but 
retained most of its relaxant activity. After freeze drying all of peak 3 decayed to 
peak 1 and this was associated with a complete loss of its relaxant activity as 
assessed on phenylephrine (0.3 pM)-precontracted strips of BRP. HPLC analysis 
was performed with an analytical column using water at pH 3.0 as the solvent.
V
IO
O
'O
Results
relaxant contained in HPLC peak 3 is relatively stable in the freezer, but is 
completely destroyed by freeze drying.
The relaxant activity contained in the HPLC peak 3 was not sensitive to oxygen 
(Figure 24). After gassing with pure oxygen for 10 minutes at room temperature, 
the behaviour of peak 3 did not change in the HPLC or bioassay; like the control, it 
partially decayed into peak 1.
Treatment of the peak 3 sample at 70°C for 10 minutes had little effect on its 
relaxant activity as assessed on phenylephrine (0.3 pM)-contracted BRP strips but a 
small reduction in peak 3 and a slight increase in peak 1 were seen when the sample 
was re-run in the HPLC (Figure 25). However, when the peak 3 sample in an open 
glass test tube was placed in boiling water for 10 minutes, much of its relaxant 
activity was lost when bioassayed (Figure 26). Furthermore, its peak 3 was almost 
completely lost and this was accompanied by a large increase in peak 1 in the 
HPLC. Thus, the new relaxant is relatively stable at 70°C but not when boiled.
The new relaxant activity was destroyed by methanol (Figure 27); mixing the peak 
3 sample with pure methanol (HPLC grade, 1:1) at 0°C for 10 minutes resulted in a 
significant decrease in relaxant activity, a reduction of its peak 3 component by 50 
%, an increase in the height of its peak 1 component and generation of three more 
new peaks in the HPLC.
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Figure 24. Bubbling the peak 3 relaxant fraction collected from the HPLC with 
oxygen for 10 minutes changed neither its behaviour in the HPLC nor its relaxant 
activity. Tone of the BRP muscle was raised by phenylephrine (0.3 pM). HPLC 
analysis was performed with an analytical column using water at pH 3.0 as the 
solvent.
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Figure 26. Treatment of the peak 3 relaxant fraction collected from the HPLC in 
an open test tube at 100°C for 10 minutes resulted in a decrease in its relaxant 
activity in association with a nearly complete conversion of peak 3 (P3) to peak 1 
(PI) in the HPLC. Tone of the BRP muscle was raised by phenylephrine (0.3 pM). 
HPLC analysis was performed with an analytical column using water at pH 3.0 as 
the solvent.
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Figure 27. Treatment of the peak 3 relaxant fraction collected from the HPLC with 
methanol (1:1 in volume) for 10 minutes resulted in a decrease in its relaxant 
activity in association with a 50% decrease in the height of peak 3 (P3), a two-fold 
increase in the height of peak 1 and the generation of three other peaks in the 
HPLC. Tone of the BRP muscle was raised by phenylephrine (0.3 pM). HPLC 
analysis was performed with an analytical column using water at pH 3.0 as the 
solvent.
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3.2.4. Conditions Favouring the Form ation of the New Relaxant in 
M ixtures of Nitric Oxide and L-Cysteine
3.2.4.1. Acid pH-Dependence
Under nominally oxygen-free conditions formation of the powerful new smooth 
muscle relaxant in mixtures of nitric oxide and L-cysteine was strictly acid pH- 
dependent. Figure 28 shows a bioassay on a rabbit phenylephrine (0.3 pM)- 
contracted aortic ring of mixtures of nitric oxide (100 pM) and L-cysteine (15 mM) 
in aqueous solutions at pH values ranging from 7.4 to 1.0. After 10 minutes these 
solutions were purged with oxygen-free nitrogen to remove free nitric oxide and 
then adjusted to pH 7.4 respectively. The lower the reaction pH, the higher was the 
relaxant activity; at pH 7.4 little relaxant activity was generated and at pH 1.0 
maximal relaxant activity was generated.
Figure 29 shows that in the HPLC the formation of the new relaxant in nominally 
oxygen-free L-cysteine aqueous solutions following mixing with nitric oxide was 
not only acid pH-dependent but also dependent upon the concentration of nitric 
oxide added. L-Cysteine (10 mM) alone gave a single peak in the HPLC rather than 
two peaks because the efficiency of the column was poor on this day. The new 
relaxant was therefore represented here as peak 2 rather than peak 3. At pH 5 and 
pH 7 more L-cysteine was oxidised to L-cystine which has 125 times the absorption 
of L-cysteine and this accounts for the high absorption of peak 1 at these pH values. 
At pH 7 the new relaxant (peak 2) was only detected when solutions of L-cysteine 
(10 mM) were gassed with nitric oxide for 10 minutes but not if nitric oxide was 
added at a concentration of 50 or 500 pM. At pH 5 all of these concentrations of 
nitric oxide generated peak 2 following reaction with L-cysteine (10 mM) and the 
size of the peak was proportional to the amounts added. At pH 3 again the
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Figure 28. Generation of powerful relaxant activity from the reaction of nitric 
oxide (100 pM) and L-cysteine (15 mM) was strictly pH-dependent; following 
removal of free nitric oxide by purging with oxygen-free nitrogen and 
neutralisation, little activity was generated at pH 7.4 and maximal activity was 
achieved at pH 1.0. Bioassay was performed in a rabbit endothelium-denuded aortic 
ring submaximally contracted by phenylephrine (0.3 pM). The concentrations refer 
to the final bath concentrations of the reactants.
Figure 29. HPLC analysis showed that the formation of the new relaxant following 
reaction of L-cysteine (10 mM) and nitric oxide (50 pM to saturation) was acid pH- 
and concentration-dependent. In this experiment the efficiency of the column was 
lower than on previous days and L-cysteine and its oxidised form, L-cystine, eluted 
as a single rather than a double peak. The new relaxant formed by reacting L- 
cysteine and nitric oxide was therefore eluted as a second rather than a third peak. 
At pH 7 the novel relaxant represented by peak 2 was only formed if nitric oxide 
was bubbled to saturation but not if it was added at 50 or 500 pM. At pH 5 peak 2 
was formed with all three concentrations of nitric oxide with the amounts formed 
being proportional to the concentrations of nitric oxide added. At pH 3 the height of 
peak 2 was again proportional to the concentrations of nitric oxide and the amounts 
formed were greater than at pH 7 or pH 5. HPLC analysis was performed with an 
analytical column using water at pH 3.0 as the solvent.
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magnitude of peak 2 was proportional to the amount of nitric oxide added, but the 
peak sizes were greater than at pH 7 or pH 5.
3.2.4.2. Oxygen Dependence
Although all previous experiments involving the reaction of nitric oxide and L- 
cysteine were conducted under nominally oxygen-free conditions, we suspected that 
the techniques used were not sufficient to completely exclude oxygen. We therefore 
adopted the more rigorous procedures described in Materials and Methods (see 
section 2.3.1. and Figure 2) in which trace amounts of oxygen and nitrogen dioxide 
were removed from nitric oxide and commercial "oxygen-free" nitrogen gases using 
Fieser's solution and sodium hydroxide respectively.
3.2.4.2.I. Assessment of Ability to Exclude Oxygen
Before investigating the reaction of nitric oxide with L-cysteine in the absence and 
presence of oxygen, it was essential to ensure that no oxygen or nitrogen dioxide 
was present in the reactants and the apparatus. Nitric oxide readily reacts with 
oxygen to form nitrogen dioxide and both oxides of nitrogen can be detected upon 
spectrophotometric examination. Under rigorous oxygen-free conditions, purified 
oxygen-free nitrogen gas was bubbled into 1 ml of purified Milli-Q water in a 
cuvette for an hour and then the solution was bubbled to saturation for 30 minutes 
with purified nitric oxide gas. Figure 30 shows the results of scanning the solution 
in a spectrophotometer between 190 to 410 nm. Nitric oxide (saturated) in water 
had only one absorption peak with a maximum at 190 nm. The stopper was then 
removed exposing the solution to the air and immediately replaced back on the 
cuvette. The nitric oxide solution was then mixed with the introduced air by 
inversion 5 times every 10 seconds with introduction of air again after every 
minute. Formation of nitrogen dioxide was indicated by its characteristic absorption
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Figure 30. Differential spectrophotometry of nitric oxide-saturated water under 
rigorous oxygen-free conditions and its spectrophotometric development of 
absorption after mixing with air for 10 seconds (10s), 3 (3m), 10 (10m) and 20 
(20m) minutes. Nitric oxide-saturated water had an absorption peak with a 
maximum at 190 nm. The appearance of the characteristic absorption in the 300-400 
nm wavelength region indicated formation of nitrogen dioxide in water. Also the 
maximum at 190 nm was gradually shifted toward 232 nm after introduction of air. 
Note the two different scales used to measure absorbance.
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(multiple peaks) at 300-400 nm. Also, the peak maximum at 190 nm gradually 
shifted toward 232 nm. Significant absorption changes were measured even with 10 
seconds of mixing with air and maximal changes were achieved in 10 minutes. 
Thus, if any trace of oxygen is present during preparation of nitric oxide solutions, 
there will be a shift of maximum at 190 nm.
Figure 31 shows the differential spectrophotometric absorption of nitric oxide under 
rigorous oxygen-free conditions in the gas phase against air. The absorption 
characteristics are identical to those described for nitric oxide in the gas phase 
(Committee on Medical and Biological Effects of Environmental Pollutants, 1977). 
The first band of absorption (multiple peaks) appears at wavelengths less than 230 
nm. Following introduction of oxygen (1:1), a deep red-brown gas was immediately 
formed in the cuvette and the spectrophotometric absorption characteristics of 
nitrogen dioxide (multiple peaks at 300 to 400 nm) appeared.
3.2.4.2.2. Reaction of L-Cysteine and Nitric Oxide at Acid pH in Oxygen-free 
Conditions
All experiments were conducted using the rigorous technique for removing oxygen 
and nitrogen dioxide described in Materials and Methods (see section 2.3.1. and 
Figure 2). In these experiments aqueous solutions of L-cysteine (10 mM, pH 3.0) 
were bubbled to saturation with nitric oxide for 10 minutes. They were then purged 
with purified oxygen-free nitrogen to remove free nitric oxide and kept in the sealed 
cuvette (Figure 32). These solutions did relax phenylephrine (0.3 pM)-precontracted 
rings of rabbit aorta but their relaxant activity was much lower than that observed 
under less rigorous oxygen-free conditions (Figure 17). This relaxant activity was 
associated with a small peak 3 in the HPLC (Figure 33) and two low absorption 
peaks with maxima at 218 and 335 nm in the spectrophotometer (Figure 34). The 
relaxant activity in the bioassay, the height of peak 3 in the HPLC, and the
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Figure 31. Differential spectrophotometry of nitric oxide in the gas phase under 
rigorous oxygen-free conditions and the change of absorption after mixing with 
oxygen (1:1 vol./vol.) for 3 and 15 minutes. In the UV-visible region the first 
electronic absorption band of nitric oxide in the gas phase occurred at wavelengths 
less than 230 nm. Formation of nitrogen dioxide was indicated by the appearance of 
its characteristic absorption (multiple peaks ) in the 300-400 nm wavelength region. 
Note the use of two different absorption scales.
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Figure 32. No changes were observed within 80 minutes in the relaxant activity of 
aqueous solutions of L-cysteine (10 mM, pH 3.0) bubbled to saturation with nitric 
oxide for 10 minutes under rigorous oxygen-free conditions and purged with 
oxygen-free nitrogen in a sealed cuvette. At the end of this time the solution was 
mixed with air for 20 minutes but again relaxant activity remained unchanged. 
Bioassay was carried out on a rabbit endothelium-denuded aortic ring submaximally 
contracted by phenylephrine (0.3 pM).
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Figure 33. In the HPLC no changes in peak 3 within 80 minutes were observed in 
aqueous solutions of L-cysteine (10 mM, pH 3.0) bubbled to saturation with nitric 
oxide for 10 minutes under rigorous oxygen-free conditions and purged with 
oxygen-free nitrogen in a sealed cuvette. Peak 3 also did not change when the 
solution was mixed with air for 20 minutes. HPLC analysis was performed with an 
analytical column using water at pH 3 as the solvent.
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Figure 34. Using differential spectrophotometry aqueous solutions of L-cysteine 
(10 mM, pH 3.0) bubbled to saturation with nitric oxide for 10 minutes under 
rigorous oxygen-free conditions and purged with oxygen-free nitrogen in a sealed 
cuvette had two absorption peaks with maxima at 218 and 335 nm. These peaks 
were not changed for up to 80 minutes while the cuvette was sealed and were not 
changed after mixing with air for 20 minutes. Note the use of two different 
absorption scales.
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absorption peaks in the spectrophotometer remained unchanged if the solutions were 
kept sealed for up to 80 minutes and these properties did not change when the 
solutions were mixed with air for 20 minutes. The solutions remained colourless 
throughout the experiment and no absorption bands were present in the visible 
region (> 5 0 0  nm). In the HPLC peaks 2 and 3 were very stable, whereas peak 1 
increased in height after mixing with air for 20 minutes.
If nitric oxide dissolved in the L-cysteine solution and that free in the head space in 
the cuvette was not removed after mixing, the relaxant activity generated was much 
greater (Figures 35 & 36) than when nitric oxide was removed by purging (Figure 
32). This was not surprising since this solution contained about 1-3 mM dissolved 
nitric oxide when saturated and free nitric oxide was also a very powerful relaxant 
(Figures 16 & 17). When assayed on phenylephrine (0.3 pM)-contracted aortic 
rings (Figure 35) or BRP strips (Figure 36) the magnitude of the relaxation induced 
by the nitric oxide-saturated L-cysteine (10 mM) solution remained unchanged for 
up to 80 minutes in the sealed cuvette and did not change even after mixing with air 
for 20 minutes. However, the duration of the relaxation was greater when assayed 
on rabbit aortic rings after exposed to the air (Figure 35) but this was not seen on 
BRP strips (Figure 36). This solution at zero time produced four peaks in the 
HPLC; peaks 1, 2, 3 and 4 corresponding to L-cystine, L-cysteine, the new relaxant 
and nitric oxide in retention time, respectively (Figure 37). When the solution was 
kept sealed in the cuvette for up to 80 minutes, peaks 1 and 3 gradually increased in 
size, and peaks 2 and 4 remained unchanged. After the solution was mixed with air 
for 10 minutes, peaks 1 and 3 increased massively, peak 2 was slightly reduced and 
peak 4 disappeared. In the spectrophotometer there were two low absorption peaks 
at 218 and 335 nm in this sealed solution at zero time (Figure 38). The height of 
these peaks increased slowly during the 80 minutes before the solution was mixed 
with air but increased massively after mixing. The peak at 218 nm was also shifted 
towards 232 nm. While remaining sealed, a third peak at 545 nm became
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Figure 35. This figure shows the relaxant activity generated under rigorous 
oxygen-free conditions when aqueous solutions of L-cysteine (10 mM, pH 3.0) 
were bubbled to saturation with nitric oxide for 10 minutes in a sealed cuvette. 
These solutions were not purged to remove free nitric oxide. The relaxant activity 
of these solutions did not change during 80 minutes while sealed. After mixing with 
air the solution instantly became pink in colour and 10 minutes later its relaxant 
activity was equal in magnitude to that before exposure to the air but was longer in 
duration. Bioassay was carried out on a rabbit endothelium-denuded aortic ring 
submaximally contracted by phenylephrine (0.3 pM).
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Figure 36. This figure shows the relaxant activity generated under rigorous 
oxygen-free conditions when aqueous solutions of L-cysteine (10 mM, pH 3.0) 
were bubbled to saturation with nitric oxide for 10 minutes in a sealed cuvette. 
These solutions were not purged to remove free nitric oxide. The relaxant activity 
of these solutions did not change during 80 minutes while sealed. After mixing with 
air the solution instantly became pink in colour but the relaxant activity remained 
unchanged. Bioassay was carried out on a BRP strip submaximally contracted by 
phenylephrine (0.3 pM).
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Figure 37. This figure shows the HPLC analysis carried out on the novel relaxant 
formed under rigorous oxygen-free conditions when aqueous solutions of L-cysteine 
(10 mM, pH 3) were bubbled to saturation with nitric oxide for 10 minutes and free 
nitric oxide was not removed by purging with nitrogen. In the HPLC peaks 1 and 3 
gradually increased but peaks 2 and 4 remained unchanged over 80 minutes while 
the cuvette remained sealed. After this time the solution was opened to the air and it 
turned pink and following mixing with air for 10 minutes, peaks 1 and 3 were 
increased massively, peak 2 was reduced slightly and peak 4 disappeared. HPLC 
analysis was performed with an analytical column using water at pH 3.0 as the 
solvent.
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Figure 38. This figure shows the differential spectrophotometric analysis carried 
out on the novel relaxant formed under rigorous oxygen-free conditions when 
aqueous solutions of L-cysteine (10 mM, pH 3) were bubbled to saturation with 
nitric oxide for 10 minutes and free nitric oxide was not removed by purging with 
nitrogen. At time zero two absorption peaks with maxima at 218 and 335 nm were 
seen in the sealed cuvette and these increased in size over 80 minutes. After 40 
minutes a new peak at 543 nm became measurable if the sensitivity was increased to 
0.05 absorption units full scale (insert) and this increased slightly by 80 minutes. 
The height of three peaks increased massively after the solution was opened to the 
air and mixed for 10 minutes. The solution turned pink immediately following 
mixing with air. The peak at 218 nm was slowly shifted toward 232 nm, but no 
shift was seen in the peaks at 335 and 543 nm.
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measurable after 40 minutes but only if the sensitivity was increased 40 times from
2.0 to 0.05 absorption units full scale. This third absorption peak rose further by 80 
minutes, and increased dramatically when the solution was mixed with air for 10 
minutes. This rise explains why the solution instantly became pink in colour when 
exposed to the air.
There were two possible explanations for the slow increase with time in the 
magnitude of these three peaks at 218, 335 and 543 nm. One was that the reaction 
between nitric oxide and L-cysteine was slow, but that seemed unlikely. A more 
likely explanation was that despite our rigorous precautions oxygen slowly 
penetrated through the sealed container and increased the rate of the reaction. This 
latter possibility could also explain why the relaxant activity was stable whereas 
peak 3 in the HPLC and the absorption peaks at 218, 335 and 543 nm in the 
spectrophotometer increased slowly with time in this particular experiment (Figures 
35-38). Our hypothesis was that because the bioassay was performed on an 
oxygenated conditions, it was possible that when the contents of the cuvette were 
added to the bath, a further rapid reaction with oxygen could take place causing a 
large increase in relaxant activity, whereas HPLC and spectrophotometric analysis 
were performed under oxygen-free conditions. Experiments were therefore designed 
to test whether oxygen played a critical role in the reaction of nitric oxide with L- 
cysteine. Solutions of L-cysteine (10 mM) were bubbled with nitric oxide gas to 
saturation under stringent oxygen-free conditions followed by purging with oxygen- 
free nitrogen to remove free nitric oxide, neutralisation and exposed to the air. 
These solutions had very low relaxant activity (Figure 39), were colourless but 
contained two small absorption peaks at 218 and 335 nm. If, however, nitric oxide 
was bubbled to saturation in solutions of L-cysteine (10 mM) and the contents were 
exposed to the air before purging and neutralisation, the relaxant activity generated 
was greatly (about 40-fold) increased and proportionate rises seen in the absorption 
peaks at 218 and 335 nm. Furthermore, a new peak became visible at 543 nm which
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Figure 39. Bubbling nitric oxide gas to saturation for 10 minutes in solutions of L- 
cysteine (10 mM) in stringent oxygen-free conditions followed by purging with 
oxygen-free nitrogen to remove free nitric oxide (NO removed), neutralisation and 
exposed to the air produced low relaxant activity as assessed on phenylephrine (0.3 
pM)-contracted, endothelium-denuded rings of rabbit aorta. These solutions were 
colourless but contained two small absorption peaks at 218 and 335 nm (continuous 
line). If, however, nitric oxide was bubbled to saturation for 10 minutes in solutions 
of L-cysteine (10 mM) and the reaction chamber was opened to the air before 
neutralisation and purging (NO present), the relaxant activity generated was greatly 
(»40-fold) increased. The absorption peaks at 218 and 335 nm (discontinuous line) 
increased by a proportionate degree and a new peak (insert) became visible at 543 
nm which was responsible for the development of a pink colour. Note the use of 
two absorption scales.
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was responsible for the development of a pink colour. These findings suggested that 
relaxant activity and magnitude of the absorption peaks at 218, 335 and 543 nm 
were strictly related. They also implied a critical involvement of oxygen in the 
reaction of nitric oxide with L-cysteine and in the slow increase of absorption in the 
sealed cuvette containing L-cysteine and nitric oxide (Figure 38).
A different type of experiment was conducted to establish if the slow rise in 
absorbance when saturated nitric oxide was left in sealed solutions of L-cysteine was 
due to a slow rate of reaction of nitric oxide with L-cysteine or to a slow entry of 
oxygen. Two samples were prepared by the same rigorous procedures to obtain 
oxygen-free conditions. One sealed sample was placed in the spectrophotometer and 
readings taken for up to 24 hours and the other was kept under water which was 
continuously bubbled with purified oxygen-free nitrogen in the sealed Amicon 
chamber for 24 hours before it was removed for spectrophotometric measurement. 
If the absorption spectra of two samples were identical at 24 hours, then the 
increase of absorption would be due to the reaction between nitric oxide and L- 
cysteine occurring at a slow rate. Alternatively, if the absorption spectra of the 
sample kept in a sealed cuvette under water which was deoxygenated by oxygen- 
free nitrogen in an Amicon chamber was lower at 24 hours than that of the sample 
placed in the spectrophotometer, then the increase of absorption would be due to 
oxygen penetrating through the container.
The details of the experiment were as follows. Two cuvettes, stoppers and needles 
were degassed under 0.06 mmHg pressure in a high vacuum freeze dryer for 24 
hours to maximally remove air in these materials. Before being taken out of the 
vacuum, the flask in which they were placed was filled with oxygen-free nitrogen. 
Then they were immediately removed from the freeze dryer into aqueous solutions 
of L-cysteine (10 mM, pH 3) that had been deoxygenated by purified oxygen-free 
nitrogen for 2 hours. These two cuvettes were completely filled with the solution,
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sealed and quickly transferred into the Amicon chamber and submerged under Milli­
es purified water that had been deoxygenated by oxygen-free nitrogen for two hours. 
The Amicon chamber was then closed and the solutions in the cuvettes were gassed 
with oxygen-free nitrogen for 1 hour. The solutions in the cuvettes were then gassed 
to saturation with purified nitric oxide for 10 minutes. One sealed cuvette remained 
in the Amicon chamber under water continuously gassed with oxygen-free nitrogen 
for 24 hours and the other was removed and the seal enhanced by pouring melted 
wax over the silicon stopper before placing the cuvette in a spectrophotometer. The 
absorption spectra of this sample were measured from 900 nm down to 190 nm at 
time zero (nominally), 80 minutes, 3, 6, 16, 18 and 24 hours and after the solution 
was exposed to the air and mixed for 10 minutes. Figure 40 shows that while 
sealed, the absorption peaks at 218, 335 and 543 nm increased with time but 
changed little when the cuvette was opened to the air at 24 hours. In contrast, the 
absorption peaks at 218, 335 and 543 of the sealed sample which remained in the 
Amicon chamber for 24 hours while under water bubbled with oxygen-free nitrogen 
were much lower. Furthermore, when this second sample was exposed to the air for 
10 minutes, all three peaks increased in magnitude. These results suggested that the 
slow rise in the three absorption peaks with time even when the cuvette was sealed 
was due to the slow entry of oxygen into the reaction chamber and that oxygen was 
a vital component in the reaction.
3.2.4.3. Investigation of Involvement of Nitrogen Dioxide
Since formation of the new relaxant in the reaction of nitric oxide with L-cysteine 
was enhanced in the presence of oxygen and since nitrogen dioxide is formed from 
the reaction of nitric oxide with oxygen, the possibility was examined that nitrogen 
dioxide was the species which reacted with L-cysteine to form the new relaxant.
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Figure 40. The top panel shows the differential spectrophotometric trace of an 
aqueous solution of L-cysteine (10 mM) at pH 3.0 bubbled to saturation with nitric 
oxide for 10 minutes in a sealed cuvette. At time zero there were two absorption 
peaks with maxima at 218 and 335 nm. After 80 minutes a new peak at 543 nm 
became measurable at an enhanced sensitivity of 0.05 absorption units full scale 
(insert). All peaks increased slowly until 18 hours. The peak with a maximum at 
217 nm shifted slowly towards 232 nm, whereas those at 335 nm and 542 nm did 
not shift. At 24 hours the peak absorption remained unchanged at 232 nm but those 
at 335 and 543 nm decreased slightly. After the solution was opened and mixed 
with air, the absorption at 232 and 543 nm increased slightly but that at 335 nm 
decreased slightly. m =  minutes; h =  hours.
The bottom panel shows the differential spectrophotometric trace of an aqueous 
solution of L-cysteine (10 mM) at pH 3 bubbled to saturation with nitric oxide for 
10 minutes in a sealed cuvette and kept for 24 hours under water which was 
continuously gassed with oxygen-free nitrogen in a sealed Amicon chamber. At 24 
hours and while sealed the three absorption peaks at 232, 335 and 543 nm were 
much lower than in the sample placed in the spectrophotometer for 24 hours. After 
the solution was opened and mixed with air, the magnitude of all three peaks was 
increased.
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Results
This investigation was performed by comparing the relaxant activity in the bioassay, 
the height of peak 3 in the HPLC and the spectrophotometric characteristics of 
mixtures of nitric oxide and L-cysteine and mixtures of nitrogen dioxide and L- 
cysteine at the same concentrations and at pH 3.0 under rigorous oxygen-free 
conditions. All solutions were purged with oxygen-free nitrogen to remove the free 
gases before bioassay or analysis in the HPLC and spectrophotometer. At a 
concentration of 0.1 mM nitric oxide, but not nitrogen dioxide, reacted with L- 
cysteine (10 mM) producing relaxant activity as assayed on a phenylephrine (0.3 p 
M)-contracted BRP strip (Figure 41). The associated relaxant peak 3 in the HPLC 
and the characteristic absorption peak at 335 nm corresponding to the relaxant in the 
spectrophotometer (Figures 41-43) were also formed only with nitric oxide. If the 
concentration of the two gasses was increased to 1 mM, relaxant activity and the 
associated third peak in the HPLC were also produced with nitrogen dioxide, but 
the magnitude of these was lower than that for nitric oxide (Figure 44). If L- 
cysteine solutions (10 mM) were gassed to saturation with nitric oxide or nitrogen 
dioxide for 10 minutes followed by removal of the gasses by purging with nitrogen, 
complete relaxation of a phenylephrine (0.3 pM)-contracted BRP strip was obtained 
by adding 10 pi of either solution, but the duration of the relaxation induced by the 
solution bubbled with nitrogen dioxide was longer than that induced by the solution 
bubbled with nitric oxide (Figure 45). In each case the relaxant activity was 
associated with the characteristic peak 3 in the HPLC. In the case of bubbling to 
saturation with nitrogen dioxide numerous other peaks were eluted from the column 
after peak 3 and were thus more lipophilic. Due to the high concentrations of L- 
cystine generated in both solutions, peak 1 and peak 2 merged (Figure 45). Clearly, 
nitrogen dioxide had the ability to generate many more new substances than nitric 
oxide. Furthermore, the solution bubbled with nitrogen dioxide was pinkish red, 
whereas that bubbled with nitric oxide was colourless. Even when the solution was 
kept in a sealed brown bottle at 4°C for up to 7 days, further reactions continued to
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Figure 41. The relaxant activity in the bioassay and the associated peak 3 
characteristic of the relaxant in the HPLC were generated under rigorous oxygen- 
free conditions from L-cysteine (10 mM) reacting with nitric oxide (0.1 mM), but 
not with nitrogen dioxide (0.1 mM), in aqueous solutions at pH 3 for 10 minutes 
followed by purging with oxygen-free nitrogen. Bioassay was carried out on a BRP 
strip submaximally contracted by phenylephrine (0.3 pM). HPLC analysis was 
performed with an analytical column using water at pH 3.0 as the solvent.
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Figure 42. Differential spectrophotometry shows that the characteristic absorption 
of the new relaxant with a peak at 335 nm was observed under rigorous oxygen-free 
conditions when aqueous solutions of L-cysteine (10 mM) at pH 3 were reacted with 
nitric oxide (0.1 mM) for 10 minutes followed by purging with oxygen-free 
nitrogen in a sealed cuvette. Note the use of two absorption scales.
L-Cyste ine 10m M
L-Cyste ine 10m M  + NO2 0 .1 m M
ll
?oor 6 0 04 0 0 5 0 0
<N |O"
W a v e le n g th  ( nm
^-WAr- 
200 3 0 0 4 0 0 5 0 0 6 0 0
Figure 43. Differential spectrophotometry shows that the characteristic absorption 
of the new relaxant with a peak at 335 nm was not observed under rigorous oxygen- 
free conditions when aqueous solutions of L-cysteine (10 mM) at pH 3 were reacted 
with nitrogen dioxide (0.1 mM) for 10 minutes followed by purging with oxygen- 
free nitrogen in a sealed cuvette. Note the use of two absorption scales.
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Figure 44. The relaxant activity in the bioassay and the associated peak 3 
characteristic of the new relaxant in the HPLC were generated under rigorous 
oxygen-free conditions when nitric oxide (0.1 mM) and nitrogen dioxide (0.1 mM) 
respectively reacted with L-cysteine (10 mM) in aqueous solutions at pH 3 for 10 
minutes followed by purging with oxygen-free nitrogen. Nitric oxide generated 
greater relaxant activity and a larger peak 3 than nitrogen dioxide. Bioassay was 
carried out on a BRP strip submaximally contracted by phenylephrine (0.3 pM). 
HPLC analysis was performed with an analytical column using water at pH 3.0 as 
the solvent.
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take place as judged by the continued formation of new peaks in the HPLC (Figure 
46). However, during these 7 days peak 3 was gradually reduced in magnitude.
Since nitrogen dioxide at high concentrations was able to react with L-cysteine to 
form the new relaxant, the possibility was considered that it was only able to do so 
after dissolving in solution to form nitrous acid which would then under acid 
conditions decay to form nitric oxide. Experiments were then conducted under 
rigorous oxygen-free conditions in which nitric oxide and nitrogen dioxide were 
gassed to saturation in distilled water and the contents assessed by bioassay and by 
HPLC. Figure 47 shows that water bubbled to saturation with nitric oxide or 
nitrogen dioxide for 10 minutes exhibited similar powerful relaxant activity when 
assayed on phenylephrine (0.3 pM)-contracted BRP strips. In the HPLC nitrogen 
dioxide-gassed water produced two peaks, the second of which was identical in 
retention time to the single peak observed for nitric oxide-gassed water. The 
relaxant activities in the bioassay were consistent with the height of the nitric oxide- 
related peak in the HPLC. Thus, solutions bubbled to saturation with nitrogen 
dioxide do generate nitric oxide and this may explain why at high concentrations 
nitrogen dioxide can react with L-cysteine to form the new relaxant and the 
associated peak 3 in the HPLC.
3.2.4.4. Further Studies of the Reactions of L-Cysteine with Nitric Oxide or 
Nitrogen Dioxide
Since the above studies on the reactions between L-cysteine and nitric oxide or 
nitrogen dioxide were shown to be optimal at acid pH and in the presence of 
oxygen, it was important to determine if the new relaxant could be formed under 
more physiological conditions. A series of experiments was therefore conducted to 
examined if the new relaxant could be formed under ambient oxygen conditions at 
neutral pH and at physiological concentrations of L-cysteine.
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Figure 46. These HPLC traces show that under rigorous oxygen-free conditions 
when aqueous solutions of L-cysteine (10 mM) at pH 3 were bubbled to saturation 
with nitrogen dioxide for 10 minutes followed by purging with oxygen-free nitrogen 
for 10 minutes the peak 3 (P3) characteristic of the new relaxant was formed. Many 
other peaks were also formed and reactions continued to occur for up to 7 days as 
indicated by the appearance of further new peaks when the solution was stored at 
4°C in a brown bottle. Bioassay was carried out on a BRP strip submaximally 
contracted by phenylephrine (0.3 pM). HPLC analysis was performed with an 
analytical column using water at pH 3.0 as the solvent.
NO-bubbled H2 O [\IO2 -bubbled H2 O
HPLC
NO
2min
NO
Bioassay 5g
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Figure 47. Deoxygenated water bubbled to saturation with nitric oxide or nitrogen 
dioxide for 10 minutes exhibited similar powerful relaxant activity on a BRP strip 
contracted by phenylephrine (0.3 pM). In the HPLC nitrogen dioxide-gassed water 
produced two peaks, the second of which was identical in retention time to the 
single peak of nitric oxide-gassed water. The relaxant activities in the bioassay were 
consistent with the height of the peak associated with nitric oxide in the HPLC. 
HPLC analysis was performed with an analytical column using water at pH 3 as the 
solvent.
Results
At ambient oxygen tension and at pH 3.0 relaxant activity and the associated 
characteristic absorption of the relaxant at 335 nm in the spectrophotometer were 
generated in aqueous solutions of L-cysteine (10 mM) following reaction with nitric 
oxide (0.1 mM) or nitrogen dioxide (0.1 mM), but the magnitude of these was 
higher for nitric oxide than for nitrogen dioxide (Figure 48). Even at neutral pH 
relaxant activity was generated when solutions of L-cysteine (10 mM) were reacted 
with nitric oxide (0.1 mM) or nitrogen dioxide (0.1 mM, Figure 49). Again, the 
activity and the associated absorption peak at 335 nm was greater when the solution 
was reacted with nitric oxide than with nitrogen dioxide. These results further 
support the oxygen- and acid pH-dependence of the formation of the new relaxant in 
the reaction of L-cysteine with nitric oxide or nitrogen dioxide. They also indicate 
that the new relaxant can be formed at physiological pH and ambient oxygen 
tension.
The reaction discussed above involved L-cysteine at a concentration of 10 mM but 
this is greatly in excess of its physiological concentration (0.15 mM in plasma, 
Ramsay, 1985). Also, the concentration of nitric oxide (0.1 mM) was greater than 
would expected physiologically. Consequently, an experiment was conducted in 
which more physiological concentrations of L-cysteine (0.15 mM) and nitric oxide 
(1 pM) were reacted and formation of the new relaxant assessed by bioassay and by 
the characteristic absorption peak at 335 nm in the spectrophotometer. Figure 50 
shows that even when under these sub-optimal conditions some relaxant activity and 
the associated absorption peak at 335 nm were observed. Thus, these studies suggest 
that the new relaxant can be formed when nitric oxide reacts with L-cysteine under 
ambient oxygen tension and at physiological pH and concentrations. Its formation is 
far from optimal under these conditions, however.
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Figure 48. At ambient oxygen tension and at pH 3.0 relaxant activity in the 
bioassay and the associated characteristic absorption peak of the relaxant at 335 nm 
in the spectrophotometer were generated in aqueous solutions of L-cysteine (10 
mM) reacting with (a.) nitric oxide (0.1 mM) or (b.) nitrogen dioxide (0.1 mM), 
but the magnitude of these was higher for nitric oxide than for nitrogen dioxide. 
These solutions were purged with oxygen-free nitrogen after the reaction to remove 
free gas. Bioassay was carried out on a rabbit endothelium-denuded aortic ring 
submaximally contracted by phenylephrine (0.3 pM). Differential absorption of the 
solutions was performed.
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Figure 49. At ambient oxygen tension and at pH 7.0 relaxant activity in the 
bioassay and the associated characteristic absorption peak of the relaxant at 335 nm 
in spectrophotometer were generated in aqueous solutions of L-cysteine (10 mM) 
reacting with (a.) nitric oxide (0.1 mM) or (b.) nitrogen dioxide (0.1 mM), but the 
magnitude of these was higher for nitric oxide than for nitrogen dioxide. These 
solutions were purged with oxygen-free nitrogen after the reaction to remove free 
gas. Bioassay was carried out on a rabbit endothelium-denuded aortic ring 
submaximally contracted by phenylephrine (0.3 pM). Differential absorption of the 
solutions was measured.
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Figure 50. At ambient oxygen tension and at pH 7.0 relaxant activity in the 
bioassay and the associated characteristic absorption peak of the relaxant at 335 nm 
in the spectrophotometer were generated in aqueous solutions of L-cysteine (150 p 
M) reacting with nitric oxide (1.0 pM). This solution was purged with oxygen-free 
nitrogen after the reaction to remove any free nitric oxide. Bioassay was carried out 
on a rabbit endothelium-denuded aortic ring submaximally contracted by 
phenylephrine (0.3 pM). Differential absorption of the solution was measured.
Results
3.2.5. Identity of the Relaxant G enerated by Reacting L-Cysteine W ith 
Nitric Oxide
The reaction of nitric oxide with L-cysteine generates a powerful new relaxant 
which may be important physiologically. It is therefore important that this novel 
substance be identified chemically.
3.2.5.1. Functional Groups Reacting with Nitric Oxide
The L-cysteine molecule has three functional groups, namely, the amine, carboxyl 
and sulfhydryl groups. The formation of the new relaxant must take place when 
nitric oxide reacts with one or more of these groups of L-cysteine. Therefore, 
removal, replacement or substitution of these functional groups on the L-cysteine 
molecule may affect the formation of the new relaxant and may provide information 
on its chemical nature. The study was extended also to L-glutathione, another 
abundant sulfhydryl-containing substance which has these three functional groups, 
and to its structural analogues as well as to a group of common non-sulfhydryl- 
containing amino acids.
In these experiments the compounds used were classified into five groups according 
to their structure. The first group comprised those compounds with all three 
functional groups intact. This group included L-cysteine and L-glutathione. The 
second group comprised only N-acetyl-L-cysteine whose amine group was 
substituted but whose carboxyl and sulfhydryl groups were free. The third group 
included those compounds whose carboxyl groups were removed or replaced with 
an ester function but whose amine and sulfhydryl groups were free. This group 
included L-cysteamine, L-cysteine ethyl ester and L-cysteine methyl ester. The 
fourth group included those compounds whose sulfhydryl groups were substituted or 
oxidised to the corresponding disulphide but whose amine and carboxyl groups were
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free. This group included L-cystamine, L-cysteic acid, L-cysteinesulphinic acid, L- 
cystine, L-glutathione (oxidised form), S-methyl-L-cysteine, S-methyl-L-glutathione 
and L-methionine. The final group included L-arginine, L-glutamic acid and L- 
glycine, all of which contain amine and carboxyl groups but not a sulfhydryl group. 
L-Arginine was also chosen since it is the precursor of nitric oxide in the body. L- 
Cysteine, L-glutamic acid and L-glycine are the amino acids which together 
comprise L-glutathione.
None of these compounds at a bath concentration of 0.15 mM had any smooth 
muscle relaxant activity when bioassayed on rabbit phenylephrine (0.3 pM)- 
contracted aortic rings (Figure 51). When aqueous deoxygenated solutions of these 
compounds (all at 15 mM) were mixed with nitric oxide (50 pM) at pH 2.0 for 10 
minutes followed by removal of free nitric oxide by purging with oxygen-free 
nitrogen and neutralisation with sodium hydroxide (1 N), relaxant activity was 
generated in the solutions of those compounds with free sulfhydryl groups (Figure 
51). Thus, L-glutathione, N-acetyl-L-cysteine, L-cysteamine, L-cysteine ethyl ester 
and L-cysteine methyl ester generated novel relaxant activity similar to that 
generated with L-cysteine. No relaxant activity was generated when the sulfhydryl 
group was removed, oxidised or substituted. Thus, L-cystamine, L-cysteic acid, L- 
cysteinesulphinic acid, L-cystine, L-glutathione (oxidised form), S-methyl-L- 
cysteine, S-methyl-L-glutathione, L-methionine, L-arginine, L-glutamic acid and L- 
glycine did not generate relaxant activity when reacted with nitric oxide. Thus, 
removal, replacement or substitution of amine or carboxyl groups in these 
compounds does not block the formation of new relaxant activity, whereas 
oxidation, removal or substitution of the free sulfhydryl group completely blocks 
the generation of new relaxants from these compounds. A summary of these results 
is shown in Table 1.
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Figure 51. Analysis of the functional group, i.e. amine, carboxyl or sulfhydryl 
group, in the L-cysteine molecule that reacted with nitric oxide in the formation of 
the new smooth muscle relaxant. None of these compounds at bath concentration of 
0.15 mM had any relaxant activity by themselves when assayed on rabbit 
phenylephrine (0.3 pM)-contracted aortic rings. When aqueous deoxygenated 
solutions of these compounds (all at 15 mM) were mixed with nitric oxide (50 pM) 
at pH 2.0 for 10 minutes followed by purging with oxygen-free nitrogen to remove 
free nitric oxide and neutralisation with sodium hydroxide (1 N), relaxant activity 
was generated in the solutions of those compounds with free sulfhydryl groups but 
not in those of compounds whose sulfhydryl groups were removed, substituted or 
oxidised to the disulphide. Removal, replacement or substitution of the amine or 
carboxyl groups did not block the formation of new relaxant activity, whereas 
oxidation, removal or substitution of the free sulfhydryl group completely blocked 
the generation of new relaxant activity.
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Table 1. Classification of compounds used to identify the functional group of
L-cysteine that reacts with nitric oxide
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Results
This structure-activity analysis by using various structural analogues of L-cysteine 
and L-glutathione indicates that the reactions with nitric oxide take place at the 
sulfhydryl group of the molecules. Therefore, the new relaxants generated are most 
likely to be the S-nitroso derivatives of these thiols.
3.2.6. Effects of Drugs on Relaxation Induced by Nitric Oxide, NANC 
Nerve Stimulation, and the New Relaxant G enerated by Reacting Nitric 
Oxide with L-Cysteine or L-GIutathione
Nitric oxide, the NANC transmitter and the novel compounds (S-nitrosocysteine and 
S-nitrosoglutathione) generated from nitric oxide reacting with L-cysteine or L- 
glutathione are all powerful relaxants. There is controversy, however, as to whether 
EDRF is nitric oxide (Palmer, et al., 1987) or an S-nitrosothiol (Myers, e ta l., 
1990). By analogy, we wanted to establish whether nitric oxide or an S-nitrosothiol 
more closely resembles the NANC transmitter in the BRP. A comparison of the 
effects of drugs on relaxation induced by nitric oxide, NANC nerve stimulation and 
the new relaxants generated by reacting nitric oxide with L-cysteine or L-glutathione 
was therefore made. It was hoped that this study would provide a vital clue to the 
precise nature of the inhibitory NANC neurotransmitter in the BRP.
3.2.6.1. Effects of N^-Nitro-L-arginine
In order to investigate the unlikely possibility that the novel relaxant generated from 
the reaction of L-cysteine with nitric oxide induced relaxation by stimulating the 
NANC nerves, the effects of a nitric oxide synthase inhibitor was examined.
N^-Nitro-L-arginine, an analogues of L-arginine, is a powerful inhibitor of nitric 
oxide synthase (Gibson, et al. , 1989). It inhibits endothelium-dependent relaxation 
in vascular smooth muscle (Moore, et al., 1989; Mulsch. & Busse, 1990) and
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NANC relaxation induced by nerve stimulation in the BRP and the rat and mouse 
anococcygeus muscles (Gibson, et al., 1989; 1990; Liu, et al., 1991).
Pretreatment of a rabbit aortic ring denuded of endothelium with N^-nitro-L- 
arginine (30 pM) for 15 minutes did not inhibit the relaxation on a phenylephrine 
(0.3 pM)-contracted ring induced by the relaxant generated by reacting nitric oxide 
(5 pM) with L-cysteine (15 mM, Figure 52). Thus, the new relaxant does not 
produce relaxation by activating the NANC nerves.
3.2.6.2. Effects of Haemoglobin
If the relaxant action of the new relaxant formed by reacting nitric oxide with L- 
cysteine is derived from the nitric oxide it releases, then its activity should be 
blocked by haemoglobin.
Haemoglobin binds nitric oxide avidly (Gibson & Roughton, 1957). It is a powerful 
inhibitor of EDRF-dependent relaxation (Martin, et al., 1985) and inhibitory 
NANC relaxation in the BRP (Bowman, et al., 1982b). In a BRP strip contracted 
by guanethidine (10 pM) oxyhaemoglobin at a concentration of 3 pM completely 
blocked the relaxation induced by authentic nitric oxide (0.3 pM), the new relaxant 
(30 pi into a 20 ml bath) generated from L-cysteine (10 mM) solutions bubbled to 
saturation with nitric oxide for 10 minutes at pH 3.0 and purged with oxygen-free 
nitrogen to remove free nitric oxide, and NANC nerve stimulation (2 Hz, 20 pulses) 
(Figure 53). It is therefore likely that the new relaxant formed from reacting nitric 
oxide with L-cysteine induces relaxation by the liberation of nitric oxide.
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Figure 52. Pretreatment of a rabbit endothelium-denuded aortic ring with N ^- 
nitro-L-arginine (30 pM) for 15 minutes did not inhibit the relaxation induced by 
the relaxant generated from L-cysteine (15 mM) reacting with nitric oxide (5 pM) 
in aqueous deoxygenated solutions at pH 3 for 10 minutes followed by purging with 
oxygen-free nitrogen and neutralisation. The rabbit aortic ring was submaximally 
contracted by phenylephrine (0.3 pM). The concentrations given on the figure are 
final bath concentrations.
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Figure 53. In BRP muscle precontracted by guanethidine (10 pM) oxyhaemoglobin 
(Hb 3 pM) completely blocked the relaxation induced by NANC nerve stimulation 
(2 Hz, 20 pulses), nitric oxide (0.3 pM) and S-nitrosocysteine generated from L- 
cysteine (10 mM) aqueous deoxygenated solutions bubbled to saturation with nitric 
oxide for 10 minutes at pH 3 followed by purging with oxygen-free nitrogen to 
remove free nitric oxide and neutralisation.
Results
3.2.6.3. Effects of Methylene Blue and N-Methyl-hydroxylamine
Methylene blue and N-methyl-hydroxylamine are both inhibitors of soluble 
guanylate cyclase (Martin, et al., 1985; Bowman & Drummond, 1984). If the novel 
relaxant formed from reacting nitric oxide with L-cysteine induces relaxation by 
activation of soluble guanylate cyclase, then its actions should be inhibited by these 
compounds. Methylene blue (10 pM) and N-methyl-hydroxylamine (1 mM) were 
found to powerfully block the relaxation induced by nitric oxide (0.3 pM), the new 
relaxant (1-10 pi into a 20 ml bath) generated from L-cysteine (10 mM) solutions 
bubbled to saturation with nitric oxide for 10 minutes at pH 3.0 and purged with 
oxygen-free nitrogen to remove free nitric oxide, and NANC nerve stimulation (2 
Hz, 20 pulses) in BRP strips contracted by guanethidine (10 pM) (Figures 54 & 
55). In addition, methylene blue (10 pM) also produced a further increase in the 
guanethidine-induced tone.
3.2.6.4. Effects of Pyrogallol, Hydroquinone and Superoxide Dismutase
Pyrogallol and hydroquinone are closely related structurally and can both produce 
superoxide anions. Furthermore, superoxide dismutase is a scavenger of superoxide 
anion and can be used to reverse or block the actions of pyrogallol and 
hydroquinone. Work from our laboratory and elsewhere has shown previously that 
although pyrogallol and hydroquinone can inhibit the relaxant actions of nitric 
oxide, they do not block those to NANC stimulation in the BRP (Gillespie & 
Sheng, 1990) or mouse anococcygeus (Gibson, et al., 1992). These findings 
suggested that the NANC transmitter was a superoxide anion-resistant, nitric oxide 
releasing molecule rather than free nitric oxide. We therefore examined whether or 
not the new relaxant formed in the reaction of nitric oxide with L-cysteine or L- 
glutathione shared the property of being resistant to destruction by superoxide 
anion.
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Figure 54. In BRP muscle precontracted by guanethidine (10 pM) methylene blue 
(10 pM) powerfully blocked the relaxation induced by NANC nerve stimulation (2 
Hz, 20 pulses), nitric oxide (0.3 pM) and S-nitrosocysteine generated from L- 
cysteine (10 mM) aqueous deoxygenated solutions bubbled to saturation with nitric 
oxide for 10 minutes at pH 3 followed by purging with oxygen-free nitrogen to 
remove free nitric oxide and neutralisation.
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Figure 55. In BRP muscle precontracted by guanethidine (10 pM) N- 
methylhydroxylamine (1 mM) powerfully blocked the relaxation induced by NANC 
nerve stimulation (2 Hz, 20 pulses), nitric oxide (0.3 pM) and S-nitrosocysteine 
generated from L-cysteine (10 mM) aqueous deoxygenated solutions bubbled to 
saturation with nitric oxide for 10 minutes at pH 3.0 followed by purging with 
oxygen-free nitrogen to remove free nitric oxide and neutralisation.
Results
In BRP muscle precontracted by guanethidine (10 pM) or phenylephrine (0.3 pM) 
pyrogallol at a concentration of 0.1 mM completely blocked nitric oxide (0.3 pM)- 
induced relaxation but had no effect on the NANC relaxation induced by field 
stimulation (Figure 56). Furthermore, pyrogallol (0.1 mM) powerfully blocked the 
relaxation induced by the new relaxant (3-100 pi in a 20 ml bath) generated when 
L-cysteine (10 mM) solutions were bubbled to saturation with nitric oxide for 10 
minutes at pH 3.0 followed by purging to remove free nitric oxide (Figures 56 & 
57). The blockade of the relaxation induced by the new relaxant was reversed by 
subsequent addition of and prevented by pretreatment with superoxide dismutase 
(100 u m H ) in phenylephrine (0.3 pM)-contracted BRP muscle (Figures 57 & 58). 
In the absence of pyrogallol superoxide dismutase (100 u ml“l) powerfully 
potentiated the activity of the new relaxant (Figure 58) but had no effect on the 
relaxation to NANC nerve stimulation (Figure 5).
In phenylephrine (0.3 pM)-contracted BRP muscle hydroquinone (0.1 mM) 
produced inhibition of the relaxation induced by the new relaxant generated from L- 
cysteine (10 mM) solutions bubbled to saturation with nitric oxide for 10 minutes at 
pH 3.0 followed by purging to remove free nitric oxide with oxygen-free nitrogen 
(Figure 59). The inhibition was, however, less powerful than that induced by 
pyrogallol (Figure 57). Treatment of the tissue with superoxide dismutase (100 u 
ml- !) not only reversed this inhibition by hydroquinone but also potentiated the 
relaxation induced by the new relaxant (Figures 59 & 60). Furthermore, 
pretreatment of the tissue with superoxide dismutase (100 u ml~l) also prevented 
this inhibition by hydroquinone (Figure 60).
In a separate series of experiments the new relaxant (100 pi into a 20 ml bath) 
generated from L-cysteine (10 mM) solutions bubbled to saturation with nitric oxide 
for 10 minutes at pH 3.0 followed by purging with oxygen-free nitrogen to remove
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Figure 56. On BRP muscle precontracted by guanethidine (10 ,uM) pyrogallol (0.1 
mM) powerfully blocked the relaxation induced by nitric oxide (0.3 pM) and S- 
nitrosocysteine generated from L-cysteine (10 mM) aqueous deoxygenated solutions 
bubbled to saturation with nitric oxide for 10 minutes at pH 3.0 followed by 
purging with oxygen-free nitrogen to remove free nitric oxide and neutralisation, 
but it did not inhibit the NANC relaxation induced by field stimulation (2 Hz, 20 
pulses).
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Figure 57. In BRP muscle precontracted by phenylephrine (0.3 pM) pyrogallol (0.1 
mM) powerfully blocked the relaxation induced by S-nitrosocysteine generated from 
L-cysteine (10 mM) aqueous deoxygenated solutions bubbled to saturation with 
nitric oxide for 10 minutes at pH 3.0 followed by purging with oxygen-free nitrogen 
to remove free nitric oxide and neutralisation. This blockade was reversed by 
addition of superoxide dismutase (SOD, 100 u m H ) to the assay tissue.
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Figure 58. (a.) Concentration-response of S-nitrosocysteine generated from L- 
cysteine (10 mM) aqueous deoxygenated solutions bubbled to saturation with nitric 
oxide for 10 minutes at pH 3.0 followed by purging with oxygen-free nitrogen to 
remove free nitric oxide and neutralisation, (b.) Pretreatment with superoxide 
dismutase (100 u ml- *) potentiated the activity of S-nitrosocysteine. (c.) In the 
presence of superoxide dismutase (100 u ml“l) the activity of S-nitrosocysteine was 
not inhibited by pyrogallol (0.1 mM). Bioassay was carried out on a BRP strip 
submaximally contracted by phenylephrine (0.3 pM).
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Figure 59. In BRP muscle precontracted by phenylephrine (0.3 pM) hydroquinone 
(0.1 mM) partially blocked the relaxation induced by S-nitrosocysteine generated 
from L-cysteine (10 mM) aqueous deoxygenated solutions bubbled to saturation 
with nitric oxide for 10 minutes at pH 3.0 followed by purging with oxygen-free 
nitrogen to remove free nitric oxide and neutralisation. Superoxide dismutase (SOD, 
100 u m l'l)  not only reversed this blockade by hydroquinone but also potentiated 
the relaxation induced by S-nitrosocysteine.
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Figure 60. (a.) Concentration-response of S-nitrosocysteine generated from L- 
cysteine (10 mM) aqueous deoxygenated solutions bubbled to saturation with nitric 
oxide for 10 minutes at pH 3.0 followed by purging with oxygen-free nitrogen to 
remove free nitric oxide and neutralisation, (b.) pretreatment with superoxide 
dismutase (100 u m l'l)  potentiated the activity of S-nitrosocysteine. (c.) In the 
presence of superoxide dismutase (100 u m H ) the relaxation induced by S- 
nitrosocysteine was not inhibited by hydroquinone (0.1 mM). Bioassay was carried 
out on a BRP strip submaximally contracted by phenylephrine (0.3 pM).
Results
free ritric oxide induced a powerful relaxation in phenylephrine (0.3 pM)- 
contracted BRP muscle strips (Figure 61). Once established, this relaxation was 
reversed quickly by pyrogallol or slowly by hydroquinone both at a final bath 
concentration of 0.1 mM (20 pi of 0.1 M into a 20 ml bath). The reversal of the 
relaxation induced by hydroquinone, but not by pyrogallol, was reversed after 
adding superoxide dismutase (100 u m l'l)  to the tissue. Furthermore, when the 
relaxant (100 pi) was mixed with either pyrogallol (20 pi of 0.1 M) or 
hydroquinone (20 pi of 0.1 M) for 10 minutes prior to their addition into the bath, 
almost all of their relaxant activity was destroyed even when assayed in tissues 
pretreated with superoxide dismutase (100 u m H , Figure 61).
When assayed on phenylephrine (0.3 pM)-contracted BRP muscle pyrogallol (0.1 
mM) and hydroquinone (0.1 mM) also powerfully blocked the relaxation induced by 
the new relaxant generated from L-glutathione (10 mM) solutions bubbled to 
saturation with nitric oxide for 10 minutes at pH 3.0 followed by purging with 
oxygen-free nitrogen to remove free nitric oxide (Figures 62 & 63). Superoxide 
dismutase (100 u m l'l) not only reversed this blockade by pyrogallol and 
hydroquinone but also potentiated the relaxation induced by the new relaxant.
Thus, superoxide anion was able to destroy the relaxant activity of nitric oxide and 
of the new relaxants formed following the reaction of nitric oxide with L-cysteine or 
L-glutathione but was unable to destroy the NANC transmitter in the BRP.
3.2.6.5. Effects of DETCA
Clearly, pyrogallol and hydroquinone are unable to block the effects of the 
inhibitory NANC transmitter but they can destroy the actions of nitric oxide or the 
new relaxants generated from L-cysteine or L-glutathione following reaction with 
nitric oxide. These findings make it unlikely that nitric oxide or the new relaxants
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Figure 61. S-Nitrosocysteine (100 pi into a 20 ml bath) generated from L-cysteine 
(10 mM) aqueous deoxygenated solutions bubbled to saturation with nitric oxide for 
10 minutes at pH 3.0 followed by purging with oxygen-free nitrogen to remove free 
nitric oxide and neutralisation induced a powerful relaxation in phenylephrine (0.3 p 
M)-contracted BRP muscle. This relaxation was blocked quickly by pyrogallol and 
slowly by hydroquinone both at final bath concentrations of 0.1 mM (20 pi of 0.1 
M into the 20 ml bath). The blockade of the relaxation by hydroquinone, but not 
that by pyrogallol, was reversed after addition of superoxide dismutase (SOD, 100 u 
m H ) into the bath. When S-nitrosocysteine (100 pi) was mixed with pyrogallol (20 
pi of 0.1 M) or hydroquinone (20 pi of 0.1 M) for 10 minutes before addition to 
the bath, the relaxant activity of S-nitrosocysteine was almost completely destroyed 
even in the presence of superoxide dismutase (100 u m l'l)  in the tissue.
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Figure 62. On BRP muscle precontracted by phenylephrine (0.3 pM) pyrogallol 
(0.1 mM) powerfully blocked the relaxation induced by S-nitrosoglutathione 
generated from L-glutathione (10 mM) aqueous deoxygenated solutions bubbled to 
saturation with nitric oxide for 10 minutes at pH 3.0 followed by purging with 
oxygen-free nitrogen to remove free nitric oxide and neutralisation. Superoxide 
dismutase (100 u ml“l) not only reversed this blockade by pyrogallol (0.1 mM) but 
also powerfully potentiated the relaxation induced by S-nitrosoglutathione.
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Figure 63. On BRP muscle precontracted by phenylephrine (0.3 pM) hydroquinone 
(0.1 mM) completely blocked the relaxation induced by S-nitrosoglutathione 
generated from L-glutathione (10 mM) aqueous deoxygenated solutions bubbled to 
saturation with nitric oxide for 10 minutes at pH 3.0 followed by purging with 
oxygen-free nitrogen to remove free nitric oxide and neutralisation. Superoxide 
dismutase (100 u m H ) not only reversed this blockade by hydroquinone but also 
potentiated the relaxation induced by S-nitrosoglutathione.
Results
act as the NANC neurotransmitter in the BRP. However, if a mechanism exists in 
the tissue to prevent the transmitter from being destroyed by superoxide anions, 
then nitric oxide, S-nitrosocysteine and S-nitrosoglutathione could still be regarded 
as candidates. Such a mechanism could be possible if the BRP contained high 
superoxide dismutase activity. Mammalian tissues contain C u+  +  , Z n+  +  
superoxide dismutase (CuZnSOD) and this is inactivated by the copper chelator 
diethyldithiocarbamate (DETCA, Halliwell & Gutteridge, 1989). An experiment 
was therefore conducted in which strips of BRP muscle were treated with DETCA 
to determine if this would make the NANC relaxation inhibitable by pyrogallol.
In guanethidine (10 pM)-contracted BRP strip preparations pyrogallol (10-100 pM) 
did not inhibit the NANC relaxation induced by field stimulation (2 Hz, 20 pulses) 
although it reduced the tone at concentrations of 100 pM (Figure 64). DETCA at a 
concentration of 10 mM neither inhibited the NANC relaxation nor affected the tone 
of the tissue. After treatment of the BRP muscle with DETCA (10 mM) for 30 
minutes pyrogallol (100 pM) remained unable to inhibit the NANC relaxation.
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Figure 64. On a guanethidine (10 pM)-contracted BRP strip pyrogallol (10-100 p 
M) did not inhibit the NANC relaxation induced by field stimulation (2 Hz, 20 
pulses) but reduced the tone at a concentration of 100 pM. DETCA at a 
concentration of 10 mM neither inhibited the NANC relaxation nor affected the tone 
o f the tissue. After treating the BRP muscle with DETCA (10 mM) for 30 minutes 
pyrogallol (100 pM) remained unable to inhibit the NANC relaxation.
Chapter 4. DISCUSSION
The phenomenon of atropine-resistant penile erection produced by electrical 
stimulation of the sacral parasympathetic outflow via the pelvic nerves in the rabbit 
(Langley & Anderson, 1895) can now been regarded as the first demonstration of 
the existence of a non-adrenergic, non-cholinergic innervation although at that time 
concept of chemical neurotransmission had not been established. The first major 
observation that provided firm evidence for the existence of NANC nerves was the 
finding that bretylium did not block the powerful inhibitory response to nerve 
stimulation of the guinea pig taenia coli (Bumstock, et al. , 1963; 1964). The 
neurogenic origin of the response was verified by its blockade by tetrodotoxin at 
low concentrations. (Bulbring & Tomita, 1967).
The retractor penis muscle possesses a typical NANC inhibitory innervation (Klinge 
& Sjostrand, 1974). Anatomically, it is an extension of the anococcygeus muscle 
(Gillespie, 1972). Both muscles receive a double innervation, the adrenergic motor 
sympathetic nerves from the spinal cord in the lumbar region with most fibres 
travelling via the pubic nerve, and the NANC inhibitory nerves from the sacral cord 
with their fibres in the pelvic parasympathetic nerves whose transmitter was 
unknown at the beginning of this study (Langley & Anderson, 1895; Langley & 
Anderson, 1895; Fletcher, 1898; Gruber, 1933; Luduena & Grigas, 1966; 
Gillespie, 1972; Gillespie & McGrath, 1973; 1974; Klinge & Sjostrand, 1974; 
Creed, et al., 1977; Gibson & Wedmore, 1981; Byrne & Muir, 1984). Until 
recently, except for local anaesthetics and tetrodotoxin, none of the drugs which 
block the actions of known neurotransmitters had any effect on the inhibitory 
response to the NANC nerve stimulation and no known neurotransmitter could 
mimic the relaxant response to NANC nerve stimulation in both tissues (Luduena & 
Grigas, 1966; 1972; Gillespie, 1972; Klinge & Sjostrand, 1974; Creed, et al., 
1977).
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Ovex the years, three potential candidates emerged for the NANC transmitter in the 
anococcygeus and the retractor penis muscles: the inhibitory factor (IF) extracted 
from the BRP, endothelium-derived relaxing factor (EDRF), and nitric oxide (NO). 
According to the conventional concept of neurotransmission, a substance must fulfil 
the following criteria before being established as a neurotransmitter (Eccles, 1964): 
1). It is synthesised and present in the nerve fibres; 2). It is released by nerve 
stimulation; 3). It should mimic the nerve-induced response to electrical stimulation; 
4). It combines with its receptor specifically; 5). Its mode of action and that of the 
neurotransmitter released from nerve should be the same; 6 ). Drugs which 
potentiate or block the nerve-induced response should have the same effect on the 
putative neurotransmitter; 7). An inactivation mechanism should be present 
consisting either of enzymatic breakdown and / or uptake. IF, EDRF and nitric 
oxide share many properties with the NANC transmitter and fulfil many of these 
criteria. For example, all act through stimulation of soluble guanylate cyclase and 
increases of cGMP levels (Murad, et al., 1978; Rapoport & Murad, 1983b; 
Bowman & Drummond, 1984) in a manner potentiated by the cGMP-selective 
phosphodiesterase inhibitor, M&B 22,948 (Bowman & Drummond, 1984), and 
inhibited by haemoglobin and methylene blue (Murad, et al., 1978; Bowman & 
Gillespie, 1982; 1983; Bowman, et al., 1982b; Bowman & Drummond, 1984; 
Bowman, etal., 1986; Martin, et al., 1985; Gibson & Mirazadeh, 1989).
EDRF was first discovered by Furchgott and Zawadzki (1980) and was suggested to 
be nitric oxide by Furchgott (1988) and Ignarro et al. (1988). Following this 
suggestion, nitric oxide was detected in the fluid perfusing cultured porcine aortic 
endothelial cells following stimulation by bradykinin at concentrations that induce 
EDRF release (Palmer, et al., 1987). The amount of nitric oxide released by the 
cells was sufficient to account for the relaxation of vascular strips by EDRF. A 
study using ^C >2 and mass spectrometry showed that molecular oxygen is
95
Discussion
incorporated into both nitric oxide and its co-product L-citrulline (Leone, et al.,
1991). By applying a radiochemical technique involving [^H] arginine coupled with 
mass spectrometry, L-citrulline was confirmed to be a product derived from L- 
argimine metabolism (Moncada & Palmer, 1990). This formation was specific since 
the metabolism of L-arginine was competitively blocked by A^-monomethyl-L- 
arginine but not its D-isomer, an effect competitively reversed by L- but not D- 
argimine (Palmer, et a/., 1988).
The clear involvement of nitric oxide in NANC neurotransmission was first revealed 
by the ability of L-NMMA , but not D-NMMA, to block NANC relaxation in the 
anococcygeus of the rat and mouse, and the retractor penis of the bull, an effect 
reversed by L-arginine, but not its D-isomer (Gibson, et al., 1989; 1990; Gillespie 
& Xiaorong, 1989; Gillespie, et al., 1989; 1990; Li & Rand, 1989). It is also 
widely accepted that the L-arginine: nitric oxide system mediates NANC inhibitory 
transmission in many other tissues including the canine ileocolonic junction 
(Boeckxstaens, et al., 1991), the guinea-pig trachea (Li & Rand, 1991), the human 
corpus cavemosus (Ignarro, et al., 1990; Pickard, et al., 1991), the dog and 
monkey cerebral artery (Toda & Okamura, 1990a; 1990b), and the bovine penile 
artery (Liu, et al., 1991). However, nitric oxide binds to and / or reacts at great 
speed with many substances normally present in the body and thus its action on 
soluble guanylate cyclase could be blocked by these substances preventing it from 
reaching its target cells. For example, haeme has a high binding affinity for and 
reactivity with nitric oxide and this is also true for haemoproteins. The binding 
affinity of haemoproteins is about 1,500 times higher for nitric oxide than for 
carbon monoxide (Gibson & Roughton, 1957) and about 200 times higher for 
carbon monoxide than for oxygen (Giardina & Amiconi, 1981). It is difficult to 
imagine how nitric oxide produced in one cell could travel a distance and activate 
soluble guanylate cyclase in a distant cell without binding to other haemoproteins 
such as haemoglobin and myoglobin. Moreover, nitric oxide reacts readily with
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oxygen according to the following equation (Committee on Medical and Biological 
Effects o? Environmental Pollutants, 1977; Olbergts, 1985):
2NO + O2  -► 2N02 
The rate Df the above reaction is given by the following third-order rate equation:
d[N02]= 2*[N0]2[02l*
The reaction takes place at a rate which is about 4,000 times higher in aqueous 
solution lhan in the gas phase (Pogrebnaya, et al., 1975). That nitric oxide may not 
be the exact form of the NANC transmitter was supported by the evidence that the 
superoxide anion-generating drugs, pyrogallol and hydroquinone, inhibit the 
relaxant actions of authentic nitric oxide but not those of NANC nerve stimulation 
in the BRP and mouse anococcygeus (Gillespie & Sheng, 1990; Gibson, et al.,
1992).
The effects of pyrogallol and hydroquinone suggest that the NANC neurotransmitter 
in these tissues may be a superoxide anion-resistant, nitric oxide-releasing molecule 
rather than free nitric oxide. Indeed, an analogous debate continues concerning the 
precise nature of EDRF: Palmer et al. (1987) reported that the levels of nitric oxide 
produced by endothelium as measured by chemiluminescence could account for the 
biological activity of EDRF, but Myers et al., (1989), using the same technique, 
found that the levels of nitric oxide detected were roughly 10-fold lower than 
required to account for its activity. In fact, Myers et al. (1990) suggest that EDRF 
more closely resembles S-nitrosocysteine than nitric oxide. If a compound does exist 
which binds nitric oxide and acts as a delivery system between synthesis in the 
nerve endings or endothelium and action on soluble guanylate cyclase in the effector 
cell it would ideally meet certain conditions. Specifically, it would bind nitric oxide
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securely enough to prevent non-specific interactions with proteins and other 
substances and prevent destruction by oxygen and superoxide anion. Furthermore, 
the binding must be reversible so as to deliver nitric oxide to soluble guanylate 
cyclase in the target cell.
This study investigated the possibility that the NANC inhibitory neurotransmitter in 
the BRP was S-nitrosocysteine or S-nitrosoglutathione rather than authentic nitric 
oxide. This was done firstly, by examining whether free sulfhydryl groups are 
required for NANC relaxation to nerve stimulation in the BRP muscle, and 
secondly, by examining the properties of S-nitrosocysteine and S-nitrosoglutathione 
and finally, by comparing the effects of drugs on the properties of the S-nitrosothiols 
and the NANC transmitter. In this study the initial investigation into the possibility 
of an S-nitrosothiol being the NANC transmitter in the BRP muscle was based on: 
1). The NANC inhibitory transmitter, IF, and S-nitrosothiols share many 
properties, typically stimulating soluble guanylate cyclase and relaxing smooth 
muscle (Gillespie, et al., 1990; Ignarro, 1990; Moncada, et al., 1991). 2). Thiols 
are required for relaxation of vascular smooth muscle (Needleman, et al., 1973) and 
for the activation of soluble guanylate cyclase by certain nitrovasodilators including 
glyceryl trinitrate (Ignarro & Gruetter, 1980; Ignarro, et al., 1981b). 3). The 
unactivated form of IF contains 4pM nitrite and the activation of IF by exposure to 
acid at pH 2 is associated with a 75% loss of nitrite (Martin, et al., 1988). 4). The 
relaxant activity and loss of nitrite in solutions of activated IF is closely related to 
the content of sulfhydryl groups in general and L-cysteine in particular (Yui, et al. , 
1989; Kerr, et al., 1993). 5). S-Nitrosothiols are synthesised by acidification of 
sodium nitrite in the presence of thiols (Gibson, et al., 1992; Kerr, et al., 1993). In 
the study reported here, L-cysteine and L-glutathione were chosen since they are the 
most abundant sulfhydryl-containing substances in the body, for example, blood 
plasma contains L-cysteine at 150 pM and the intracellular concentration is several 
times higher than this (Apps & Hamden, 1985).
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Free sulfhydryl inactivating agents have previously been employed to investigate the 
involvement of S-nitrosothiols in the activity of EDRF, but with equivocal results 
(Siegle, et al., 1993; Minor, et al., 1989). Minor et al. (1989) reported that basal 
EDRF release was inhibited by depletion of L-cysteine from endothelial cells, 
whereas Siegle et al. (1993) found that sulfhydryl depleting agents inhibited 
stimulated but not basal EDRF release from cultured endothelial cells. We examined 
the actions of two sulfhydryl-depleting agents, diamide which oxidises free 
sulfhydryl groups to the corresponding disulphide (Kosower, et al., 1969) and N- 
ethylmaleimide which covalently alkylates free sulfhydryl groups (Siegle, et al., 
1993), on NANC relaxation to nerve stimulation in the BRP muscle. Consistent 
with involvement of an S-nitrosothiol in NANC neurotransmission, we found that 
both agents blocked NANC relaxation and this was prevented by pretreating the 
tissues with excess sulfhydryl groups in the form of L-cysteine, L-glutathione or 
dithiothreitol. These three sulfhydryl compounds were also effective in reversing the 
actions of diamide, presumably through reduction of the -S-S- bonds formed 
following its action (Kosower, et al., 1969). The actions of N-ethylmaleimide were 
not reversed, suggesting that blockade had not resulted from covalent inactivation of 
the sulfhydryl groups of endogenous L-cysteine or L-glutathione. The most 
compelling evidence against the blockade having resulted from loss of the ability to 
form S-nitrosothiols was obtained when we found that relaxation to glyceryl 
trinitrate (GTN) and isoprenaline was also blocked by these two sulfhydryl 
inactivating agents and was not reversed by the three sulfhydryl-containing 
compounds. Since GTN and isoprenaline activate soluble guanylate cyclase and 
adenylate cyclase, respectively, the sulfhydryl inactivating agents were clearly 
blocking the effector pathways for these diverse relaxants and that any additional 
action in preventing formation of S-nitrosothiols by the NANC nerves would be 
impossible to discern. However, the involvement of free sulfhydryl groups in the 
NANC relaxation is still suggested by the evidence that the sulfhydryl compounds
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partially reversed the blockade by diamide on relaxation to NANC nerve stimulation 
but not to GTN and isoprenaline. Because the relaxant actions of both NANC 
transmitter and GTN are via activation of soluble guanylate cyclase and increases in 
cGMP levels, at least two different subtypes of soluble guanylate cyclase in the BRP 
muscle, one responding to NANC transmitter and the other responding to GTN, 
were suggested since we found that the sulfhydryl compounds, L-cysteine, L- 
glutathione and dithiothreitol, reversed the blockade by diamide on the relaxation 
induced by NANC nerve stimulation but not by GTN. These results extend the 
previous finding (Needleman, et al., 1973) that the sulfhydryl-depleting agent, 
ethycrinic acid which covalently alkylates free sulfhydryl groups, blocked the 
vasorelaxant action of GTN in rabbit aortic strips, and also provides further 
evidence in support of a common mechanism of free sulfhydryl-requirement in 
smooth muscle relaxation (Needleman, et al., 1973).
It has been reported that various disulphides such as L-cystamine, -SH oxidants such 
as diamide and thiol alkylating agents inhibit both basal activity of partially purified 
hepatic soluble guanylate cyclase and activity stimulated by nitric oxide and S- 
nitrosocysteine (Ignarro, et al., 1981b). The -SH groups at the catalytic site in the 
enzyme are believed to interact with enzyme activators since preincubation of the 
enzyme with enzyme activators markedly protects the enzyme against inhibition by 
various thiol reactive agents. Two closely juxtaposed -SH groups at the catalytic site 
are proposed since 2,3-dimercaprol, which possesses vicinal dithiols, but not 
dithiothreitol, markedly inhibited enzyme activity (Ignarro, et al., 1981b). The 
oxidation-reduction reactions involving -SH groups were suggested to govern 
guanylate cyclase activity (DeRubertis & Craven, 1977; Goldberg & Haddox, 1977; 
Craven & DeRubertis, 1978b), with -SH to -S-S- transformation as a potential 
mechanism of enzyme activation (DeRubertis & Craven, 1977; Craven & 
DeRubertis, 1978b). Although Ignarro et al. (1981b) also supported the 
involvement of this redox system governing activation of the enzyme, they
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proposed, in contrast, that -S-S- to -SH transformation activates the guanylate 
cyclase (Ignarro, et al., 1981b) since various oxidants inhibit activation of the 
enzyme by nitric oxide (Ignarro & Gruetter, 1980; Ignarro, et al., 1980b; 1981b). 
In this study, our findings were not completely consistent with either of these 
proposals regarding the activation of guanylate cyclase. The proposed mechanism of 
-S-S- to -SH in the activation of guanylate cyclase was supported by our findings in 
this study that the sulfhydryl-containing compounds, L-cysteine, L-glutathione and 
dithiothreitol, all produced relaxation lasting for 10 minutes in contracted BRP 
strips. These free sulfhydryl compounds may have reduced -S-S- to -SH in soluble 
guanylate cyclase and thereby activated the enzyme in the BRP muscle. It may also 
explain why GTN-induced relaxation was blocked by sulfhydryl oxidising and 
alkylating agents in this study if the action of GTN via stimulation of soluble 
guanylate cyclase involves an -S-S- to -SH transformation (Ignarro, et al., 1981b). 
It is not clear why the blockade of GTN-induced relaxation by diamide was not 
reversed after treating the tissue with the sulfhydryl compounds, L-cysteine, L- 
glutathione and dithiothreitol in this study. Thus, this blockade may not simply have 
been due to oxidation of sulfhydryl groups but may have involved other mechanism. 
In contrast, the proposed mechanism of -SH to -S-S- transformation in the activation 
of guanylate cyclase was also supported by our findings in this study that in addition 
to its small and transient relaxant action, dithiothreitol at high concentrations 
subsequently produced small but sustained inhibition of NANC relaxation to nerve 
stimulation and contraction of the BRP muscle. Although inhibition by dithiothreitol 
of endothelium-dependent relaxation (Griffiths, et al., 1984) was reported to be due 
to generation of superoxide anion (Moncada, et al., 1991), the inhibition of NANC 
relaxation to nerve stimulation and the associated increase in tone by dithiothreitol 
in the BRP muscle was not through generation of superoxide anion since its actions 
were not prevented or reversed by superoxide dismutase.
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Our next approach was to examine the properties of S-nitrosothiols. A number of 
methods are available for the synthesis of these compounds, including the reaction 
of L-cysteine and nitrogen dioxide in cold methanol (Myers, et al., 1990), 
acidification of sodium nitrite in the presence of L-cysteine and other sulfhydryl 
compounds (Kowaluk & Fung, 1990; Gibson, et al., 1992; Kerr, et al., 1993), and 
the reaction of nitric oxide with L-cysteine and other sulfhydryl compounds under 
anaerobic conditions (Ignarro & Gruetter, 1980; Ignarro, et al., 1981). Although 
differences exist in the properties of S-nitrosothiols generated by these methods, one 
of the properties in common is that the S-nitrosothiols produced by each of these 
routes are powerful smooth muscle relaxants whose actions both in magnitude and 
time course can not be attributed to nitric oxide alone. The S-nitrosothiols produced 
by each of these routes are normally pink in colour and have been monitored 
spectrophotometrically at wavelengths of 210, 335 and 545 nm (Ignarro & Gruetter, 
1980; Ignarro, et al., 1981; Myers, et al., 1990; Feelisch, 1991). There is, 
however, enormous variability in the reported stability of the S-nitrosothiols 
produced by these methods. For example, Myers et al. (1990) reported that S- 
nitrosocysteine is extremely unstable with a half-life of about 30 seconds and must 
be kept under nitrogen in the dark; Feelisch (1991) said that S-nitrosocysteine must 
be kept from light and has a half-life of about 60 minutes; whereas Ignarro and 
Gruetter (1980) reported that S-nitrosocysteine has a half-life of 7-10 days. S- 
Nitrosoglutathione has also been described as very unstable (Hart, 1985) or 
unusually stable for 32 days with only 25% loss at room temperature (Park & 
Means, 1989). It was possible therefore that all of these groups did indeed 
synthesise S-nitrosothiols but that their reaction conditions differed sufficiently to 
account for the different half-lives reported. Our initial approach was to use the 
simple technique of generating S-nitrosocysteine with acidified nitrite in the 
presence of L-cysteine.
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We confirmed the finding that the weak vasodilator activity of sodium nitrite is 
greatly enhanced by acidification (Furchgott, 1988); little activity was generated at 
pH values above 5.0 and maximum generation occurred at pH 2. This was probably 
due to the acid-pH dependent generation of the relaxant, nitric oxide, according to 
the following chemical reactions (Sisler, 1956):
NO2 '  +  H + -> HNO2 (1)
2 HNO2  -> NO + NO2  +  H20 (2 )
2NO +  O2  -» 2N02 (3)
NO +  NO2  <-> N2 O3 (4)
2 N0 2  +  H20  <-» HN0 2  +  HNO3 (5)
The activity generated in this study in aqueous solutions of sodium nitrite at pH 2.0 
was greater under deoxygenated conditions than under oxygenated conditions, 
probably because oxygen destroys nitric oxide, according to equation (3). The 
increase in relaxant activity upon acidification was associated with decrease in 
nitrite content, according to equation (2), as previously reported (Martin, et al., 
1988). Moreover, the relaxant activity was greatly increased and prolonged by 
acidifying nitrite in presence of L-cysteine. Again, optimum generation of the 
relaxant was obtained at pH 2. The relaxant activity was not abolished upon 
neutralisation whereas that of acidified nitrite decayed rapidly. Furthermore, the 
generation of powerful relaxant activity was immediately associated with an even 
greater decrease in nitrite content than in the absence of L-cysteine and the 
development of a pink colour. These observations can be explained by the 
generation of the powerful relaxant, S-nitrosocysteine, upon acidification of sodium 
nitrite in the presence of L-cysteine (Kowaluk & Fung, 1990; Gibson, et al., 1992; 
Kerr, et al., 1993). We found that this relaxant activity was blocked by 
haemoglobin, methylene blue and N-methylhydroxylamine but not by N^-nitro-L- 
arginine confirming that its action is through liberation of nitric oxide and activation
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of soluble guanylate cyclase (Ignarro, et al., 1981b) but that it is not a substrate or 
stimulant of nitric oxide synthase (Gibson, et al. , 1989). This process is reminiscent 
of the "acid-activation" of inhibitory factor extracted from BRP (Gillespie & 
Martin, 1980). The unactivated form of inhibitory factor contains inorganic nitrite 
and upon acidification generates nitric oxide which binds to a substance that 
stabilises its activity (Martin, et al., 1988). It has recently been proposed that the 
acid-activated inhibitory factor is S-nitrosocysteine or S-nitrosoglutathione (Yui, et 
al., 1989; Kerr, et al., 1993). Yui et al. (1989) found that IF contained 8  pM 
nitrite and the loss of nitrite in the activated IF was closely related to the content of 
both sulfhydryl groups and L-cysteine in an HPLC analysis. However, they neither 
monitored the formation of S-nitrosothiols nor measured biological relaxant activity. 
A correlation of nitrite loss with the formation of S-nitrosothiols and biological 
activity was not made, and therefore IF could not be verified conclusively as an S- 
nitrosothiol in their study although this seems likely. More recently, Kerr et al. 
(1992) confirmed that IF contains 1-10 pM nitrite and 40-200 pM thiol. They found 
that S-nitrosothiols, but not nitric oxide from acidified nitrite, could reproduce 
similar effects to those of IF including smooth muscle relaxant activity, stability to 
argon purging and ability to stimulate cGMP formation by platelet soluble guanylate 
cyclase. Our results supplement their findings and support their proposal that IF is 
an S-nitrosothiol.
Acidification of sodium nitrite in the presence of thiols in aqueous solution has been 
adopted by many groups as a means of generating S-nitrosothiols (Kowaluk & 
Fung, 1990; Gibson, et al., 1992; Kerr, et al., 1993). However, the precise 
nitrosating species in the chemical reaction is far from clear. Obviously, nitrous 
acid, nitric oxide, nitrogen dioxide, dinitrogen trioxide are present in the aqueous 
solutions, according to the above reaction equations. We adopted an alternative 
method of synthesising S-nitrosothiols by reacting thiols and nitric oxide under 
oxygen-free conditions (Ignarro & Gruetter, 1980; Ignarro et al., 1980a) since we
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wished to determine if nitric oxide itself rather than higher oxides of nitrogen could 
react with the -SH moiety of L-cysteine. Also, this method would simplify the 
reaction because nitric oxide cannot generate nitrous acid, nitrogen dioxide and 
dinitrogen trioxide under oxygen-free conditions in aqueous solutions, according to 
the above reaction equations.
We confirmed nitric oxide is a powerful smooth muscle relaxant. Nitric oxide 
induced a rapid concentration-dependent transient relaxation of strips of BRP and 
rabbit aortic rings denuded of endothelium, whereas L-cysteine at concentrations 
less than 4.5 mM produced no relaxant activity. We found that in the presence of L- 
cysteine in the baths, exogenous nitric oxide-induced relaxation was slightly reduced 
in magnitude and significantly prolonged in duration. Also, the time course of the 
relaxation both in onset and offset was changed from fast to slow. After washing L- 
cysteine out of the bath, the magnitude and the duration of exogenous nitric oxide- 
induced relaxation were greatly reduced but they slowly recovered. The finding 
implied that nitric oxide is not the NANC transmitter since L-cysteine was without 
effect on the NANC relaxation to nerve stimulation.
Furthermore, we found that mixing nitric oxide with L-cysteine in nominally 
oxygen-free aqueous solution at pH 2 followed by removal of free nitric oxide and 
neutralisation produced a more powerful and sustained relaxation than nitric oxide 
alone could account for. The possibility that a new powerful relaxant had been 
generated from this mixture was investigated. HPLC analysis confirmed the 
generation of a novel compound that was entirely responsible for relaxant activity in 
the mixture of nitric oxide and L-cysteine. L-Cysteine produced two peaks in the 
HPLC, the first one corresponded to its oxidised form, L-cystine. The retention 
time of peak 1 in L-cysteine solutions was identical to that of standard L-cystine 
solutions. The second peak corresponded to authentic L-cysteine. Mixing L-cysteine 
with nitric oxide in oxygen-free aqueous solution at pH 3 followed by removal of
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free nitric oxide by purging with oxygen-free nitrogen produced three peaks; the 
first two peaks corresponded to oxidised and reduced forms of L-cysteine, 
respectively, with the third peak being the new substance. This new substance 
collected from the HPLC exhibited powerful and sustained relaxant activity when 
assayed on rabbit thoracic aortic rings, whereas the reduced and oxidised forms of 
L-cysteine had no relaxant activity. There was no difference in the height of peak 1 
before and after mixing with nitric oxide, whereas the height of peak 2 was reduced 
by 2% after mixing with nitric oxide. This would indicate that the amount of the 
new substance represented by peak 3 was no more than 2% of the original content 
of L-cysteine. The height of peak 3, however, was 22% that of peak 2, suggesting 
that the new substance had a higher extinction coefficient than L-cysteine. By 
comparing the height of peak 1 in solutions of L-cysteine with that of standard L- 
cystine solutions, the extinction coefficient of L-cystine was found to be 125 times 
that of L-cysteine. Thus, although peak 1 was often equal to or greater than peak 2 
in height, it normally represented a content of 1-2 % of the oxidised form.
We extended these studies to L-glutathione, another abundant sulfhydryl compound. 
L-Glutathione itself produced a single peak in the HPLC and had no relaxant 
activity. After mixing with nitric oxide, it produced a new peak associated with 
powerful relaxant activity. Thus, both L-cysteine and L-glutathione could react with 
nitric oxide to generate a powerful new relaxant.
Spectrophotometric studies revealed that the new relaxant formed from reacting 
nitric oxide with L-cysteine had three absorption peaks with maxima at 193, 218 
and 335 nm, whereas L-cystine and L-cysteine each produced only one absorption 
peak with maxima at 193 nm and 195 nm, respectively. These findings could 
explain why the new relaxant had been measured at 210 nm (Myers, et al., 1990) 
and 335 nm (Feelisch, 1991). However, in our study under nominal oxygen-free
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conditions no absorption was observed around 540-550 nm and no pink colour was 
seen in contrast to the report |of Ignarro, et al. (1981).
We found that the new relaxant was unstable. HPLC analysis revealed that the new 
relaxant continuously decomposed to form L-cystine. This process was slow in 
aqueous solutions at -20°C but enhanced by freeze-drying under high vacuum. 
These findings are therefore consistent with the reported stability of S- 
nitrosocysteine in aqueous solution and with its instability in the solid form (Ignarro 
& Gruetter, 1980; Ignarro, et al., 1981). These properties can be explained by 
spontaneous decomposition of the relaxant to nitric oxide gas and corresponding 
disulphide L-cystine (Ignarro, 1990; Feelisch, 1991):
2R-SNO -> R-SS-R +  2NO
In the HPLC the relaxant continuously generated L-cystine, implying its ability to 
release nitric oxide. The release of nitric oxide from the relaxant was consistent 
with the role of L-cysteine acting as a carrier which reversibly binds and releases 
nitric oxide and thus with the possibility of S-nitrosocysteine being the NANC 
transmitter. We also found that the activity of the new relaxant was unchanged after 
bubbling with oxygen for 10 minutes. This would be a valuable asset for a 
substance proposed as the NANC transmitter since this would mean that it would 
not be destroyed in oxygenated environments within the body.
We found that placing the new relaxant in a boiling water bath for 10 minutes 
resulted in substantial reduce of its activity in the bioassay and its associated peak 3 
in the HPLC, whereas at 70°C little decay was observed. Neutralisation of solutions 
of the new relaxant did not affect their relaxant activity. Thus, the new relaxant was 
similar in this respect to IF (Gillespie & Martin, 1980; Gillespie, et al., 1981b) but 
was different from authentic nitric oxide (Furchgott, 1988).
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In this study we found that S-nitrosocysteine generated from the reaction of nitric 
oxide and L-cysteine was destroyed by methanol (50 %, vol./vol.), and this is 
consistent with the earlier finding that IF is destroyed by methanol (Gillespie, et al. , 
1981b).
Another important but unexpected finding in this study was that the reaction of 
nitric oxide with L-cysteine was pH dependent: little relaxant activity was generated 
at pH 7.4, but as the pH was lowered, relaxant activity was increased until an 
optimum was reached at pH 1. The pH dependence in the formation of the new 
relaxant was further confirmed by the finding that the height of the associated peak 
3 in the HPLC was increased in parallel with relaxant activity. Although it is well 
established that acidification of nitrite leads to liberation of nitric oxide (Furchgott, 
1988), it is unclear why acidification should have the additional effect of catalysing 
the reaction of nitric oxide with L-cysteine.
At the beginning of this study, commercially available "oxygen-free" nitrogen gas 
(British Oxygen Company) was used to deoxygenate aqueous solutions of L-cysteine 
in which nitric oxide gas (99.9 %, Air Products Ltd., UK) was to be mixed with L- 
cysteine. However, there was a numerous variation in the amount of relaxant 
activity and the associated peak 3 in the HPLC generated despite our best efforts to 
keep reaction conditions constant and prevent introduction of oxygen. Thus, some 
critical variable was having a profound effect upon the outcome of the reaction of 
nitric oxide and L-cysteine under nominally oxygen-free conditions.
Later, we found that commercially available oxygen-free nitrogen contains trace 
amounts of oxygen so our reaction conditions were not strictly oxygen-free. 
Furthermore, we learned that commercially available nitric oxide gas (99.9%) in 
steel cylinders also contains impurities including higher oxides of nitrogen,
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particularly nitrogen dioxide (Committee on Medical and Biological Effects of 
Environmental Pollutants, 1977). These higher oxides of nitrogen are much more 
reactive and soluble than nitric oxide (Hammond, 1966; Cotton & Wilkinson, 
1972), so their presence in proposed experiments involving the mixing of nitric 
oxide with amino acids such as L-cysteine and L-glutathione in aqueous solution 
would result in extremely complicated reactions, even chain reactions with 
numerous uncharacterised products (Hart, 1985; Hart, et al., 1985; Wink, et al.,
1993).
Consequently, methods were sought to remove the remaining trace amounts of 
oxygen from commercial oxygen-free nitrogen (British Oxygen Company, UK) and 
nitrogen dioxide from commercial nitric oxide (Air Products Ltd., UK). This was 
achieved by washing the gases through Fieser’s solution and concentrated solutions 
(10%) of sodium hydroxide, respectively, since Fieser's solution is an active 
absorbent for even trace amounts of oxygen (Fieser & Fieser, 1967) and sodium 
hydroxide is an effective absorbent for nitrogen dioxide (Committee on Medical and 
Biological Effects of Environmental Pollutants, 1977). Apart from purification of 
nitrogen and nitric oxide gases, it was absolutely vital that atmospheric oxygen was 
prevented from entering the reaction chamber. To this end, we devised a system 
(illustrated in Figure 2) in which a sealed reaction chamber was immersed under 
water deoxygenated by purified oxygen-free nitrogen in an oxygen-impermeable 
Amicon chamber under positive pressure, purified oxygen-free nitrogen and nitric 
oxide gasses were delivered to the reaction chamber and the Amicon chamber via 
stainless steel tubing rather than polythene tubing which is permeable to oxygen and 
reacts with nitrogen dioxide. By using purified nitric oxide and nitrogen in this 
system, nitric oxide in water produced only one low absorption peak at 190 nm 
when tested within 10 minutes of preparation. In contrast, if either of the gases had 
not been purified, the presence nitrogen dioxide was indicated by a shoulder in the 
210 nm region, a shift of the peak from 190 nm towards 232 nm and the
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characteristic multiple peaks at 300-400 nm (Committee on Medical and Biological 
Effects of Environmental Pollutants, 1977). Thus, the new rigorous system for 
generating an oxygen-free environment appeared to be satisfactory, at least within 
commitments of preparing samples.
Using this system, we found that if nitric oxide was bubbled to saturation in 
solutions of L-cysteine under stringent oxygen-free conditions in sealed cuvettes and 
free nitric oxide was not removed by purging, then the absorption peaks at 218 and 
335 nm grew slowly with time over a period of 80 minutes, but if the solutions 
were opened to the air, they rose roughly 40-fold within a few seconds to stable 
new values and the solution became pink in colour owing to a new absorbance peak 
developing at 543 nm. The peaks at 335 and 543 nm did not shift, but that at 218 
nm shifted to 232 nm with increased absorption. The increase in absorption was 
associated with an increase of peak 3 in HPLC. In contrast, however, the relaxant 
activity which was powerful at zero time did not change over 80 minutes while 
sealed and also did not change when the solution was exposed to the air. These 
findings initially suggested to us that relaxant activity could be dissociated from 
peak 3 in the HPLC and the absorption peaks at 218, 335 and 543 nm. There were 
two possibilities for the slow increases in absorption peaks while the cuvette 
remained sealed in presence of nitric oxide: one explanation was that it was possible 
that the reaction between nitric oxide and L-cysteine took place at a very slow rate, 
but this was unlikely since chemical reactions proceed extremely fast. Alternatively, 
it was possible that despite our rigorous efforts oxygen was able to slowly enter the 
reaction chamber and play a critical role in the reaction of nitric oxide with L- 
cysteine. This was more likely since nitric oxide is less active than higher oxides of 
nitrogen such as nitrogen dioxide which could be formed in the presence of oxygen 
(Cotton & Wilkinson, 1972; Committee on Medical and Biological Effects of 
Environmental Pollutants, 1977; Moody, 1991).
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By using the closed system described above and purified gases, we found that the 
growth of absorption peaks at 218, 335 and 543 nm with time following the reaction 
of nitric oxide and L-cysteine when free nitric oxide was not removed by purging 
was not due to slow rate reaction. The growth of peaks was much faster if the 
mixture contained in a sealed cuvette was surrounded by air for 24 hours than if the 
sealed cuvette was submerged under stringent oxygen-free water. It was almost 
certain therefore that the more rapid rises in the absorption peaks in the sealed 
cuvette in air were due to penetration of oxygen through the cuvette.
Therefore, the presence of oxygen was vital in the reaction of nitric oxide with L- 
cysteine in generation of absorption peaks at 218, 335 and 543 nm and in the 
generation of peak 3 in the HPLC. What was less clear, however, was whether 
these absorption peaks and peak 3 in the HPLC were related to the relaxant activity. 
Previous experiments suggested that there was no relationship because when nitric 
oxide and L-cysteine were reacted together and free nitric oxide was not removed 
by purging, exposure to the air led to massive rises («40-fold) in the absorption 
peaks and the magnitude of peak 3 in the HPLC but relaxant activity did not 
change. We considered the possibility that the apparent lack of relationship was not 
correct. Our reason was that although spectrophotometry and HPLC analysis could 
be conducted unaerobically, the bioassay required us to add the new relaxant into an 
oxygenated tissue bath. It was therefore possible that the sample taken from the 
sealed cuvette reacted rapidly with oxygen in the bath to generate a more powerful 
relaxant than was originally present. This possibility was tested in a number of 
experiments in which purified nitric oxide was bubbled to saturation in solutions of 
L-cysteine followed by purging to remove free nitric oxide before exposure to the 
air and the relaxant activity and the magnitude of absorption peaks at 218, 335 and 
543 nm were compared with solutions which were not purged to remove free nitric 
oxide before exposure to the air. It was absolutely clear that those solutions in 
which nitric oxide was removed by purging before exposure to the air had low
i l l
Discussion
relaxant activity and the magnitude of the absorption peaks at 218, 335 and 543 nm 
were corresponding low. In sharp contrast, however, these solutions which were not 
purged had much greater («40-fold) relaxant activity and proportionately higher 
peaks at 218, 335 and 543 nm. Under controlled conditions therefore, there was a 
strict relationship between relaxant activity and the magnitude of the absorption 
peaks generated. Clearly, oxygen was a vital component in the generation of the 
new relaxant following reaction of nitric oxide with L-cysteine.
The requirement for oxygen in the development of relaxant activity and associated 
absorption peaks suggested that nitric oxide itself was unable to react with L- 
cysteine to form the new relaxant and that a higher oxide of nitrogen was the 
reactive species. Indeed the method of Ignarro et al. (1981b) of reacting nitric oxide 
with L-cysteine under anaerobic conditions adopted by us has been criticised by 
Feelisch (1991) who reported that the presence of oxygen was a prerequisite for 
nitrosation to proceed, and our later observations supported this. There is debate 
over the precise nature of the nitrosating species; some have suggested that it is 
N2 O3  or N2 O4  (Leaf, et al., 1990). Wink et al. (1993), however, disagree and 
claim that none of these species is the nitrosating agent in the reaction. They 
investigated the reaction kinetics of nitric oxide oxidation in aerobic aqueous 
solutions by employing various techniques including production of nitrite and 
trapping of the strongly oxidising and nitrosating intermediates formed in this 
reaction. They found that the key oxidising and nitrosating intermediates are none of 
those commonly proposed, including NO+, NO2 , N2 O3  and C^NO" and suggest 
that as yet uncharacterised NOx species are involved. We also dismissed the 
possibility that it was nitrogen dioxide, since this gas generated less relaxant activity 
than nitric oxide following reaction with L-cysteine either at neutral pH or at acid 
pH (pH 3.0) with or without presence of oxygen. It was not surprising to find that 
the relaxant activity and the associated peak 3 in the HPLC were generated in 
aqueous solutions of L-cysteine gassed to saturation with nitrogen dioxide for 10
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minutes since nitrogen dioxide dissolves in aqueous solutions to generate HNO2 , 
NO, NO2 , N2 O4  and N2 O3 , according to the following reaction equations:
2N02  +  H20  <-> HNO2  +  HNO3  (i)
2 HNO2  -> NO + NO2  +  H20  (2)
NO + NO2  <-> N2 O3  (3 )
2N02 ** n 2°4 (4)
Consistent with the generation of nitric oxide in the above reactions, we found that 
nitrogen dioxide-saturated water produced two peaks in the HPLC, one of which 
was identical to that of nitric oxide-saturated water in retention time. Furthermore, 
in the bioassay, the relaxant activity of saturated solutions of nitrogen dioxide could 
be accounted for by the height of the peak with the retention time of nitric oxide.
In our experiments optimal generation of the new relaxant occurred at pH 1-2 
following the reaction of high concentrations of nitric oxide (saturated «3 mM) and 
L-cysteine (10 mM). If the new relaxant was found in the body and acted as an 
important mediator, it would have to be formed under more physiological 
conditions. We therefore examined whether the new relaxant could be formed at 
neutral pH and at more reasonable concentrations of nitric oxide and L-cysteine. We 
found that in aqueous solution L-cysteine (10 mM) could react sufficiently with 
nitric oxide to produce relaxant activity and the associated absorption peaks at 218 
and 335 nm at pH 7 but the magnitude of these was much less than at pH 3. Again, 
the presence of oxygen increased the amount of the new relaxant generated both in 
the bioassay and in the spectrophotometer. L-Glutathione (10 mM) was also shown 
to react with nitric oxide at pH 7 to generate new relaxant activity and the 
associated absorption peaks in the spectrophotometer. Thus, new relaxant activity 
can be formed at neutral pH from the reaction of nitric oxide with L-cysteine and L- 
glutathione.
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Our next step was to determine if new relaxant activity could be generated at neutral 
pH when physiological concentrations of nitric oxide and L-cysteine were allowed 
to react. It is not inconceivable that concentrations of 1 pM nitric oxide could be 
produced locally under physiological conditions and L-cysteine is normally 
presented in blood plasma at 150 pM with that in cells being several times higher 
(Apps & Hamden, 1985). We found that when nitric oxide (1 pM) was mixed with 
L-cysteine (150 pM) at neutral pH under ambient oxygen tension, some new 
relaxant activity and its associated absorption peaks at 218, 335 and 543 nm were 
generated. Although these conditions were far from optimal, it is possible that this 
new relaxant activity could be formed in vivo. It is unlikely that such an inefficient 
process would be used physiologically as the basis of NANC neurotransmitter. 
Formation may be particularly important, however, in pathophysiological conditions 
such as septic shock where massive quantities of nitric oxide is produced by 
activated macrophages and could contribute to the associated hypotension (Petros, et 
al., 1991). Furthermore, Gaston et al. (1993) reported that S-nitrosothiols, 
predominantly the adduct with L-glutathione, have been measured at micromolar 
concentrations in the airways of normal subjects. They have used these finding to 
propose that S-nitrosothiols are endogenous bronchodilators in human airways. 
Therefore, further investigation is needed into the potential roles of S-nitrosothiols 
in the airways of normal subjects and in other physiological and pathophysiological 
processes.
We have assumed that the new smooth muscle relaxants generated from the reaction 
of nitric oxide and L-cysteine or L-glutathione are the corresponding S- 
nitrosothiols, S-nitrosocysteine and S-nitrosoglutathione, respectively. We have 
made this assumption in the basis of previous reports in the synthesis and properties 
of these compounds (Ignarro & Gruetter, 1980; Ignarro, et al., 1981). For 
example, in infra-red spectrophotometry the characteristic absorption of the nitroso
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moiety as a sharp peak at 1440-1490 cm 'l is present following reaction of nitric 
oxide with thiols but is absent in the corresponding thiols. Furthermore, the 
characteristic peak of the sulfhydryl moiety at 2540-2580 cm"! present for the thiols 
but is absent from the corresponding S-nitrosothiols (Ignarro & Gruetter, 1980). 
However, N-nitrosation of amines by nitrosating species such as nitrogen dioxide 
and acidified nitrite has been described (World Health Organization, 1977). Thus, it 
was necessary for us to further identify precisely the chemical structure of the new 
relaxant generated from the reaction of nitric oxide and L-cysteine or L-glutathione.
We established a collaboration with chemists to identify the new relaxant using IR 
spectroscopy and mass spectroscopy but these were unsuccessful because we were 
unable to prepare sufficient material in concentrated form. We therefore adopted 
another strategy by using a series of analogues of L-cysteine and L-glutathione in 
order to determine the functional group in the molecule with which nitric oxide 
reacts. L-Cysteine and L-glutathione have three functional groups in the molecule 
which could potentially react, namely, the sulfhydryl, the amine and the carboxyl 
groups. Five groups of analogues were chosen for study. The first group comprised 
those compounds with all three functional groups intact. This group included L- 
cysteine and L-glutathione. The second group comprised only N-acetyl-L-cysteine 
whose amine group was substituted but whose carboxyl and sulfhydryl groups were 
free. The third group included those compounds whose carboxyl groups were 
removed or replaced with an ester function but whose amine and sulfhydryl groups 
were free. This group included L-cysteamine, L-cysteine ethyl ester and L-cysteine 
methyl ester. The fourth group included those compounds whose sulfhydryl groups 
were substituted or oxidised to the corresponding disulphide but whose amine and 
carboxyl groups were free. This group included L-cystamine, L-cysteic acid, L- 
cysteinesulphinic acid, L-cystine, L-glutathione (oxidised form), S-methyl-L- 
cysteine, S-methyl-L-glutathione and L-methionine. The final group included L- 
arginine, L-glutamic acid and L-glycine, all of which contain amine and carboxyl
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groups but not a sulfhydryl group. L-Arginine was chosen since it is the precursor 
of nitric oxide in the body. L-Cysteine, L-glutamic acid and L-glycine are the 
amino acids which together comprise L-glutathione. The findings were clear cut. 
Those compounds in which the amine group or the carboxyl group was removed or 
substituted but in which the sulfhydryl was intact were all able to react with nitric 
oxide to form new relaxant activity. In contrast, if the sulfhydryl group was 
removed, substituted or oxidised to disulphide, the ability to form new relaxant 
activity was completely lost. Thus, it was clear that the new relaxants formed were 
the corresponding S-nitrosothiols and that N-nitrosation or nitrosation of the 
carboxyl group was not involved in the generation of relaxant activity. Furthermore, 
the spectral absorption characteristics of the relaxant generated from the reaction of 
nitric oxide with L-cysteine were identical to those previously reported (Ignarro, et 
al., 1980; Feelisch, 1991). We felt confident in our conclusion that the relaxants 
produced were the respective S-nitrosothiols.
We confirmed that the smooth muscle relaxant action of the S-nitrosothiols (Ignarro, 
et al., 1981; Gibson, et al., 1992) is blocked by haemoglobin, which binds and 
inactivates nitric oxide (Bowman & Drummond, 1984; Martin, et al., 1985), and 
by methylene blue and N-methylhydroxylamine, which inhibit soluble guanylate 
cyclase (Bowman & Drummond, 1984; Martin, et al., 1985). The blockade by 
haemoglobin suggests that the action of S-nitrosothiols is via dissociation of nitric 
oxide from the S-nitrosothiols which subsequently activates soluble guanylate 
cyclase. Whether S-nitrosothiols can activate soluble guanylate cyclase directly 
without release of nitric oxide has not yet been established. S-Nitrosothiols thus 
fulfil one more of the requirements for consideration as the NANC neurotransmitter 
in the BRP since its mode of action through activation of soluble guanylate cyclase 
is the same as that of the NANC transmitter (Bowman & Gillespie, 1982; 1983; 
Bowman, et al., 1982b; Bowman & Drummond, 1984; Bowman, et al., 1986).
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Haemoglobin competes with soluble guanylate cyclase for the binding nitric oxide, 
EDRF, IF and the NANC transmitter (Miki, et al., 1977; Murad, et al., 1978; 
Bowman & Gillespie, 1981; 1982; Bowman, et al. , 1982b; Martin, et al., 1985) 
since both guanylate cyclase and haemoglobin contain the same active site i.e. a 
ferrous haeme receptor moiety (Craven & De Rubertis, 1978). The action of 
haemoglobin is selective since it does not affect relaxation induced by stimulation of 
adenylate cyclase and increases of cAMP levels such as by forskolin, PGEi or VIP 
(Bowman & Drummond, 1984).
It has been reported that activation of soluble guanylate cyclase isolated from lung, 
liver or platelet by nitric oxide, S-nitrosothiols, and other nitric oxide-generating 
chemicals such as sodium nitroprusside is haeme-dependent since haeme deficient 
purified soluble guanylate cyclase is not activated by these agents but is activated 
either by addition of nitric oxide and haeme or addition of preformed NO-haeme 
complex (Ignarro, 1991; Ignarro, et al., 1983). Reduced iron (Fe^+ ) binds with 
protoporphyrin IX to form haeme. Nitric oxide reacts with haeme iron (Fe^+ ) to 
yield nitrosyl-haeme adducts (Keilin & Hartree, 1937; Kon, 1968; Gibson & 
Roughton, 1957). The requirement of haeme in soluble guanylate cyclase is 
attributed to the formation of the paramagnetic nitrosyl-haeme (NO-haeme) adduct, 
which is responsible for enzyme activation (Craven & DeRubertis, 1978; Craven, et 
al., 1979). The molecular mechanism by which NO-haeme activates guanylate 
cyclase is unknown but is indistinguishable from that of protoporphyrin IX (Ignarro, 
et al., 1982b; Wolin, et al., 1982): the binding of haeme to guanylate cyclase 
involves the complexing of iron to the enzyme protein, and this binding prevents 
enzyme activation. When nitric oxide reacts with haeme iron to form NO-haeme, 
the bond between haeme iron and enzyme protein is broken but the porphyrin ring 
remains tightly bound to the enzyme. Thus, a protoporphyrin IX-like binding 
interaction occurs, and this is responsible for enzyme activation. Consequently, the 
increased cGMP in the target cells stimulates extrusion and binding of intracellular
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free calcium, and prevents calcium entry, resulting in smooth muscle relaxation ( 
Ignarro, 1990).
The superoxide anion-generating agents, pyrogallol and hydroquinone, have 
previously been reported to destroy the activity of authentic nitric oxide, but do not 
affect NANC relaxation in the BRP or mouse anococcygeus (Gillespie & Sheng, 
1990; Gibson, et al., 1992), suggesting that the NANC transmitter involved is a 
superoxide anion-insensitive, nitric oxide-releasing molecule rather than free nitric 
oxide. We found that pyrogallol and hydroquinone destroyed the relaxant activity of 
S-nitrosocysteine, S-nitrosoglutathione and nitric oxide when added to their 
respective solutions or to the BRP assay tissue, but as before, neither affected 
relaxation to NANC nerve stimulation. The blockade of the relaxant activity of the 
S-nitrosothiols by pyrogallol and hydroquinone was completely prevented and 
reversed by superoxide dismutase, implying that the blockade was indeed via the 
generation of superoxide anion. Furthermore, superoxide dismutase potentiated the 
relaxant actions of nitric oxide and the S-nitrosothiols but had no effect on those of 
NANC transmitter. Our findings confirm those of Gibson et al. (1992) who also 
found that hydroquinone inhibits the relaxant activity of S-nitrosocysteine, but not 
of NANC nerve stimulation in the mouse anococcygeus. In contrast to our findings, 
however, they reported that hydroquinone did not block the actions of S- 
nitrosoglutathione. Whether this disparity is due to differences in concentrations of 
drugs used or methods in preparing the nitrosothiol is unclear at present. We are in 
agreement, however, that the ability of free radical-generating drugs to destroy the 
activity of S-nitrosocysteine precludes the involvement of this substance in NANC 
transmission in the BRP and anococcygeus muscles.
Superoxide anion can rapidly and nearly completely destroy nitric oxide 
(Gryglewski, et al., 1986; Moncada, et al., 1986; Rubanyi & Vanhoutte, 1986; 
Ignarro, et al., 1988). Moreover, superoxide dismutase protects nitric oxide by
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destroying superoxide anion (Gryglewski, et al., 1986; Rubanyi & Vanhoutte, 
1986; Ignarro, et al., 1988). There is no clear data In vivo to show the extent to 
which superoxide anion contributes to inactivation of nitric oxide. However, in 
physiological environments it is unlikely that superoxide anion contributes 
significantly to the inactivation of nitric oxide for a number of reasons. Firstly, the 
widespread distribution and high activity of superoxide dismutase in tissues make it 
unlikely that sufficient levels of superoxide anion are present to destroy nitric oxide. 
Secondly, in physiological conditions about 90% nitric oxide is converted to nitrite 
(Feelisch, et al., 1987; Kelm, et al., 1988) whereas the oxidation of nitric oxide by 
superoxide anion leads to the production of nitrate (Blough & Zafiriou, 1985).
The inability of pyrogallol and hydroquinone to block the inhibitory NANC 
relaxation but not the relaxation induced by nitric oxide or the new relaxants 
generated from L-cysteine or L-glutathione reacting with nitric oxide suggests that 
the NANC neurotransmitter in the BRP is unlikely to be nitric oxide, S- 
nitrosocysteine or S-nitrosoglutathione. However, if a mechanism exists in the tissue 
to prevent the transmitter from being destroyed by superoxide anions generated 
from pyrogallol or hydroquinone, then nitric oxide, S-nitrosocysteine and S- 
nitrosoglutathione could not be ruled out as candidates. Such a mechanism could 
exist if high levels of superoxide dismutase were present in the BRP which could 
inactivate any superoxide anion generated within the tissue and so protect any 
endogenously produced nitric oxide or S-nitrosothiols. The endogenous superoxide 
dismutase would clearly be unable to remove superoxide anion generated in the 
tissue bath and so be unable to prevent destruction of exogenously added nitric 
oxide or S-nitrosothiols. Consequently, attempts were made to re-examine the 
effects of pyrogallol on NANC relaxation in the BRP muscle after the activity of 
superoxide dismutase had been inhibited. Mammalian tissues contain Cu+ +  , 
Zn+ +  superoxide dismutase (CuZnSOD, Halliwell & Gutteridge, 1989). This 
enzymatic activity is inhibited by very few substances. Cyanide is one such inhibitor
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and is effective at millimolar concentrations. However, it could not be used for this 
purpose in the BRP since at these concentrations it causes complete loss of tone. 
Diethyldithiocarbamate (DETCA) is another inhibitor of superoxide dismutase 
(Halliwell & Gutteridge, 1989; Omar, et al., 1991). It has been reported to inhibit 
CuZnSOD activity in isolated erythrocytes, intestinal cells, and in whole animals, 
by binding and removing the copper from the active site on the enzyme (Halliwell 
& Gutteridge, 1989). Furthermore, at a concentration of 10 mM it has been shown 
to inhibit acetylcholine-induced endothelium-dependent relaxation in the isolated 
bovine coronary arteries (Omar, et al., 1991). This inhibition was likely to have 
occurred due to build up of superoxide anion which would destroy EDRF. 
Therefore, we wished to test the hypothesis that the inability of pyrogallol to inhibit 
NANC relaxation of BRP was due to high endogenous levels of superoxide 
dismutase by inhibiting the enzyme with DETCA. We found, however, that after 
treatment of the BRP muscle with DETCA (10 mM) for 30 minutes, pyrogallol 
(100 pM) remained unable to block NANC relaxation. We therefore have no 
evidence that the inability of pyrogallol to inhibit NANC relaxation can be 
explained by high endogenous levels of superoxide dismutase. Our experiments 
could be criticised, however, since we had no independent evidence that we had 
indeed blocked activity of superoxide dismutase in the BRP. The concentration used 
in our study has, however, been shown to be effective in other tissues (Omar, et al., 
1991).
In conclusion, the major aim of this study was to determine whether an S- 
nitrosothiol rather than nitric oxide functions as the NANC transmitter in the BRP. 
Although the sulfhydryl inactivating agents, diamide and N-ethylmaleimide, inhibit 
NANC relaxation in the BRP, this occurs through a non-selective action rather than 
from an inability to form an S-nitrosothiol since the relaxant actions of glyceryl 
trinitrate and isoprenaline are also blocked. Nitric oxide can react in the presence of 
oxygen and at acid pH with sulfhydryl compounds to produce S-nitrosothiols which
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are potent, long-lasting smooth muscle relaxants. The ability of superoxide anion- 
generating drugs to inhibit the relaxant actions of these S-nitrosothiols as well as of 
nitric oxide but not of the NANC transmitter in the BRP, suggests that these 
substances are not candidates for the NANC inhibitory transmitter. The data suggest 
that the NANC neurotransmitter is more likely to be a superoxide anion-resistant 
nitric oxide-releasing molecule.
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